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The ability to precisely position functionality in three-dimensional space is a long term 
goal for our group.  Some progress has been made so far.  Using oligomers of our bis-amino 
acids, we are able to control the distance between two groups, ranging from 2-4nm.  Also we are 
able to control shape and curvature by incorporating monomers that make bends or kinks.  There 
are many potential applications.  Some of the most powerful are described in the following 
pages.  We have made a bivalent ligand for Cholera Toxin varying the number of monomers and 
found that all bivalent molecules that bind more tightly than the natural ligand GM1.  The 
oligomeric scaffold is rigid and the linker contains about 5 rotatable bonds.  We have made 
bivalent vancomycins and bivalent D-Ala-D-Ala, each consisting of linkers of between 1-6 
building blocks.  These molecules should be capable of associating into matched or mismatched 
bivalent pairs.  In addition, we have made large macrocycles capable of forming a binding 
pocket.  Ligands for these receptors will be identified using phage display.  Also, our rigid chiral 
scaffolds have been studied to determine the influence of chirality on the efficiency of electron 
transfer.  Finally, a scaffold detergent was synthesized, with the application of solubilization of 
membrane proteins in mind.  These are all promising applications of our unique technology and 
will be explored further in the future. 
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1.  INTRODUCTION 
1.1 PRECISION ENGINEERED NANOSTRUCTURES 
Nanoscience is an emerging field of study of objects ranging in size from a few nanometers to 
less than 100 nanometers.  Advances and discoveries in this area are likely to be part of the 
engine that drives the future economy of this country and the world, much like the Internet and 
information technology spurred the productivity and efficiency of the economy of the 1990s.   
Opportunities for chemists are numerous as chemists have the most expertise in making 
molecules by joining together smaller fragments.  The safe, efficient synthesis of sub-nanometer 
scale molecules on huge scales is a major part of the plastics and pharmaceutical industries.  All 
of the marketing and manufacturing support systems are in place for a vibrant industry to be 
based on the coming advances in nanoscience made possible by the discoveries of chemists and 
scientists. 
There are two approaches for making nanoscale molecules.  The first is a top-down 
approach and uses bulk patterning similar to that employed by the semi-conductor industry, but 
on a smaller scale.[1]  The top-down approach best lends itself towards the fabrication of 
nanoscale semiconductors, as well as microfluidic devices used as sensors[2] and analytical tools 
for the emerging concept of lab-on-a-chip approaches,[3, 4] because there is a lack of atomic-
level control.  On the other hand, a bottom-up approach builds nanoscale structures by arranging 
atoms and molecules, either through bonds or self-association.  This ensures that the nanoscale 
molecule has a uniform and atomically defined constitution. 
A bottom-up approach gives the chemist more control over the length and dimension of 
the nanostructure.  The chemist often employs a segment condensation approach, where units of 
shorter length are grafted together to give larger molecules.  Large molecules are not necessarily 
nanostructures.  Nanostructured molecules require design and control on the nanoscale.  Nature 
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is the preeminent nanoscale designer and chemists would do well to mimic the approach that 
nature takes in designing and assembling molecules on the nanoscale, which are ordered and 
adopt a structure or shape.   
These “foldamers” could potentially have functions similar to biomolecules, including 
molecular recognition, information storage and catalysis.  Moore has defined a foldamer “any 
oligomer that folds into a conformationally ordered state in solution, the structures of which are 
stabilized by a collection of noncovalent interactions between nonadjacent monomer units. There 
are two major classes of foldamers: single-stranded foldamers that only fold (peptide-like) and 
multiple-stranded foldamers that both associate and fold (nucleotide-like).”[5] 
Many varieties of foldamers exist as seen in Figure 1, including β-peptides,[6, 7] 
peptoids,[8] carbopeptoids,[9] polypyrrolinones,[10] vinylagous peptides[11] and 
sulfamidepepides,[12] oligoanthranalamide,[13] oligoureas,[14] and phenylene-ethynylene 
oligomers.[15]  Foldamers employ non-covalent interactions such as hydrogen bonding, steric 
repulsions, or π-stacking, in order to self-associate into helices, turns or sheet-like structures. 
 
Figure 1 Selected examples of foldamers. 
 3 
 
 To date most foldamers form simple helices, but no foldamers have been created that fold 
back on themselves to create complex functionalized cavities like those seen in proteins.  The 
most important capability that nature has and we need to develop is the ability to create 
functional macromolecules.  Proteins are linear chains of amino acids that fold into functional 
three-dimensional structures.  The process of folding is complex and the folded conformation of 
a protein is not predictable.  Chemists have worked to create monomers that can be assembled 
into oligomers and then fold intro predictable folded conformations. 
 Our laboratory has developed an approach to macromolecules with defined structures 
(Figure 2).  The macromolecules are assembled from our collection of monomers which are 
connected through pairs of bonds to create spiroladder oligomers. 
 
 
Figure 2 A comparison of monomers linked through single-bonds and pairs-of-bonds. 
 
The chemistry of the amide bond is well developed, as are ways to make them with 
efficiency and control.[16]  Cyclic monomers linked together through pairs of amide bonds will 
form structured oligomers dictated by the stereochemistry of the monomers, as well as the 
conformations of the rings (Figure 3).  Predicting the conformations of the rings is a manageable 
task that molecular modeling programs can handle, allowing for the design and prediction of 
oligomeric structures.  By incorporating monomers of different stereochemistry, regiochemistry, 
and ring size, nanostructures with any controlled shape or length are possible. 
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Figure 3 Toolbox of bis-amino acid building blocks that we have developed synthetic access to. 
 
 The syntheses of these bis-amino acid monomers have been published and used to make 
short oligomers.[17-20]  These syntheses employ about 10 steps which transform cheap, amino 
acids into the desired products, in multigram scales (Figure 4).  The nomenclature used here is 
derived from the building block name (pro4 (1) – proline with substitution at position 4, pip4 (2) 
or pip5 (3) – pipecolic acid with substitution at position 4 or 5, and hin (4) – derived from 




Figure 4 Building blocks are made from readily available amino acid starting material. 
 
 Our building blocks are bis-amino acids and require orthogonal protecting groups which 
can be removed at different stages in the solid-phase synthesis of oligomers (Figure 5).  The 
Fmoc- group is the temporary protecting group which is removed in order to elongate the 
oligomer chain and allows the implementation of all traditional Fmoc based solid-phase peptides 
synthesis methods and commercially available reagents.  The Boc group remains intact 
throughout the synthesis being removed using various conditions, but most often with the strong 
acid used to cleave the oligomer from the solid support (5).  Treatment with base catalyzes 
multiple DKP ring closures when the liberated amine of one building block (or amino acid) 
attacks the methyl ester of the preceding building block, ejecting methanol as a leaving group to 









Figure 5 General scheme illustrating oligomer synthesis, cleavage, and DKP closure to form a rigidified 
scaffold. 
 
The three-dimensional structure of these oligomeric structures have been solved using 2-
D NMR in order to determine the conformational preferences of the rings, as these are some of 
the key determinants of the global oligomeric shape (Figure 6).  For the pro4 class of monomers, 
the diketopiperazine (DKP) between two building blocks adopts a shallow boat conformation, 
such that the substituent, R1, is in a pseudo-equatorial position.  The 5-membered ring adopts an 
envelope conformation so that the 1-3 strain and steric clash between the indicated carbonyl and 




Figure 6 The conformational preference of a pro4 monomer within the context of an oligomer 
 
 The bulk of the research contained in the following chapters of this thesis deals with the 
design and synthesis of functionalized nanoscale molecular scaffolds and exploring their 
potential applications, including bivalent ligands and bivalent interactions, artificial antibodies, 
nanoelectronics, and designer detergents for membrane proteins.  An additional project yielded 
structural insights into these molecular scaffolds by high-resolution measurements of the 
distance between the two ends.   
The toolbox of building blocks used for all projects consisted of the four stereoisomers of 
the pro4-class pictured in Figure 7.  A simple two-letter abbreviation system will therefore be 








2. A BIVALENT LIGAND FOR CHOLERA TOXIN 
 
2.1 INTRODUCTION 
Multivalent interactions are comprised of recognition and binding events between multiple 
ligands and multiple receptors.  Multivalent interactions form the basis of virus-host cell 
recognition and the pathogenic features of some bacteria.  Multivalent interactions form the basis 
of the immune system and its ability to recognize non-self, and have importance in DNA 
recognition and intercalation as well as in cellular communication and signal transduction 
pathways.  The binding affinity of a multivalent interaction is larger than the sum of its 
monovalent binding affinities.  These interactions can act to iteratively agonize or antagonize a 
biological target, which is a property excluded from monovalent interactions. 
Multivalent interactions, relative to monovalent interactions can be positively 
cooperative, additive or negatively cooperative, depending on the value of α, a ratio of free 
energies.  The classical example of positive cooperativity is that of hemoglobin, where binding 
of each oxygen makes the next bind easier.  Another metric of multivalent enhancement is β, the 
enhancement factor, which is the ratio of association constants. 
 
In terms of synthetic multivalent molecules, the structural features of the linker are most 
important.  The linker physically holds the ligands at distances suitable for simultaneous 
interactions with the multivalent target.  If two linkers, one flexible and one rigid, both hold two 
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ligands the same distance apart, the rigid linker will be energetically more favorable.  The more 
flexible the linker is, the more conformations that will exist in the unbound state.  All unbound 
conformations must coalesce into a handful of conformations upon binding and rotatable bonds 
must be restricted upon binding, which costs energy at the expense of binding affinity.  This 
entropic cost has been estimated by Jencks to be ~1.2 kcal/mol per bond.[21]  Whitesides 
suggests that the actual value is less than this, and is highly dependant on the type of bond being 
restricted.[22]  Choi groups linker types into three relative categories: rigid (polyaromatic or 
polyolefinic), intermediate (polyamide or polyether) or flexible (polymethylene or 
polythioether).[23] 
                
 
Simply tethering multiple ligands together with a flexible linker will reduce the 
translational and rotational entropies relative to monovalent, because in both monovalent and 
bivalent binding, two molecules become one.  In the bivalent system, it is hypothesized that an 
extra entropic term results from freezing the rotatable bonds found in the linker.  The degree of 
multivalent binding enhancement depends on this balance of added vs. withdrawn entropy.  
Whitesides states that “multivalent systems joined by flexible linkers (i.e. PEG) are almost 
guaranteed to fail for entropic reasons.”[24]  Many examples, nonetheless, exist where a modest 
multivalent enhancement is seen, but nothing like the exponential enhancements seen for the tris-
D-Ala-D-Ala and tris-vancomycin system consisting of minimal linker flexibility.[25]  In this 
system, the driving force of the association is the enthalpic term which is more than three times 
that of the monovalent system.  Based on the definition of the entropic contributions for a 
multivalent interaction, it is apparent that the ΔStri (conformational, linker) term corresponding to 
the flexibility in the linker is disfavoring in this multivalent association.  The number of rotatable 
bonds in the linkers is about ~25, which is much less than is found in typical polyamide or PEG 
linkers.  However, the net result is a Kdtri = 4x10-17, which is an incredible enhancement over the 
Kdmono = 1.6x10-6.  
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A model used for the estimation of the binding constant of a multivalent system lends 
insight into the most important factors for making high affinity multivalent interactions.[23]  
     
The strength of an interaction can increase exponentially with respect to valency.  Also, a strong 
monovalent interaction to start with will increase the strength of the multivalent interaction.  
Interestingly, because the distance between two sites is important in this model, one can infer 
that this a correction based on the number of rotatable bonds in the linker. 
 The kinetic aspects of multivalent interactions are also unique.  A bivalent ligand 
dissociates from its two binding sites in two steps, whereby the off-rate of the second 
dissociation closely mirrors the off-rate of the monovalent dissociation.[26] 
 
Thus the off-rate of a bivalent ligand is equal to the monovalent off-rate, times 2 because 
there are two sites where dissociation can initiate from, times the likelihood that the second site 
will dissociate as well (Kd/(Ceff+Kd)).  Since effective molarities are often several orders of 
magnitude greater than the actual molarity, a bivalent off-rate can also be drastically slower than 
a monovalent off-rate. 
 The first synthesis of a bivalent molecule was designed by Knowles as a potential 
inhibitor of influenza, shown in Figure 8.[27, 28]  Attempts to measure binding to non-
membrane bound hemagglutinin (HA) using NMR showed that all bivalent molecules, 
irrespective of linker length or type, were binding with equal affinity to the monovalent control.  
However, measurements of the bivalent molecules’ ability to inhibit the adhesion of influenza 
virus to red blood cells showed an enhancement of up to 100x relative to monovalent Kd of 
~2mM, dependant on linker length.  One interpretation of these results is that the bivalent 
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molecules are reaching between pairs of trimers of HA, instead of within the trimers, or 
intermolecular vs. intramolecular. 
 
Figure 8 Two series of bivalent sialosides inhibitors of hemagglutinin. 
 
Cholera toxin, β-subunit (CTB) is a model multivalent system, which has a low nM 
affinity for its natural ligand, the human cell ganglioside GM1.  This ligand is displayed in 
moderate density on the surface on small-intestine epithelial cells.  CTB is an AB5 protein 
excreted by the pathogenic organism vibrio cholera.  The B5 portion is involved in recognition 
and binding to GM1, while the A portion is responsible for the pathologic effect.  Because the 
cure for cholera is clean drinking water, a better understanding of multivalency is the practical  
goal in developing multivalent ligands for CTB. 
 Several groups have developed multivalent ligands for CTB.  The first and most prolific 
group of them is Erkang Fan.  Fan and coworkers have synthesized three classes of inhibitors, all 
with varying linker lengths, including a pentavalent star-shaped ligand capable of binding to all 
five sites at once,[29] a bis-pentavalent or decavalent ligand, capable of binding to two 
pentameric CTBs simultaneously,[30] and short, bivalent ligands with linker lengths unable to 
span the distance between two sites.[31] 
When the authors vary the distance between the core and the ligand from shorter to 
longer, they see an increase in inhibition in an ELLA assay (Figure 9).  The assay is similar in 
principle to an ELISA, where the natural, GM1 ligand is adhered to a polystyrene microtiter 
plate.  A CTB-horseradish peroxidase (CTB-HRP) conjugate is then incubated in a parallel 
microplate with increasing concentrations of synthetic ligand.  The ligand-CTB-HRP solutions 
are then added to GM1 coated plate, allowed to sit for ~30min, and then washed.  Upon addition 
of a chromogenic solution, the amount of color that forms is proportional to the amount of CTB-
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HRP bound to the plate, and by inference, proportional to the relative affinity of the synthetic 
ligand for CTB.  This assay is, in essence, a competition and is a non-equilibrium binding 
measurement.  Substantial gains in inhibition over monovalent ligand were attained, which the 
authors claim is due to binding affinity and not aggregation, as the dynamic light scattering 
measurements suggested a particle size on the order of a pentameric CTB plus pentavalent 
ligand.[32]  Similar trends were seen when a branch was added to each arm of the pentavalent 
core, resulting in a branched pentavalent or decavalent ligand.[30]  More insight into this 
interaction could have been achieved by increasing the length of the PEG linker further, to see if 
the multivalent enhancement decreased. 
 
Figure 9 Fan's branched pentavalent CTB inhibitors. 
 
In the case of the non-spanning bivalent ligands, a contradictory result emerged, namely 
when the linker was too short to span the distance, a bivalent enhancement was still seen (Figure 
10).  In all cases the “effective distance” was less than the desired distance, and in the case of the 
shortest linker, even the “extended distance” was too short to span.  Nonetheless, all bivalent 
ligands showed an enhancement over monovalent of between 5-15, after normalizing for the 
number of ligands.  Again, the authors refute the aggregational hypothesis by saying that the 
DLS measurements ruled out higher-order aggregates and that the concentration of CTB in 
solution is so low (~100pM).  The author’s explanation for this observation was that of steric 
blocking.  When the binding sites of CTB are partially saturated, the dangling arm of a bivalent 
ligand which is bound monovalently could prevent access of the CTB to the surface of the GM1-
microtiter plate.  This hypothesis would be best tested by synthesizing a bivalent linker, but only 
attaching one ligand to it, which the author states is currently ongoing. 
 14 
 
Figure 10 Fan's non-spanning bivalent ligands. 
 
Two more examples of multivalent ligands for CTB are the bivalent truncated GM1-
analog containing a PEG linker with a calixarene core (Figure 11) and multivalent dendrimers 
(Figure 12) containing a lactose thiourea derivative.  In both cases, binding constants were 
measured using a Trp fluorescence intensity shift.  The bivalent GM1 analog produces an 
enhancement of 2000 over monovalent, making this interaction stronger than the natural GM1 
ligand Kd of 200nM.[33]  The dendrimers do not show large bivalent enhancements, especially 
when considering the density of ligands.  The D-2Lac has twice the ligands as the monovalent, 
but no difference in binding affinity.   Likewise, the D-4Lac has four ligands, but only twice the 
binding affinity of the monovalent.  Finally, the D-8Lac has eight times the ligands, but only 8 
times the binding affinity.  This dendrimer work illustrates the point that multivalent interactions 
require a careful organization of ligands.  It is not sufficient to just present a cluster of ligands 
and expect to get enhancement.  On the contrary, a dense cluster of ligands can cause steric clash 
which can result in a multivalent interaction much less than the sum of its parts.  
 
 
Figure 11 GM1 analog with PEG linker and calixarene core. 
Monovalent Kd = 190μM 
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Figure 12 Lactose-thiourea dendrimers. 
  
 The bis-amino acid technology being developed in our lab is ideal for furthering the 
understanding of bivalency.  By varying the number of building blocks, we can change the 
length of the rigid linker (Figure 13). 
 
Figure 13 Bivalent scaffolds of varying lengths. 
 
The influence of the length and flexibility of the linker on binding affinity can also be 
evaluated by varying the type of linker from PEG to βAla, as well as the number of βAla.  One 
goal along these lines is to synthesize a series of lengths of bivalent ligands that differ in binding 
affinity.  Ideally, the series would have a transition from low affinity when the linker was too 
short, to high affinity when the linker was length was ideal, to low affinity again when the linker 
was too long.  This “Goldilocks” effect has been demonstrated before with varying lengths of 
PEG linkers, from 18 atoms to over 1300 atoms in length (Figure 14).[26] 
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Figure 14 Bivalent ligands with varying linker lengths. 
 
 Controversy in this field exists when considering the mechanism of bivalent 
enhancement.  Fan and coworkers believe that chelation binding or intramolecular complexation 
between one multivalent ligand and one protein is the best explanation for their data.[29-32]  The 
other opinion, championed by Toone, advocates that multivalent enhancements are primarily the 
result of aggregation, or intermolecular complexation involving multiple ligands interacting with 
multiple proteins.[34, 35]  By controlling the shape of a linker and the orientation by which two 
ligands are presented, it is conceivable that we could synthesize a bivalent ligand that could only 
bind by chelation and not aggregation (Figure 15). 
 
Figure 15 Cartoon depiction of a potential molecule that would disfavor aggregation, and a molecule that would be 
indifferent toward aggregation. 
 
 Another contribution that we are uniquely poised to achieve is bivalent selectivity.  This 
principle is based on observations from pharmaceutical companies that bivalent molecules that 
show promise in vitro, always fail in vivo (personal communication with Eric Toone).  It is likely 
that most bivalent ligands are indiscriminate in binding to receptors.  Any receptor with binding 
sites spaced within a large distance window would be targeted by a flexible bivalent ligand.  By 
precisely and exactly controlling not just spacing, but orientation of the two ligands, a specific, 
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desired target can be selectively inhibited without side effects or sequestering of material in 
undesired targets. 
 By addressing these two critical areas of deficiency in multivalent interactions, our group 
is striving to open up a new area of biological targets to medicinal chemistry.  Bivalent ligands 
that interact through complexation and not aggregation, along with a rigid, designed linker that 
arranges two ligands in an ideal binding geometry may lead to a renaissance in therapeutics.  No 
longer will the medicinal chemist have to spend long hours trying achieve binding constants in 
the low nM.  The result of attaching two 100μM binders together with a custom-tailored rigid 
linker will be a 10nM inhibitor with inherent specificity, while devoid of the toxic functionality 
sometimes needed to maximize binding affinity. 
2.2 RESULTS AND DISCUSSION 
2.2.1 Galactose Ligand 
Initial attempts to synthesize a bivalent ligand employed the nitrophenyl galactoside ligand and 
utilized fluorescence polarization to measure binding (Figure 16).  The degree of polarization of 
fluorescently labeled ligand can be used to calculate binding constants based on the principle that 
large (protein) molecules tumble slower than small (ligand) molecules.  Using polarized light as 
the source of excitation, only fluorophores having the dipole aligned with the excitation vector 
will be excited, and after a lifetime of a few nanoseconds, light is emitted.  A ligand molecule 
that is not bound will tumble rapidly and emit light in a randomized orientation relative to the 
initial.  A ligand-protein complex is much larger and will tumble slower, thus emitting light in 
directions closer to the orientation of the initial excitation polarization.  Polarization is minimal 
in the absence of receptor and will increase with added receptor as the ligand bound, until it 
plateaus when all ligand is bound.  A plot of [receptor] vs polarization yields a sigmoidal shaped 
curved and the binding can be found by using regression analysis. 
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Figure 16 Cartoon depiction of how the size of a molecule and relates to the polarization. 
 
The synthesis of the components of the ligand were similar to that outlined by Fan[36, 
37] and Rickards.[38]  Starting with commercially available 3,5-dinitrobenzoic acid, alternative 
solvent were explored to facilitate the SnAr methoxide displacement reaction 7.  The original 
procedure calls for hexamethylphosphoramide (HMPA), however alternative polar aprotic 
solvents were tested as HMPA had a high boiling point (235˚C) and would therefore be difficult 
to purify by distillition, not to mention the toxicity potential, especially in the large volumes 
(~500mL) needed for this reaction.  Dimethylsulfoxide (DMSO), dimethylformamide (DMF), N-
methyl-2-pyrrolidone (NMP) and dimethyl-tetrahydropyrimidinone (DMPU) were all tested and 
DMSO was found to be as effective a solvent as HMPA for this reaction (Figure 17).  In the 
second step, phenol ether was hydrolyzed in refluxing aqueous HBr and acetic acid to the 
phenol.  This step resulted in brown salts that were very problematic to remove.  Efforts beyond 
extraction were required, which consisted of trituration with hot EtOAc: hexanes (1:3).  When 
doing this, the product was soluble in the solvent, while the impurities oiled up as the bottom 
layer.  Decanting and repeating the process resulted in a yellow-orange product 8 that served as 
the substrate for the glycosidic bond formation without further purification. 
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Figure 17 Synthesis of the substituted phenol. 
 
Synthesis of the glycosidic linkage, as the desired α-anomer 9 (Figure 18), was the next 
step.  Fan and coworkers used tin(IV) chloride in dichloromethane and claimed a selectivity of 
40% for the α-anomer, in a 40% overall yield.  However, using exactly the same procedure and 
conditions, the best that was achieved was an overall yield of 30% with an anomeric ratio of 1:4 
(α:β).  The net yield of this single reaction was 6% for the desired anomer.  Obviously this was 
unacceptable, so alternate solvents and catalysts were explored. 
 
 
Figure 18 Conflicting preferences of the anomeric effect and the neighboring group effect. 
  
 The degree of anomeric selectivity was found to be dependant on several factors, 
including choice of the Lewis acid, choice of solvent, reaction time, and stoichiometry (Figure 
19).  Issues of solubility also arose, as it appeared that the phenol was not readily soluble in 
DCM.  Changing the solvent to ACN with tin chloride resulted in greater solubility but identical 
selectivity and yield.  Changing the Lewis acid to boron-trifluoride inverted the selectivity to the 
desired anomer.  Increasing the equivalents of BF3 added allowed the reaction time to be 
decreased by a factor of ten.  The overall yield was still poor, with large of amounts of 
7 8
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unconverted starting material remaining.  However this could be recovered and re-used.  In the 
end, the objective of inverting the anomeric selectivity to the desired alpha anomer was achieved. 
 
Figure 19 Table of formation of glycosidic bond.  First entry is Fan published results.[37] 
 
Simply being able to purify large amounts of material from the glycosylation reaction 
was a challenge, until a reversed phase C18 Isco column was used.  Trying to separate a minor 
product from a mixture of other carboxylic acids is no easy task.  However, reactions mixtures 
consisting of greater than 3g were routinely purified to ~90% purity using a 130g RP-C18 Isco 
column.  The remaining steps in the synthesis (Figure 20) of the ligand were removal of the 
acetyl groups with NaOMe in methanol to give 10, followed by selective enzymatic hydrolysis 
of the β-anomer using β-galactosidase, yielding 11.  This was required because it was not 
possible to resolve the anomers using chromatography, neither normal phase nor reversed-phase.  
At this point, the material was re-protected with acetic anhydride (12), purified, and used to 




Figure 20 Remaining steps in the synthesis of the protected α-ligand 
 
The first approach to make a bivalent ligand would involve the synthesis of a molecule 
varying in the number of building blocks separating the two ligands (Figure 22).  Additional 
molecules would be synthesized varying in the number of β-Ala linking the ligand to the 
scaffold.  These molecules were synthesized on the Rink Amide AM resin.  The first residue was 
the diamino acid Fmoc-Ornithine (Orn) with an orthogonal 1% TFA cleavable methyltrityl (Mtt).  
The building blocks used in this part were all Boc-pro4(2S4S).  An additional step in the 
synthesis of the building block was the conversion of the Cbz group to a Boc group in a one-pot 
reaction involving hydrogenolysis of the Cbz followed by spontaneous incorporation of a Boc 
group from Boc-anhydride, in tetrahydrofuran.[39]  This procedure has been now been 
universally adopted in the synthesis of nearly all building blocks in our lab.  The Boc-building 
block was a requirement for the synthesis of a bivalent ligand, as the best approaches to remove a 
Cbz groups (H2, Pd/C or triflic acid) were both incompatible with the nitroaromatic, glycosylated 
ligand.   
The elongation of the sequence continued with additional building blocks until the last 
building block in the sequence.  It was desired to couple another Orn followed by coupling of 




likelihood of being able to acylate the amine was slim, as the formation of the DKP was very 
rapid.  To eliminate this reaction, a building block containing a primary amide instead of a 
methyl ester was synthesized (13).  Reaction of the building block intermediate after Fmoc 
protection with HOBt/ HBTU and an ammonia/ dioxane solution resulted in desired product in 
good yield.  The remaining steps of tert-butyl ester removal and Cbz-to-Boc were then 
performed to yield the building block-amide (Figure 21). 
 
Figure 21 Synthesis of the building block-amide. 
 
 After incorporation of the building block-amide, the 2nd Orn was coupled, followed first 
by attachment of 5-carboxyfluorescein (5-FAM) using diisopropylcarbodiimide (DIC) and N-
hydroxybenztriazole (HOBt).  During the course of this overnight reaction, the beads changed to 
a yellow-orange color.  This implied that the xanthate hydroxyls were confined in bonds made to 
other FAMs, creating a dendrimeric network.  If this product was cleaved, the characteristic 
absorbance peaks for fluorescein were absent as was the predicted mass.  Only after a few 
treatments of the resin with piperidine/DMF was the red color restored to the beads, and the 
typical absorbance spectrum of fluorescein returned and the desired mass appeared (14).  After 
this, the resin was treated with 1% TFA to remove the 2 side chain protecting groups.  
Neutralization of the resin followed by coupling of the acetyl protected ligand using 
HOBt/HBTU produced the desired bivalent scaffolds (15).  Use of HATU as the coupling 




Figure 22 Solid phase synthesis of FAM-bivalent scaffolds. 
 
Upon completion of the solid phase synthesis, the scaffold was cleaved (Figure 23) and 
the solvent removed (16, Figure 25).  The residue was dissolved in MeOH and solution of 
NaOMe in methanol was added.  The solution color changed from orange to bright red.  This 
Zemplen deactylation reaction needed only 10min for completion, after which it was quenched 
with HCl, changing the color back to orange-yellow (17, Figure 26).  LCMS analysis at this 
point showed desired, deacetylated product, along with some amount of material with 1 or 2 
diketopiperizines (DKPs) closed.  The solvent was removed and the residue and salts were 
dissolved in 20% piperidine/NMP. Incubation at room temperature for 36hrs served to close the 




labeled bivalent scaffolds (18, Figure 27) which were to be analyzed for binding using 
fluorescence polarization. 
 
Figure 23 Cleavage, deacetylation, and DKP closure of FAM-bivalent scaffolds. 
 
In addition to the five molecules above, of lengths 5-9 building blocks, additional 
molecules of this same length were also made in parallel (Figure 24).  Two series, containing one 
(19) or two β-alanines (20) on both ends between the scaffold and ligand were made by coupling 
Fmoc-β-Ala to both ends, after the Mtt groups had been removed from the Orn.  After the 
remaining steps were complete, 3 series of varying length having linkers of varying flexibility 
were successfully synthesized in quantities of ~100nmol, more than enough for FP 





Figure 24 Bivalent scaffolds with linkers containing 0, 1, or 2 β-Ala and the monovalent control. 
 
Figure 25 Representative cleavage of 5mer-FAM bivalent ligand. 





Figure 26 Representative deacetylation of the 5mer-FAM bivalent ligand. 
 
Figure 27 Representative final purified diketopiperazine closed product of the 5mer-FAM bivalent ligand. 
 
The measurements of the fluorescence polarization were done on a LJL Analyst HT in 
the School of Public Health (Figure 28).  The amount of fluorescent label in each 50μL well was 




amounts above 500pM were linearly related to the concentration.  However, the signal-to-noise 
ratio of concentrations below 1nM was borderline acceptable, so 3nM was chosen for all 
titrations.  Inconsistent measurements of the polarization at low protein concentrations were 
likely due to adherence of the molecules to the plastic.  When small amounts of bovine serum 
albumin or bovine gamma globulins were added to each well, the data at low concentrations of 
protein became linear and a binding curve was generated.  Titrations involved the addition of 
recombinant Cholera Toxin β-subunit (CTB), ranging from 10nM up to 200μM. 
Initial studies hoped to test the effects that distance and flexibility between the two 
ligands had on the binding affinity.  Three series of five molecules were made containing 5-9 
building blocks and linker composed of 0, 1, or 2 β-Ala.  Unfortunately, the FP values for these 
molecules showed little difference from the monovalent control.  Initial interpretations as to why 
no bivalent enhancement was obtained settled on the fact that perhaps the ideal distance and 
orientation of the two ligands was not achieved.  Because these scaffold molecules have a helical 
pitch, changing the distance also changed the orientation, such that every building block added 
90˚ rotation between the first ligand and the second.  So perhaps one scaffold length held the two 




Figure 28 FP data on the 5-9mer series consisting of a linker with 0, 1, or 2 β-Ala. 
 
The apparent solution to the problem of controlling distance and orientation between two 
ligands was to exploit the unique properties of molecular scaffolds.  Scaffolds were made up of a 
series of fused rings and molecular modeling was used to search through all possible structures 
for sequences of building blocks that held the two ligands in an ideal binding orientation and 
distance.  Using the coordinates from crystal structure of this ligand bound to the CTB pentamer, 
sequences were “scored” on their ability to hold two ligands in a “perfect” binding orientation.  
The ends of the bivalent ligand had a few rotatable bonds, which were limited to rotomers 
adopting a low energy conformation. The energy of the two ends was also factored into the 
score, so that the ideal score would have the two flexible ends in a low energy conformation and 
a given scaffold sequence would position the ligands precisely into the binding pocket.  The 
variables for the in silico screening were 8mers or 9mers using all four stereoisomers of the pro4 
building block (SS, RR, SR, RS) with a L-Dpr or D-Dpr at each end, which generated 1.3 million 
scaffolds.  Six scaffolds (Figure 30; seq3 disappeared upon DKP closure), having the highest 
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score and the greatest likelihood of being able to hold two ligands in an ideal bivalent binding 
orientation, were synthesized (Figure 29, 31) and tested using FP.  Additionally, two new 
positive control compounds were synthesized to investigate whether the fluorescein had any 
effect on the binding of the ligand by varying the distance between the ligand and the fluorescein 
(Figure 30, compounds 23, 24). 
 
 

















Figure 32 FP binding titrations of (+) controls and predicted sequences. 
 
The results (Figure 32) for the bivalent predicted sequences (25) implied that these 
ligands were not binding bivalently, as the enhancement seen was no more than a factor of five.  
Further study of the structure of these molecules was required.  2D-Electron Paramagnetic 
Resonance (EPR) techniques are capable of measuring distances between two unpaired electrons 
with angstrom precision.  Attachment of two nitroxyl spin labels to seq5, 6, and 7, (26) instead of 
a ligand, would lend insight into whether the two ligands were spaced the proper distance apart, 
allowing experimental validation of the molecular modeling predictions.  The distances that were 
measured (Figure 33) were between 30Å-33Å, indicating that these bivalent scaffolds were 
entirely capable of holding two ligands the desired distance apart (30Å -35Å). 
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Figure 33 2-D EPR measurements of the distance between two nitroxide spin labels for seq5, seq6, and seq7. 
 
Two final molecules were synthesized as controls.  As mentioned in the introduction, 
many groups have seen impressive bivalent enhancements with a simple PEG linker.  A PEG 
linker was attached to seq5 (28) between the ligand and scaffold (Figures 31, 34).  Also, since it 
was known that the sugar portion of this ligand was primarily responsible for the specific binding 
interactions in the pocket, replacement of the sugar portion with a methyl group (7) should 
eliminate any binding in the bivalent 27 (Figures 31, 34). 
 





Figure 35 FP titration of PEG-bivalent ligand (-) control and (+) control. 
 
The results (Figure 35) were that the PEG-bivalent ligand 28 bound only a factor of two 
better than the positive control 21 and that the des-galactose bivalent ligand 27 bound with 
similar affinity to the monovalent control.  The interpretation of this result was damaging, 
because, not only did it appear that there was no potential to create a bivalent ligand because the 
PEG-seq5 failed to reveal an enhancement, it was reasoned that the ligand itself was not 
interacting in the binding site.  A bivalent scaffold, stripped of the galactose portion, was binding 
with similar affinity to the monovalent ligand control.  Our conclusion at this point was we had 
been led astray by at least one of three possible root causes: the protein was bad, the ligand was a 
non-specific binder, or the assay conditions were flawed. 
2.2.2 Lactose Ligand 
The next ligand to be synthesized, attached to scaffolds, and evaluated for bivalent enhancements 
was a lactose-thiazoline-benzoic acid derivative that had some appealing features.[40, 41]  First, 
the synthesis was fairly quick and straightforward, devoid of multiple purifications.  Each step 
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was reasonably high-yielding.  But most appealing was the fact the glycosidic linkage was the β-
anomer, which was much easier to control, as the selectivity for it was near unity.  As with the 
synthesis of the previous ligand, this published procedure was modified and optimized. 
Starting with Boc-protected propargyl amine 29 (Figure 36), a Sonagashira reaction 
between the alkyne and meta-iodomethylbenzoate produced the desired product 30, which was 
purified using normal phase chromatography.  TFA deprotection yielded a brown sludge which 
was initially used in the next step without further purification, as Vrasidas suggested.  
Purification of a free amine 31 would normally be challenging, but the RP-C18-Isco column 
proved highly capable.  Five grams of crude amine salt was purified using a water/ACN gradient.  
Removal of the solvent afforded a tan solid in >75% recovery, and use of this material resulted in 
higher yields and purity in subsequent reactions. 
 
Figure 36 Synthesis of the aromatic-propargyl-amine fragment. 
 
 The synthesis of the lactose amine (Figure 37) involved two standard sugar-chemistry 
reactions: first peracetylation of lactose with acetic anhydride and DMAP to form a mixture of 
anomeric acetates 32, followed by HBr in AcOH treatment, which resulted in α-peracetyl-lactose 
bromide 33.  At this point, the authors recommend a neat melt of the lactose bromide in the 
presence of KSCN for large scale preparation the β-lactose isothiocyante 36.  This reaction 
produced multiple products and was deemed unworkable in our hands.  Otherwise, the authors 
recommended a three-step procedure involving initial phase-transfer catalyzed (PTC) formation 
of the lactose azide 34, followed by reduction with H2, Pd/C (35), and immediate reaction with 
thiophosgene to form 36.  This sequence proved to much more useful, as it yielded the desired 
product as ~10:1 mixture of anomers, favoring the desired β-isomer.  The anomeric impurity was 
traced back to the reduction step, which was logical because having the electron withdrawing 
amine group in the β-position was destabilizing.  In the presence of trace water or acid, the 
pyranose ring could open and reform, resulting in the amine (35) adopting the more stable α-
position.  This α-impurity could be removed in subsequent steps.  However, a literature search 
29 30 31 
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revealed yet another way to make sugar-isothiocyanates, which utilized the same PTC along with 
KSCN to make the desired β-product 36, in 1 step vs. 3 steps, but more importantly, the 
anomeric ratio was >50:1.  This reaction was done on a 5g scale to afford large amounts of 
material for subsequent steps. 
 
Figure 37 Synthesis of lactose isothiocyanate. 
 
Reaction between the isothiocyanate and amine (Figure 38), to initially form the thiourea 
(37), proceeded cleanly with the purified amine, using a modified procedure.  When amine was 
the limiting reagent or excess base was used, which was a requirement when using the crude oil 
from the TFA deprotection, an extra peak on the LCMS was seen, corresponding to a mass of 2-
NCS, 1-amine.  The reaction proceeded with ~100% conversion when the purified amine was the 
excess reagent and 1eq base was used.  The reaction was found to be complete in less than 1hr, 
as opposed to the 12hr reaction time used by Vrasidas.  After the initial reaction time, 10eq of 
acetic acid were added to form the thiazoline cyclized product (38).  This also was a 
modification, as the authors worked up the reaction before adding the acid.  The thiazoline was 
purified on the RP-C18-Isco column, as a single injection of the crude product dissolved in acetic 
acid.  As Vrasidas desired to keep the methyl ester (39, R=Me) while removing acetyl groups 
from the lactose, we diverged from them in the next step.  Saponification of all esters was 
accomplished in a solution of methanol and lithium hydroxide, and by extending the reaction 
time from 1hr to 12hrs (39, R=H).  Initial inspection of the crude product by LCMS showed 
three peaks, all with the same mass.  Addition of HCl until the pH was neutral caused the three 





methanol in order for the highly polar product to be retained by the RP-C18-Isco column because 
it was found that the elevated temperatures used to expedite the removal of solvent in vacuo 
would scramble the product distribution from a single peak to multiple peaks, again having the 
same mass.  Removal of the methanol without heating resulted in little, if any, rearranged 
product.   
 
Figure 38 Remaining steps of the synthesis of the lactose containing ligand, with the two possible tautomers 
highlighted. 
 
Comparison of the 1H-NMR spectra for this product with the published spectra of the 
methyl ester showed differences that appeared to be not solely due to the differences between a 
carboxylic acid and a methyl ester.  The experimental 1H-NMR and the published 1H-NMR was 
mainly congruent, however one discrepancy was apparent, besides the difference between 
methyl ester and free acid.  The -CH2- proton peak had shifted from about δ 5ppm to δ 4ppm in 
the carboxylic acid ligand product.  Furthermore, when the free acid was converted to the methyl 
ester using TMSCHN2, the two H-NMR spectra should have been identical, but they were not, 
with the -CH2- peak again being farther upfield.  2-D NMR spectra were acquired of the ligand 
carboxylic acid consisting of an HSQC and an HMBC (Figure 39) to elucidate whether the 
structure was more consistent with 39 or 40.  The HSQC produced cross peaks for JHC 1-bond 
coupling, which identified the protons attached directly to carbons.  The HMBC showed cross 
peaks for JHC 3-4 bond coupling, which identified the protons and carbons that were nearest to a 
given signal.  From the HMBC spectrum, we determined that the -CH2- was closer to the 







Figure 39 2-D NMR spectra (HSQC and HMBC) of the final ligand used in tautomer identification (39 or 40). 
 
 Thus far, the CTB that had been used was expressed in E.Coli and purified on a galactose 
affinity column, followed by diafiltration to remove the excess galactose (plasmid was a gift 
from Minke at UWash).  This recombinant CTB (rCTB) formed a complex with anti-CTB 
monoclonal antibody which had a molecular mass around 10kDa.  LCMS analysis of this protein 
gave a mass of ~11803 Da.  Sequence analysis predicts a mass of ~11606 Da.  Additionally, 
comparison of the fluorescence spectrum (Figure 40) of the rCTB with what was seen in the 
literature or with CTB purchased from Sigma proved brought more suspicion upon the rCTB.  
From this point on, we exclusively used CTB purchased from Sigma. 
 
Figure 40 FI spectra comparing two sources of CTB. 
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The ligand (39 or 40) was evaluated for binding using a tryptophan fluorescence assay 
(Figure 41).[40]  CTB contains 1 Trp residue and the fluorescence intensity (FI) was plotted 
against increasing concentration of ligand, while the protein concentration was maintained at 
100nM, 250nM or 500nM.  Trp FI is very sensitive to its environment, and since this Trp is 
found in the binding pocket, the FI is directly correlated with the extent of binding.  As more 
ligand binds, fluorescence of the Trp decreases, until saturation occurs, then no more change in 
FI is seen.  Plotting of ΔFI vs. ligand concentration generated a sigmoidal curve, and regression 
analysis yielded a binding constant.  The synthetic ligand-carboxylic acid (39 or 40) was tested 
for binding to CTB, at a CTB (monomer) concentration of 500nM.  The ligand was varied from 
0 to 150μM.  These are the exact conditions used by Vrasidas, and he obtained a binding 
constant of ~23μM.  Our carboxylic acid ligand had a binding constant of ~42μΜ, which was 
derived from a Scatchard plot of (fraction bound/free ligand) vs. (fraction bound).  The slope of 
the line is equal to –Ka.  Additionally, the x-intercept of the Scatchard line = Vmax, and was 595 
ΔFI units.  It was gratifying to finally see an irrefutable sigmoidal binding curve and derive a 
binding constant that made sense. 
 
Figure 41 (A) structure of carboxylic acid ligand (39 or 40) used for FI assay (B) fluorescence intensity curves with 
increasing amounts of ligand (C) binding curve of ΔFI vs. [ligand] (D) Vrasidas binding curve from publication (E) 
Scatchard plot of (C) 
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 The initial test of the ligand (39 or 40), shown above, validated that the synthetic ligand 
bound to CTB with similar affinity to that of Vrasidas.  However, precise structural 
characterization of the ligand by 2-D NMR methods was not done until months later, by this time 
this initial batch of ligand was long gone.  The 2-D NMR spectra in Figure 39 shows that the ring 
structure in our molecule is different than Vrasidas’.  Comparison of the FI binding curves 
(Figure 42) of the “First titration” with that of the structurally assigned ligand, called “Last 
titration”, showed that the two bound with different affinities.  One conclusion of this is that the 
“First” ligand may have been structurally different than the “Last” ligand, which only could have 
been the result of differential reaction conditions when the esters were saponified in the final step 
with LiOH.  The tautomer of the “First” may have been similar to Vrasidas, that of the 
conjugated exocyclic double bond (39), while the “Last” was confirmed to be the tautomer 
containing a benzyl -CH2- between two aromatic rings (40).  If this conclusion is accurate, this 
tautomer, having a Kd of ~3μM, represents the strongest binding monomeric CTB ligand 
discovered to date.  A medicinal chemist would have been thrilled with this 10-fold improvement 
in binding affinity, however the consequences for this project were negative, because now the 
dynamic range for the FI assay to measure potential bivalent enhancement had also been reduced 
by a factor of 10. 
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Figure 42 FI binding curves comparing the ligand binding of the very first titration with that of a later batch of 
ligand. 
 
Incorporation of this ligand into the scaffold was initially fraught with difficulty.  The 
final ligand (39/40) was protected with acetyl groups, as this was thought to aid in making the 
coupling reaction more specific.  Using similar techniques as in the previous synthesis of 
bivalent galactose-based ligands, involving coupling of the acetyl-protected ligand, followed by 
cleavage, de-acetylation, and finally DKP formation were found to be incompatible with this 
ligand.  For reasons not understood, incubation of the ligand, with or without acetyl groups, in 
the 20% piperidine/ NMP solution needed to close the DKPs produced a large, broad LCMS 
peak not seen before.  A possible solution to this problem was to couple the ligand in solution 
after the scaffold DKPs had been closed.  This failed because of the difficulty involved in 
separating bivalent product from monovalent and starting material.  Clean bivalent product was 
an absolute requirement for the evaluation of any bivalent enhancements.   
An alternative solution to this problem was to close the DKP first on the resin, then 
couple the ligand on the resin.  This had routinely been done in the lab by others, however they 
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employed a resin that was stable to the TFA Boc-deprotection conditions, with cleavage being 
done with triflic acid.  Triflic acid, and even TFA, are known to readily hydrolyze glycosidic 
bonds.  Fortunately, the glycosidic bond in this ligand showed negligible hydrolysis when 
exposed to TFA for less than two hours, but complete hydrolysis in triflic acid occurred in less 
than 5 minutes.  This meant that the Rink Amide resin had to be used, but non-TFA Boc-
deprotection conditions would be needed. 
Other on-resin-Boc-deprotection conditions were tried, both thermally (190˚C in acetic 
acid for 2hr) and chemically (cerium ammonium nitrate), but both were ineffective.  The third set 
of conditions attempted utilized the Lewis acid TMSOTf (trimethylsilyl triflate), which would 
complex with the carbonyl oxygens, and 2,6-lutidine would then attack the carbonyl.[42] The 
difference in reactivity of carbamates vs. amides allowed these conditions to selectively remove 
the Boc group.  Although the Rink linker was not cleaved under these conditions, other parts of 
the linker were reactive when using the Rink Amide AM resin.  Switching to the plain Rink 
Amide resin resulted in clean removal of the Boc group, in three treatments of 3min each, while 
keeping the scaffold attached to the solid support (Figure 43).  This was a major breakthrough, 
especially when it was found that the DKPs could be quantitatively closed on the resin with 
NMP/piperidine in only 10hrs, simply by raising the temperature to 37˚C (41). 
 
 
Figure 43 On-resin Boc-deprotection and DKP closure, followed by acylation to form bivalent ligands with varying 
linkers. 
With conditions in hand to close DKPs on-resin, the next step was to attach the ligand.  It 
was found that the ligand, without the hydroxyls protected, could be coupled cleanly and 
efficiently using HOBt/HBTU activation, 2 x 2eq (per 2 amines) in DMSO:DMF for 2 x 1hr with 
stirring.  The cleavage conditions were found to critical.  If the cleavage in 95%TFA was 
allowed to proceed for more than 1hr, significant amounts of hydrolysis of the glycosidic bond 
became apparent.  This was particularly problematic because the both the desired product and the 
des-galactose products had nearly identical retention times by RP-HPLC, as the sugar portion 
seemed to be the dictator of polarity.  On several occasions, material had to be discarded as 
41 
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inseparable, but limiting the cleavage time to one hour and using the Speedvac to quickly remove 
the TFA after cleavage proved to remedy this problem.  The final bivalent products were easily 
purified on a preparative HPLC to homogeneity.  An HPLC calibration curve was used to 
estimate the concentration, and the HPLC fraction was aliquoted into fractions consisting of 
enough material for one FI titration, and then lyophilized.  This was required because it was 
found that large amounts of bivalent ligand were presumably adhering to the plastic tube when 
the sample was allowed to stand in buffer at 4˚C.  When the time for titration came, the pellet 
was resuspended and the absorbance spectrum was measured.  Using the extinction coefficient 
(ε = 8855) derived from a Beers law plot of the glycine methyl ester acylated with the ligand 
carboxylic acid, the concentration of the bivalent ligand was determined.    
A series of bivalent ligands were synthesized containing various linker lengths.  These 
series included bivalent ligands with PEG linkers, bivalent ligands with 1 or 2 β-Ala ligands, and 
finally, bivalent ligands with no linker, as seen in Figure 44.   
 
Figure 44 Representative LCMS chromatogram illustrating the effectiveness of the scaffold synthesis, Boc-
deprotection, on-resin DKP closure, and coupling of the unprotected lactose ligand.  5mer-bivalent ligand described 




Scaffolds containing 5-9 building blocks with a PEG linker (Figure 45) connecting the 
ligand to the scaffold were synthesized (42) and purified. Of these, the 5mer and 6mer were 
chosen for binding measurements, this time using 100nM protein.  The apparent binding constant 
of these samples were less than 100nM (Figure 46).  As the Kd is defined as the concentration of 
free ligand where half of the protein is bound, the lowest Kd that could be conceivably measured 
was 50nM.  However, when deriving binding constants at less than 100nM, our fitting software 
became temperamental and was prone to producing nonsensical answers.  To test the effect of 
the PEG linker on binding, an additional bivalent ligand consisting of only diaminopropionic 
acid (Dpr) with two PEG tethered ligands (43).  The binding constant of this molecule was also 
less than 100nM (Figure 47).  If the goal of these bivalent experiments was to make a bivalent 
molecule that binds with enhanced affinity, this would have been achieved.  However, the goal 
was to observe bivalent selectivity, where one length of a scaffold binds strongly and other 
lengths, both shorter and longer, bind with less affinity.  In order to observe this, shorter linkers 
were necessary, consisting of too short, too long, and just right (Goldilocks effect). 
 






Figure 46 PEG-linker-Bivalent FI-Titration Curves 
 
The next set of molecules varied in length from 5-9 building blocks and had either one or 
two βAla between the ligand and the scaffold (Figure 47).  All ten molecules were successfully 
synthesized and purified as described previously.  The shortest scaffold was a 5mer (44) with a 
one-βAla linker.  The binding of this to CTB was measured and found to be under 100nM 
(Figure 48).  A 7mer (45) with a 2-βAla linker was also tested and found to have a Kd also less 
than 100nM.  It was at this point that it was realized that the linker would have to be removed in 
order to have any chance of bivalent selectivity. 
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Figure 47 β-Ala derivatives tested for binding by FI. 
 
 





 Accordingly, two sets of molecules were synthesized (Figure 50) consisting of a series of 
2-7 building blocks with a ligand at the trailing end and, either a glycine DKP (47) or a second 
ligand at the leading end (46).  These bivalent ligands position the two ligands between 10Å and 
35Å apart.  From this, it was anticipated that the shortest ligands would be unable to span the 
35Å between adjacent binding sites and bivalent selectivity would be achieved.  In essence, we 
were looking for a bivalent ligand that bound monovalently, and we believed that the shortest 
bivalent ligands would achieve this.  This series of bivalent ligands, containing scaffold of 
lengths 2-7 building blocks, were tested using the FI assay (Figure 49).  GM1 ganglioside, the 
natural ligand for CTB was also tested.  In this assay, GM1 had a Kd of 63.8 nM, which is similar 
to what Bernardi measured for the GM1 oligosaccharide (without the hydrophobic tail) 
employing an identical assay (219nM).[33]  When the binding constants were derived for the 
bivalent ligands and GM1, it was clear that all bound stronger than the GM1.  Although 
differences can be seen, due to the imprecision of this measurement, closer inspection is not 
warranted.  The only statement that can be made with confidence is that the binding constants 
were all less than 100nM.  Of particular note is that the 2mer-2TZ and the 3mer-2TZ were both 
known to be too short to span the distance required to bind to two binding sites at once.  One 
explanation for this would be that the ligand was binding between two protein pentamers and not 
within a single pentamer.[34]  This would be considered preliminary evidence of an 
aggregational mechanism as opposed to chelation, but more experiments are necessary and 
ongoing, especially the development of assays capable of accurately measuring binding constants 




Figure 49 Bivalent scaffold FI-titration curve. 
 
Figure 50 Bivalent ligands directly attached to the scaffold and Glycine-monovalent scaffold ligands. 
 
Additionally, the monovalent scaffold (47) series was synthesized in order to evaluate 
Fan’s explanation for an enhancement of a bivalent ligand incapable of spanning the required 
distance between two binding sites.[31]  Fan and coworkers put forth steric blocking as an 
explanation for the observance of a bivalent enhancement for non-spanning bivalent ligands.  In 
our case, this monovalent series was designed to assess whether the scaffold had any 
contribution to the binding affinity.  Additionally, a ligand-amide monovalent control was 
synthesized as the basis for comparing the binding affinity of this monovalent-scaffold series.  
46 47 
 49 
From the binding constants, two things are apparent (Figure 51).  First, all samples have similar 
binding constants of ~200nM.  No difference was seen between the TZ-GlyOMe (Figure 52, 
compound 48) and the monovalent scaffold series.  Therefore, it didn’t appear that the scaffold 
made any contribution to the binding affinity.  The second thing that was apparent was that the 
TZ-GlyOMe (48) bound about 10 times more tightly than the free acid, but more investigation of 
the observation is needed.  If this stands, though, it would definitely be the highest affinity 
monovalent ligand for CTB ever made. 
 
 
Figure 51 Monovalent Glycine/Ligand FI-titration curve 
 
Figure 52 Ligand-glycine methyl ester control used for the monovalent-amide binding control, as well as for the 




Fluorescein labeled bivalent ligands were also synthesized (Figure 53) with the intention 
that FP would be used to accurately measure higher affinity binding.  Incorporation of an Fmoc-
Dab(ivDde)-OH as the first residue, followed by n pro4(2R4R) building blocks (n=2-7) yielded 
the series of scaffold lengths.  Removal of the Boc groups on-resin, followed by on-resin DKP 
closure gave a resin bound product with two free amines (49).  Acylation with the free ligand 
(50), followed by removal of the ivDde proved to be compatible.  Reaction between the Dab 
amine and fluorescein was slightly challenging.  Using methods developed for the galactose-
based bivalent ligands failed to selectively form the desired product.  Using fluorescein-N-
hydroxy succinyl ester was promising.  Desired product was seen when using sub-stoichiometric 
amounts of DIPEA, but numerous impurities were also present as well.  Base-free conditions, 
over the period of 2-4 days yielded desired product (51) cleanly and efficiently.   
 
Figure 53 Synthesis of FAM-labeled bivalent ligands. 
 
The FAM-labeled bivalent 6mer was tested for bivalent binding using FP.  
Concentrations of CTB (Sigma) ranged from 10nM to 3μM were used, however no change in 





measuring bivalent enhancements into the low nM-pM range, but further study and optimization 
are needed. 
2.3 CONCLUSIONS 
Two different types of ligands were successfully synthesized and incorporated into scaffolds.  It 
was found that conditions leading to the carboxylic acid-thiazoline based ligand also produced a 
tautomer which is one of the tightest binding ligands known for CTB.  Bivalent ligands, varying 
in number of building blocks, linker type, and linker length were synthesized.  Using 
fluorescence polarization to measure binding constants requires further optimization.  
Tryptophan fluorescence intensity shifts were employed to measure equilibrium binding 
constants of a number of series of molecules, including PEG-linked bivalent scaffolds, 1 or 2 
βAla-linked bivalent scaffolds, bivalent scaffolds directly attached to the ligands, and 
monovalent controls, consisting of the full scaffold with only 1 ligand attached.  A bivalent 
enhancement was seen for all bivalent ligands, although the lower limit of the dynamic range of 
this assay was quickly surpassed.  Further work is ongoing to implement assays having the 
ability to measure low nanomolar-to-picomolar binders, capable of yielding impressive bivalent 
enhancements, and allowing the further study of factors affecting the strength and specificity of 
bivalent interactions, as well as the mechanism.  In summary, bivalent display of two ligands 
using an oligomeric bis-amino acid scaffold has been validated as a potential “killer app” for the 
bis-amino acid technology being developed in this lab and should be pursued with vigor on 
multiple fronts. 
2.4 EXPERIMENTAL 
General: Dichloromethane was distilled from CaH2.  All other reagents were used as received, 
unless stated otherwise.  Column chromatography was performed using ICN Silitech 32-63 D 
(60 Ǻ) grade silica gel and TLC analysis was performed on EM Science Silica Gel 60 F254 plates 
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(250μm thickness).  NMR spectroscopy was performed using a Bruker 300 MHz instrument.  
Chemical shifts were reported in parts per million downfield relative to trimethylsilane and 
categorized as br = broad, s = singlet, d = doublet, dd = doublet of doublet, ddd = doublet of 
doublet of doublet, t = triplet, q = quartet, and m = multiplet.  Solid phase synthesis was 
performed in a 1.5mL disposable polypropylene reaction column, connected to a three-way valve 
equipped with vacuum and argon for mixing.  Dichloromethane (DCM) used in coupling 
reactions was distilled over calcium hydride.  Dry grade of dimethylformamide (DMF) from 
Aldrich was used for coupling.  N,N-diisopropylethylamine (DIPEA) was distilled under 
nitrogen sequentially from ninhydrin and potassium hydroxide and stored over molecular sieves.  
O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorphospate (HATU) was 
obtained from Acros.  O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorphospate 
(HBTU) and N-Hydroxybenzotriazole hydrate (HOBt) were obtained from Novabiochem.  All 
solid phase reactions were mixed by bubbling argon up through reactor, allowing for mixing and 
an inert atmosphere over the reaction.  HPLC-MS analysis was performed on a Hewlett-Packard 
Series 1050 instrument equipped with a Waters Xterra MS C18 column (3.5μm packing, 4.6 mm 
x 150 mm) and a diode-array detector, while the MSD-ESI was Series 1100.  Preparative 
purification was done using a Varian Prostar 500 equipped with a Waters Xterra Prep MS-C18 
column (5μm packing, 10 mm x 100 mm), equipped with a dual wavelength detector. 
 
3-methoxy-5-nitrobenzoic acid (7). 
To a flame dried 1L, 3-neck round bottom flask equipped with a water-cooled condenser, N2 
line, and rubber septa, 65mL (1.5mol) of ultra-dry methanol was added through the rubber 
septum.  To this, ~1.4g (189mmol) of lithium ribbon was added with vigorous stirring, which 
was prepared by washing away the preservative mineral oil in a 100mL beaker of hexanes.  Care 
was taken to minimize air exposure of the washed lithium, which needed to quickly be weighed 
and returned to the hexanes until added to the reaction in a series of about 5 additions.  Vigorous 
reaction occurred between the methanol and lithium, producing heat and hydrogen gas 
(CAUTION).  A rubber septum was removed from the flask to minimize the dangerous pressure.  
Once the reaction subsided, the septum was replaced and the reaction allowed to stir for 30min.  
The solvent was then removed in vacuo and allowed to dry in vacuo for 30min.  The white solid 
was dissolved in 250mL of freshly distilled dimethylsulfoxide.  To this purple solution, 10.0g 
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(47.1mmol) of 3,5-dinitrobenzoic acid was added, and the reaction was stirred at ~50˚C under 
nitrogen for 18hrs.  The entire reaction contents were slowly poured into 750g ice and 75mL of 
concentrated H2SO4 (CAUTION), with care to avoid to splattering.  An orange precipitate which 
formed, which was mainly product, was filtered and put aside.  The remaining liquid was 
extracted 3 x 250mL EtOAc.  The organic layers were pooled to redissolve the orange 
precipitate.  The organic layers were washed 3 x 100mL water and 2 x 100mL brine, dried over 
sodium sulfate, and filtered.  The solvent was removed in vacuo to yield 8.5g (91%) product 
which was used without further purification.  1H NMR (300MHz, 25˚C, d6-acetone) δ 8.36 (m, 
1H), 7.96 (t, 1H), 7.90 (m, 1H), 4.02 (s, 3H). 
 
3-hydroxy-5-nitrobenzoic acid (8). 
To a 500mL round bottom flask equipped with a water cooled condenser, 150mL of aqueous 
hydrobromic acid (CAUTION) was added.  In a 250mL Erlenmeyer flask, 100mL of acetic acid 
was heated on a hot plate to ~50˚C and 6.8g (34.5mmol) of 3-methoxy-5-nitrobenzoic acid was 
added, and the mixture was allowed to stir until all product dissolved, with additional heating if 
necessary.  This solution was added to the HBr in the round bottom and the mixture was heated 
to 145˚C under nitrogen for 12hrs.  The solvent was removed with heating in vacuo, until a 
brown oil resulted.  After cooling, 250mL of EtOAc:hexanes (1:3) was added and stirred for 
5min.  The yellow top layer was carefully decanted away from the brown bottom layer.  This 
process was repeated at least three more times.  In most cases, additional brown oil would settle 
to the bottom.  Again, the yellow solution was carefully decanted away, and the solvent was 
removed in vacuo to yield 6.3g of product (86% yield).  The product could be recrystallized from 
25% aqueous HCl if needed, but in most cases the product was sufficiently pure by NMR and 
LCMS.  1H NMR (300MHz, 25˚C, d6-acetone) δ 8.27 (m, 1H), 7.90 (m, 2H). 
 
3-O-(2,3,4,6-tetraacetyl-D-galactopyranose)-5-nitrobenzoic acid (9). 
To a 250ml flame dried round bottom flask, 1.6g (8.7mmol) of 3-hydroxy-5-nitrobenzoic acid 
was added along with 2.9g (7.4mmol) peracetylgalactose, which was dried at 50˚C in vacuo for 
2days.  Then 90mL of extra-dry acetonitrile was added, along with a septum and nitrogen needle.  
The mixture was stirred under nitrogen for 10min, then 11.0mL (87.4mmol) boron trifluoride-
diethyletherate was added, and the reaction was stirred for 12hrs.  The solvent was removed in 
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vacuo.  The crude product reaction was dissolved in 15mL of methanol and loaded as a single 
injection onto a 120g-RP-C18-Isco column, equilibrated in 5% ACN (0.05% formic acid) / 95% 
water (0.1% formic acid).  A gradient from 5-95% ACN separated the mixture.  Product fractions 
were identified by reinjection onto an HPLC or LCMS and pooled, and the solvent was removed 
by lyophilization to yield about 600mg of product, usually in ~15% yield.  1H NMR (300MHz, 
25˚C, d6-acetone) δ 8.68 (m, 1H), 8.46 (t, 1H), 8.37 (m, 1H), 6.32 (d, 1H, J = 3.6Hz), 5.94 (d, 
0.2H, J = 7.8), 5.76 (m, 2H), 5.59 (dd, 1H, J = 3.6Hz, 10.7Hz), 4.75 (t, 1H, J = 6.3Hz), 4.39 (d, 
2H, J = 6.4Hz), 2.38 (s, 3H), 2.27 (s, 3H), 2.18 (s, 3H), 2.04 (s, 3H). 
 
3-O-(D-galactopyranose)-5-nitrobenzoic acid (10). 
To a 250mL round bottom flask, 780mg (1.52mmol) of 3-O-(2,3,4,6-tetraacetyl-D-
galactopyranose)-5-nitrobenzoic acid was added into 50mL of methanol.  To this, 1.1mL of 
25%NaOMe/MeOH was added and allowed to stir for 15min (color change to yellow when 
methoxide added).  The reaction was quenched by addition of 1mL TFA in 20mL of methanol, 
which changed the color back to clear.  The solvent was removed in vacuo to yield a crude 
product that was used without further purification or characterization besides LCMS. 
 
3-O-(α-D-galactopyranose)-5-nitrobenzoic acid (11). 
The crude product from the previous step was dissolved in autoclaved buffer consisting of 50mM 
Tris-HCl (pH 7.4), 250mM NaCl, and 1mM MgCl2, at an estimated concentration of 10mM.  To 
this, a few flakes (~10-100μg) of β-galactosidase were added, and the enzyme was allowed to 
react in a 50mL conical for 12hrs.  The reaction was deemed to be complete (no more beta 
anomer) when the starting material peak and the hydrolyzed phenol peak ceased to change, as 
seen by HPLC.  The reaction was lyophilized, redissolved an 5mL of 10% ACN/water, and 
injected onto the 40g-RP-C18-Isco and separated using a 5-45% ACN gradient using ACN 
(0.05% formic acid) and 95% water (0.1% formic acid).  Fractions containing pure product were 
identified by LCMS or HPLC and lyophilized to give desired product, typically 100-300mg 
depending on initial scale and anomeric purity.  1H NMR (300MHz, 25˚C, d4-methanol) δ 8.37 
(m, 1H), 8.20 (m, 1H), 8.10 (m, 1H), 5.71 (d, 1H, J = 3.0Hz), 4.02 (m, 3H,), 3.93 (t, 1H, J = 
6.0Hz), 3.73 (d, 2H, J = 6.0Hz). 
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3-O-(2,3,4,6-tetraacetyl-α-D-galactopyranose)-5-nitrobenzoic acid (12). 
The purified alpha product (200mg, 0.58mmol) was transferred to a 25mL round bottom flask 
and 3mL of acetic anhydride was added along with 10mg dimethylaminopyridine.  The reaction 
proceeded as a suspension initially, but after ~30min all product was in solution.  At this point, 
the unsymmetrical carboxy-anhydride as well as the excess acetic anhydride were both 
hydrolyzed by the addition of 10mL ACN:water (1:1).  Two layers initially formed, but after 
10min a single layer remained.  The reaction could be accelerated by addition of ~0.1mL TFA, in 
which case, a single layer formed immediately.  The reaction was directly injected onto the 40g-
RP-C18-Isco column, and purified using a 5-95% ACN gradient using ACN (0.05% formic acid) 
and 95% water (0.1% formic acid).  Fractions containing pure product were identified by LCMS 
or HPLC and lyophilized to give desired product (280mg) in a ~90% yield.  1H NMR (300MHz, 
25˚C, d6-acetone) δ 8.68 (m, 1H), 8.46 (t, 1H), 8.37 (m, 1H), 6.32 (d, 1H, J = 3.6Hz), 5.76 (m, 
2H), 5.59 (dd, 1H, J = 3.6Hz, 10.7Hz), 4.75 (t, 1H, J = 6.3Hz), 4.39 (d, 2H, J = 6.4Hz), 2.38 (s, 
3H), 2.27 (s, 3H), 2.18 (s, 3H), 2.04 (s, 3H). 
 
4-Carbamoyl-4-Fmoc-1-Cbz-pyrrolidine-2-carboxylic acid-tert-butyl ester (2S4S in this 
case). 
To a 25mL round bottom flask, 917mg of 4-Carboxy-4-Fmoc-1-Cbz-pyrrolidine-2-carboxylic 
acid-tert-butyl ester[17] (1.56mmol) was added along with 8.0mL of DMF.  To this, 715mg of 
HATU (1.88mmol) was added, followed by 0.8mL of DIPEA (4.0mmol).  After stirring for 
5min, a yellow color was observed, to which 3.6mL of 0.5M solution of ammonia in dioxane 
(1.8mmol) was added, and allowed to stir under nitrogen for 3hr.  The crude reaction was 
injected onto a 40g Isco column, equilibrated in chloroform.  A gradient of chloroform to 10% 
methanol/chloroform served to purify the product.  The product fractions were pooled and the 
solvent removed in vacuo to yield 760mg of product (83%).   
 
4-Carbamoyl-4-Fmoc-1-Cbz-pyrrolidine-2-carboxylic acid (2S4S in this case). 
To a 50mL round bottom flask, 500mg of 4-Carbamoyl-4-Fmoc-1-Cbz-pyrrolidine-2-carboxylic 
acid-tert-butyl ester (0.85mmol) was added, followed by 0.5mL of DCM, then 17mL of TFA.  
The reaction was stirred for 2hrs.  The solvent was removed in vacuo, and methanol or DCM 
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were alternatively added and then removed in vacuo to azeotrope the TFA.  The material was 
used for the next step without further purification. 
 
4-Carbamoyl-4-Fmoc-1-Boc-pyrrolidine-2-carboxylic acid (2S4S in this case) (13). 
To a 100mL round bottom flask, ~450mg of crude 4-Carbamoyl-4-Fmoc-1-Cbz-pyrrolidine-2-
carboxylic acid (0.85mmol) was added, followed by 25mL of tetrahydrofuran.  To this stirred 
solution, 0.78mL of Boc-anhydride (3.4mmol) and 100mg of Pd/C were added.  A double-thick 
balloon filled with hydrogen was added to a three-way valve attached to the greased round 
bottom.  An aspirator was added and at least 5 cycles of aspiration followed by H2 backfill 
served to degas the solvent and charge the palladium with hydrogen.  The reaction was stirred for 
between 24-96hr, until the Cbz had entirely been exchanged for a Boc, as judged by LCMS.  The 
reaction was filtered, and the Pd/C was washed several times with DCM.  The solvent was 
removed in vacuo.  The crude reaction was dissolved in 5mL of chloroform and injected onto a 
40g Isco column, equilibrated in chloroform.  A gradient of chloroform to 10% 
methanol/chloroform served to purify the product.  The product fractions were pooled and the 
solvent removed in vacuo to yield 370mg of product (87% over two steps).  1H NMR (300MHz, 
25˚C, CDCl3) δ 7.75 (d, 2H, J=7.4Hz), δ 7.54 (d, 2H, J=7.2Hz), δ 7.39 (m, 4H), δ 6.32 (br 1H), δ 
6.13 (br, 1H), δ 5.85 (br, 1H), δ 4.52 (m, 2H), δ 4.19 (m, 1H), δ 4.01 (m, 1H), δ 3.85 (m, 1H), δ 
2.56 (m, 2H), δ 1.45 (s, 9H), 
 
Synthesis of the fluorescein labeled Orn (+) control (21). 
 




To a 1.25mL polypropylene solid phase peptide synthesis (SPPS) reaction vessel was 
added Rink Amide Resin (Novabiochem) (5mg, 3.2μmol loading).  The resin was swelled for 1hr 
in DMF.  The terminal Fmoc-protected amine was deprotected in 1mL of 20% piperidine/DMF 
for 40min.  By measuring the absorbance at 301nm of a 1/100 dilution, the number of moles of 
Fmoc removed was calculated by using ε = 7800 M-1 cm-1.  The resin was washed with DMF, 
isopropanol, DMF, isopropanol, DMF, for 2min each. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 9.6mg 
(15.8μmol) of Fmoc-L-Orn(Mtt)-OH (Novabiochem) and 6.0mg of HATU (15.8μmol) in 80μL 
of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 5.5μL 
(31.5μmol) of DIPEA was added to make the active ester.  After 10min activation time, the 
solution was added to the deprotected resin, and allowed to react by argon mixing for 30min.  
The resin was then washed 3 x 2min with DMF.  Double couplings allowed for quantitative 
acylation, as judged by subsequent Fmoc release in the same manner described above. 
 (ALL steps forward done in the dark)  In a 1.5mL microcentrifuge tube, the coupling 
solution was made by dissolving 11.8mg (31.5μmol) of 5-carboxyfluorescein (Probes) and 
4.8mg of HOBt (31.5μmol) in 165μL of DMF.  This solution was mixed using a micropipettor, 
after which 4.9μL (31.5μmol) of diisopropylcarbodiimide was added to make the active ester.  
After 10min activation time, the solution was aliquoted to the deprotected resin, and allowed to 
react by argon mixing for 12hr  The resin was then washed 3 x 2min with DMF, the 3 x 1min 
~5%piperidine/DMF, repeating these two washes 3x more.  Then the resins were extensively 
washed with DMF, IPA, DMF, IPA, and DMF for 2min each. 
The resin was swelled in DCM with slight bubbling for 30min.  The Orn side chain 
protecting group, methytrityl, was removed using a 1% trifluoroacetic acid, 5% triisopropylsilane 
solution in DCM.  10 x 1mL, each reacting for about 2-3 minutes was sufficient to completely 
unmask the side chain amine.  Neutralization with 2 x 0.5mL of 5% DIPEA in DCM followed by 
swelling in DMF readied the resin for acylation.   
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 8.1mg 
(15.8μmol) of the acetyl-protected ligand (12) and 6.0mg of HATU (15.8μmol) in 80μL of 20% 
DCM/DMF.  This solution was mixed using a micropipettor, after which 5.5μL (31.5μmol) of 
DIPEA was added to make the active ester and then after 10min, aliquoted to the resins as above, 
followed by washing, and a second coupling.  The resin was then washed 3 x 2min with DMF, 
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the 3 x 1min ~5%piperidine/DMF, repeating these two washes 3x more.  Then the resins were 
extensively washed with DMF, IPA, DMF, IPA, DMF, MeOH, DCM, MeOH, DCM, MeOH, 
DCM, and then dried overnight, in vacuo. 
The product was cleaved in 0.75mL of 2.5% water, 2.5% triisopropylsilane in 
trifluoroacetic acid, with stirring for 2hour.  The solution was drained and the beads were then 
washed with 2 x 2mL additional TFA.  The washes were pooled with the cleavage solutions in a 
13mm glass tube and the solvent was removed in a SpeedVac.   
The acetylated ligand was dissolved in 200μL of methanol and mixed with a pipettor.  
Then, 2μL of 25% NaOMe/MeOH was added to each sample, mixed via pipettor, and allowed to 
react for 15min.  The reaction was quenched with 400μL of 0.1M HCl, frozen, and lyophilized. 
The crude product, along with NaCl salts, was dissolved in 75μL of 20% piperidine/NMP 
and allowed to react at room temperature for 36hrs.  The crude reaction was filtered, and injected 
as a single injection onto the analytical HPLC column for purification.  Fractions containing the 
desired product were identified by reinjection on the LCMS and lyophilized.  The sample was 
stored in the dark at 4˚C until needed. 
 
Synthesis of the fluorescein labeled resin-bound intermediate (14). 
 
Figure 55 Resin-bound scaffold used in the synthesis of fluorescein labeled bivalent ligands, varying in βAla. 
 
To a 15mL polypropylene solid phase peptide synthesis (SPPS) reaction vessel was 
added Rink Amide Resin (Novabiochem) (25mg, 16μmol loading).  The resin was swelled for 
1hr in DMF.  The terminal Fmoc-protected amine was deprotected in 1mL of 20% 
piperidine/DMF for 40min.  By measuring the absorbance at 301nm of a 1/200 dilution, the 
14 
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number of moles of Fmoc removed was calculated by using ε = 7800 M-1 cm-1.  The resin was 
washed with DMF, isopropanol, DMF, isopropanol, DMF, for 2min each. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 45.8mg 
(75μmol) of Fmoc-L-Orn(Mtt)-OH (Novabiochem) and 28.5mg of HATU (75μmol) in 375μL of 
20% DCM/DMF.  This solution was mixed using a micropipettor, after which 26.1μL (150μmol) 
of DIPEA was added to make the active ester.  After 10min activation time, the solution was 
added to the deprotected resin, and allowed to react by argon mixing for 30min.  The resin was 
then washed 3 x 2min with DMF.  Double couplings allowed for quantitative acylation, as 
judged by subsequent Fmoc release in the same manner described above. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 15.3mg 
(30μmol) of Boc-protected pro4(2S4S)[17] building block and 11.4mg of HATU (30μmol) in 
150μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 10.5μL 
(60μmol) of DIPEA was added to make the active ester, as above, followed by washing, a second 
coupling, washing, and Fmoc release.   
This process of coupling/deprotection was repeated three additional times. After the 
fourth Fmoc deprotection, the resin was washed with DCM several times, and allowed to dry for 
five minutes via aspiration.  The beads were now easily removed from the reactor and then 
weighed.  An appropriate weight fraction (i.e. 1/5th removed after 4th building block was coupled, 
then 1/4th after 5th building block, etc.) was then removed, placed in a fresh 1.0 mL reactor and 
stored in a desiccator.  The remaining resin was then swelled in DMF for 10 min.  The process of 
coupling/deprotection/aliquot removed was repeated four additional times, making 5 portions of 
equimolar amounts of 5 different lengths, 4-8 building blocks, with the final amine deblocked, 
yielding the sequence, resin-Orn(Mtt)-SS3-(SS)n-free amine (n=1-5). 
The final building block coupled to all of the sequences was the SS-Amide (13).  In a 
1.5mL microcentrifuge tube, the coupling solution was made by dissolving 14.9mg (30μmol) of 
Boc-protected pro4(2S4S)-amide building block and 11.4mg of HATU (30μmol) in 150μL of 
20% DCM/DMF.  This solution was mixed using a micropipettor, after which 10.5μL (60μmol) 
of DIPEA was added to make the active ester and then after 10min, aliquoted to the resins as 
above, followed by washing, and a second coupling, washing, and Fmoc release. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 45.8mg 
(75μmol) of Fmoc-L-Orn(Mtt)-OH (Novabiochem) and 28.5mg of HATU (75μmol) in 375μL of 
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20% DCM/DMF.  This solution was mixed using a micropipettor, after which 26.1μL (150μmol) 
of DIPEA was added to make the active ester and then after 10min, aliquoted to the resins as 
above, followed by washing, and a second coupling, washing, and Fmoc release. 
(ALL steps forward done in the dark)  In a 1.5mL microcentrifuge tube, the coupling 
solution was made by dissolving 56.4mg (150μmol) of 5-carboxyfluorescein (Probes) and 23.0 
of HOBt (150μmol) in 750μL of DMF.  This solution was mixed using a micropipettor, after 
which 23.2μL (150μmol) of diisopropylcarbodiimide was added to make the active ester.  After 
10min activation time, the solution was aliquoted to the deprotected resin, and allowed to react 
by argon mixing for 12hr  The resin was then washed 3 x 2min with DMF, the 3 x 1min 
~5%piperidine/DMF, repeating these two washes 3x more.  Then the resins were extensively 
washed with DMF, IPA, DMF, IPA, and DMF for 2min each (14) 
The resin was swelled in DCM with slight bubbling for 30min.  The Orn side chain 
protecting group, methytrityl, was removed using a 1% trifluoroacetic acid, 5% triisopropylsilane 
solution in DCM.  10 x 1mL, each reacting for about 2-3 minutes was sufficient to completely 
unmask the side chain amine.  Neutralization with 2 x 0.5mL of 5% DIPEA in DCM followed by 
swelling in DMF readied the resin for acylation.  Then the resins were extensively washed with 
DMF, IPA, DMF, IPA, DMF, MeOH, DCM, MeOH, DCM, MeOH, DCM, and then dried 
overnight, in vacuo.  Each length sample were aliquoted into 3 equal portions for incorporation 
of n βAla (n = 0, 1, or 2). 
 
Synthesis of fluorescein labeled bivalent ligands (18). 
 




In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 33.6mg 
(60μmol) of the acetyl-protected ligand (12) and 22.8mg of HATU (60μmol) in 600μL of 20% 
DCM/DMF.  This solution was mixed using a micropipettor, after which 20.9μL (120μmol) of 
DIPEA was added to make the active ester and then after 10min, aliquoted to the resins as above, 
followed by washing, and a second coupling.  The resin was then washed 3 x 2min with DMF, 
the 3 x 1min ~5%piperidine/DMF, repeating these two washes 3x more.  Then the resins were 
extensively washed with DMF, IPA, DMF, IPA, DMF, MeOH, DCM, MeOH, DCM, MeOH, 
DCM, and then dried overnight, in vacuo. 
The scaffolds were cleaved in 0.75mL of 2.5% water, 2.5% triisopropylsilane in 
trifluoroacetic acid, with stirring for 2hour.  The solutions were drained and the beads were then 
washed with 2 x 2mL additional TFA.  The washes were pooled with the cleavage solutions in a 
13mm glass tube and the solvent was removed in a SpeedVac.   
The bivalent-acetylated ligands were dissolved in 200μL of methanol and mixed with a 
pipettor.  Then, 2μL of 25% NaOMe/MeOH was added to each sample, mixed via pipettor, and 
allowed to react for 15min.  The reaction was quenched with 400μL of 0.1M HCl, frozen, and 
lyophilized. 
The crude product, along with NaCl salts, was dissolved in 75μL of 20% piperidine/NMP 
and allowed to react at room temperature for 36hrs.  The crude reaction was filtered, and injected 
as a single injection onto the analytical HPLC column for purification.  Fractions containing the 
desired product were identified by reinjection on the LCMS and lyophilized.  The samples were 
stored in the dark at 4˚C until needed. 
 
Synthesis of fluorescein labeled bivalent ligands containing 1βAla (19). 
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Figure 57 Fluorescein labeled bivalent ligands containing 1 βAla, with lengths of 5-9 building blocks. 
 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 22.3mg 
(75μmol) of Fmoc-βAla-OH (Novabiochem) and 28.5mg of HATU (75μmol) in 375μL of 20% 
DCM/DMF.  This solution was mixed using a micropipettor, after which 26.1μL (150μmol) of 
DIPEA was added to make the active ester and then after 10min, aliquoted to the resins as above, 
followed by washing, and a second coupling, washing, and Fmoc release. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 33.6mg 
(60μmol) of the acetyl-protected ligand (12) and 22.8mg of HATU (60μmol) in 600μL of 20% 
DCM/DMF.  This solution was mixed using a micropipettor, after which 20.9μL (120μmol) of 
DIPEA was added to make the active ester and then after 10min, aliquoted to the resins as above, 
followed by washing, and a second coupling.  The resin was then washed 3 x 2min with DMF, 
the 3 x 1min ~5%piperidine/DMF, repeating these two washes 3x more.  Then the resins were 
extensively washed with DMF, IPA, DMF, IPA, DMF, MeOH, DCM, MeOH, DCM, MeOH, 
DCM, and then dried overnight, in vacuo. 
The scaffolds were cleaved in 0.75mL of 2.5% water, 2.5% triisopropylsilane in 
trifluoroacetic acid, with stirring for 2hour.  The solutions were drained and the beads were then 
washed with 2 x 2mL additional TFA.  The washes were pooled with the cleavage solutions in a 
13mm glass tube and the solvent was removed in a SpeedVac.   
The bivalent-acetylated ligands were dissolved in 200μL of methanol and mixed with a 
pipettor.  Then, 2μL of 25% NaOMe/MeOH was added to each sample, mixed via pipettor, and 




The crude product, along with NaCl salts, was dissolved in 75μL of 20% piperidine/NMP 
and allowed to react at room temperature for 36hrs.  The crude reaction was filtered, and injected 
as a single injection onto the analytical HPLC column for purification.  Fractions containing the 
desired product were identified by reinjection on the LCMS and lyophilized.  The samples were 
stored in the dark at 4˚C until needed. 
 
Synthesis of fluorescein labeled bivalent ligands containing 2βAla (20). 
 
Figure 58 Fluorescein labeled bivalent ligands containing 2 βAla, with lengths of 5-9 building blocks. 
 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 22.3mg 
(75μmol) of Fmoc-βAla-OH (Novabiochem) and 28.5mg of HATU (75μmol) in 375μL of 20% 
DCM/DMF.  This solution was mixed using a micropipettor, after which 26.1μL (150μmol) of 
DIPEA was added to make the active ester and then after 10min, aliquoted to the resins as above, 
followed by washing, and a second coupling, washing, and Fmoc release. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 22.3mg 
(75μmol) of Fmoc-βAla-OH (Novabiochem) and 28.5mg of HATU (75μmol) in 375μL of 20% 
DCM/DMF.  This solution was mixed using a micropipettor, after which 26.1μL (150μmol) of 
DIPEA was added to make the active ester and then after 10min, aliquoted to the resins as above, 
followed by washing, and a second coupling, washing, and Fmoc release. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 33.6mg 
(60μmol) of the acetyl-protected ligand (12) and 22.8mg of HATU (60μmol) in 600μL of 20% 
DCM/DMF.  This solution was mixed using a micropipettor, after which 20.9μL (120μmol) of 
DIPEA was added to make the active ester and then after 10min, aliquoted to the resins as above, 
followed by washing, and a second coupling.  The resin was then washed 3 x 2min with DMF, 
20 
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the 3 x 1min ~5%piperidine/DMF, repeating these two washes 3x more.  Then the resins were 
extensively washed with DMF, IPA, DMF, IPA, DMF, MeOH, DCM, MeOH, DCM, MeOH, 
DCM, and then dried overnight, in vacuo. 
The scaffolds were cleaved in 0.75mL of 2.5% water, 2.5% triisopropylsilane in 
trifluoroacetic acid, with stirring for 2hour.  The solutions were drained and the beads were then 
washed with 2 x 2mL additional TFA.  The washes were pooled with the cleavage solutions in a 
13mm glass tube and the solvent was removed in a SpeedVac.   
The bivalent-acetylated ligands were dissolved in 200μL of methanol and mixed with a 
pipettor.  Then, 2μL of 25% NaOMe/MeOH was added to each sample, mixed via pipettor, and 
allowed to react for 15min.  The reaction was quenched with 400μL of 0.1M HCl, frozen, and 
lyophilized. 
The crude product, along with NaCl salts, was dissolved in 75μL of 20% piperidine/NMP 
and allowed to react at room temperature for 36hrs.  The crude reaction was filtered, and injected 
as a single injection onto the analytical HPLC column for purification.  Fractions containing the 
desired product were identified by reinjection on the LCMS and lyophilized.  The samples were 
stored in the dark at 4˚C until needed. 
 
Synthesis of the fluorescein labeled Dpr (+) controls (23, 24). 
 
Figure 59 Fluorescein labeled Dpr-(+) controls 
 
To 2 x 1.25mL polypropylene solid phase peptide synthesis (SPPS) reaction vessels were 
added Rink Amide Resin (Novabiochem) (5mg, 3.2μmol loading).  The resins were swelled for 
23 24 
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1hr in DMF.  The terminal Fmoc-protected amine was deprotected in 1mL of 20% 
piperidine/DMF for 40min.  By measuring the absorbance at 301nm of a 1/100 dilution, the 
number of moles of Fmoc removed was calculated by using ε = 7800 M-1 cm-1.  The resin was 
washed with DMF, isopropanol, DMF, isopropanol, DMF, for 2min each. 
In 2 x 1.5mL microcentrifuge tube, the coupling solutions were made by dissolving 
9.2mg (15.8μmol) of Fmoc-L-Dpr(Mtt)-OH (Novabiochem) OR 6.7mg (15.8μmol) of Fmoc-L-
Dpr(Boc)-OH (Novabiochem) and 6.0mg of HATU (15.8μmol) in 80μL of 20% DCM/DMF.  
These solutions were mixed using a micropipettor, after which 5.5μL (31.5μmol) of DIPEA was 
added to make the active ester.  After 10min activation time, the solutions were added to the 
deprotected resin, and allowed to react by argon mixing for 30min.  The resins were then washed 
3 x 2min with DMF.  Double couplings allowed for quantitative acylation, as judged by 
subsequent Fmoc release in the same manner described above. 
In 2 x 1.5mL microcentrifuge tube, the coupling solutions were made by dissolving 
3.2mg (6.3μmol) of Boc-protected pro4(2S4S) building block [17] and 2.4mg of HATU 
(6.3μmol) in 40μL of 20% DCM/DMF.  These solutions were mixed using a micropipettor, after 
which 2.2μL (12.6μmol) of DIPEA was added to make the active ester, as above, followed by 
washing, a second coupling, washing, and Fmoc release.   
The final building block coupled to all of the sequences was the Boc-protected Amide-
pro4(2S4S) (13).  In 7 x 1.5mL microcentrifuge tube, the coupling solutions were made by 
dissolving 3.2mg (6.3μmol) of Boc-protected pro4-amide building block and 2.4mg of HATU 
(6.3μmol) in 40μL of 20% DCM/DMF.  These solutions were mixed using a micropipettor, after 
which 2.2μL (12.6μmol) of DIPEA was added to make the active ester and then after 10min, 
aliquoted to the resins as above, followed by washing, and a second coupling, washing, and 
Fmoc release. 
In 2 x 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 6.7mg 
(15.8μmol) of Fmoc-L-Dpr(Boc)-OH (Novabiochem) OR 9.2mg (15.8μmol) of Fmoc-L-
Dpr(Mtt)-OH (Novabiochem) and 6.0mg of HATU (15.8μmol) in 80μL of 20% DCM/DMF.  
These solutions were mixed using a micropipettor, after which 5.5μL (31.5μmol) of DIPEA was 
added to make the active ester and then after 10min, aliquoted to the resins as above, followed by 
washing, and a second coupling, washing, and Fmoc release. 
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 (ALL steps forward done in the dark)  In a 1.5mL microcentrifuge tube, the coupling 
solution was made by dissolving 11.8mg (31.5μmol) of 5-carboxyfluorescein (Probes) and 
4.8mg of HOBt (31.5μmol) in 165μL of DMF.  This solution was mixed using a micropipettor, 
after which 4.9μL (31.5μmol) of diisopropylcarbodiimide was added to make the active ester.  
After 10min activation time, the solution was aliquoted to the deprotected resin, and allowed to 
react by argon mixing for 12hr  The resin was then washed 3 x 2min with DMF, the 3 x 1min 
~5%piperidine/DMF, repeating these two washes 3x more.  Then the resins were extensively 
washed with DMF, IPA, DMF, IPA, and DMF for 2min each. 
The resin was swelled in DCM with slight bubbling for 30min.  The Orn side chain 
protecting group, methytrityl, was removed using a 1% trifluoroacetic acid, 5% triisopropylsilane 
solution in DCM.  10 x 1mL, each reacting for about 2-3 minutes was sufficient to completely 
unmask the side chain amine.  Neutralization with 2 x 0.5mL of 5% DIPEA in DCM followed by 
swelling in DMF readied the resin for acylation.   
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 8.1mg 
(15.8μmol) of the acetyl-protected ligand (12) and 6.0mg of HATU (15.8μmol) in 80μL of 20% 
DCM/DMF.  This solution was mixed using a micropipettor, after which 5.5μL (31.5μmol) of 
DIPEA was added to make the active ester and then after 10min, aliquoted to the resins as above, 
followed by washing, and a second coupling.  The resin was then washed 3 x 2min with DMF, 
the 3 x 1min ~5%piperidine/DMF, repeating these two washes 3x more.  Then the resins were 
extensively washed with DMF, IPA, DMF, IPA, DMF, MeOH, DCM, MeOH, DCM, MeOH, 
DCM, and then dried overnight, in vacuo. 
The product was cleaved in 0.75mL of 2.5% water, 2.5% triisopropylsilane in 
trifluoroacetic acid, with stirring for 2hour.  The solution was drained and the beads were then 
washed with 2 x 2mL additional TFA.  The washes were pooled with the cleavage solutions in a 
13mm glass tube and the solvent was removed in a SpeedVac.   
The acetylated ligand was dissolved in 200μL of methanol and mixed with a pipettor.  
Then, 2μL of 25% NaOMe/MeOH was added to each sample, mixed via pipettor, and allowed to 
react for 15min.  The reaction was quenched with 400μL of 0.1M HCl, frozen, and lyophilized. 
The crude product, along with NaCl salts, was dissolved in 75μL of 20% piperidine/NMP 
and allowed to react at room temperature for 36hrs.  The crude reaction was filtered, and injected 
as a single injection onto the analytical HPLC column for purification.  Fractions containing the 
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desired product were identified by reinjection on the LCMS and lyophilized.  The sample was 
stored in the dark at 4˚C until needed. 
 
Synthesis of resin bound predicted fluorescein labeled scaffolds (22). 
 
Figure 60 Generic resin bound scaffold structure used in the synthesis of predicted fluorescein labeled bivalent 
ligands. 
 
To 7 x 1.25mL polypropylene solid phase peptide synthesis (SPPS) reaction vessels were 
added Rink Amide Resin (Novabiochem) (5mg, 3.2μmol loading).  The resins were swelled for 
1hr in DMF.  The terminal Fmoc-protected amines were deprotected in 1mL of 20% 
piperidine/DMF for 40min.  By measuring the absorbance at 301nm of a 1/200 dilution, the 
number of moles of Fmoc removed was calculated by using ε = 7800 M-1 cm-1.  The resins were 
washed with DMF, isopropanol, DMF, isopropanol, DMF, for 2min each. 
 




In 7 x 1.5mL microcentrifuge tube, the coupling solutions were made by dissolving 
9.2mg (15.8μmol) of Fmoc-Dpr(Mtt)-OH (Novabiochem) and 6.0mg of HATU (15.8μmol) in 
80μL of 20% DCM/DMF.  These solutions were mixed using a micropipettor, after which 5.5μL 
(31.5μmol) of DIPEA were added to each to make the active ester.  After 10min activation time, 
the solutions were added to the deprotected resin, and allowed to react by argon mixing for 
30min.  The resin were then washed 3 x 2min with DMF.  Double couplings allowed for 
quantitative acylation, as judged by subsequent Fmoc release in the same manner described 
above. 
In 7 x 1.5mL microcentrifuge tube, the coupling solutions were made by dissolving 
3.2mg (6.3μmol) of Boc-protected pro4 building block [17] and 2.4mg of HATU (6.3μmol) in 
40μL of 20% DCM/DMF.  These solutions were mixed using a micropipettor, after which 2.2μL 
(12.6μmol) of DIPEA was added to make the active ester, as above, followed by washing, a 
second coupling, washing, and Fmoc release.   
This process of coupling/deprotection was repeated 6 or 7 additional times. The final 
building block coupled to all of the sequences was the SS-Amide (13).  In 7 x 1.5mL 
microcentrifuge tube, the coupling solutions were made by dissolving 3.2mg (6.3μmol) of Boc-
protected pro4-amide building block and 2.4mg of HATU (6.3μmol) in 40μL of 20% 
DCM/DMF.  These solutions were mixed using a micropipettor, after which 2.2μL (12.6μmol) of 
DIPEA was added to make the active ester and then after 10min, aliquoted to the resins as above, 
followed by washing, and a second coupling, washing, and Fmoc release. 
In 7 x 1.5mL microcentrifuge tube, the coupling solutions were made by dissolving 
9.2mg (15.8μmol) of Fmoc-Dpr(Mtt)-OH (Novabiochem) and 6.0mg of HATU (15.8μmol) in 
80μL of 20% DCM/DMF.  This solutions were mixed using a micropipettor, after which 5.5μL 
(31.5μmol) of DIPEA was added to make the active ester, as above, followed by washing, a 
second coupling, washing, and Fmoc release.   
 (ALL steps forward done in the dark)  In 7 x 1.5mL microcentrifuge tube, the 
coupling solutions were made by dissolving 11.8mg (31.5μmol) of 5-carboxyfluorescein 
(Probes) and 4.8 of HOBt (31.5μmol) in 160μL of DMF.  These solutions were mixed using a 
micropipettor, after which 4.9μL (31.5μmol) of diisopropylcarbodiimide was added to make the 
active ester.  After 10min activation time, the solutions were aliquoted to the deprotected resin, 
and allowed to react by argon mixing for 12hr  The resins were then washed 3 x 2min with DMF, 
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the 3 x 1min ~5%piperidine/DMF, repeating these two washes 3x more.  Then the resins were 
extensively washed with DMF, IPA, DMF, IPA, and DMF for 2min each. 
The resins were swelled in DCM with slight bubbling for 30min.  The Orn side chain 
protecting groups, methytrityl, were removed using a 1% trifluoroacetic acid, 5% 
triisopropylsilane solution in DCM.  10 x 1mL, each reacting for about 2-3 minutes was 
sufficient to completely unmask the side chain amine.  Neutralization with 2 x 0.5mL of 5% 
DIPEA in DCM followed by swelling in DMF readied the resin for acylation.  Then the resins 
were extensively washed with DMF, IPA, DMF, IPA, DMF, MeOH, DCM, MeOH, DCM, 
MeOH, DCM, and then dried overnight, in vacuo.  Each of the 7 sequences were split into ~4 
portions, to be used for bivalent ligands, bivalent PEG ligands, bivalent spin labels or bivalent (-) 
controls. 
 
Synthesis of predicted fluorescein labeled bivalent scaffolds (25). 
 
Figure 62 Fluorescein labeled predicted bivalent ligands (seq1-7). 
 
In 7 x 1.5mL microcentrifuge tubes, the coupling solutions were made by dissolving 
7.1mg (12.6μmol) of the acetyl-protected ligand (12) and 4.8mg of HATU (12.6μmol) in 65μL 
of 20% DCM/DMF.  These solutions were mixed using a micropipettor, after which 4.4μL 
(25.2μmol) of DIPEA was added to make the active ester and then after 10min, aliquoted to the 
resins as above, followed by washing, and a second coupling.  The resins were then washed 3 x 
2min with DMF, the 3 x 1min ~5%piperidine/DMF, repeating these two washes 3x more.  Then 
the resins were extensively washed with DMF, IPA, DMF, IPA, DMF, MeOH, DCM, MeOH, 
DCM, MeOH, DCM, and then dried overnight, in vacuo. 
25 
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The scaffolds were cleaved in 0.75mL of 2.5% water, 2.5% triisopropylsilane in 
trifluoroacetic acid, with stirring for 2hour.  The solutions were drained and the beads were then 
washed with 2 x 2mL additional TFA.  The washes were pooled with the cleavage solutions in a 
13mm glass tube and the solvent was removed in a SpeedVac.   
The bivalent-acetylated ligands were dissolved in 200μL of methanol and mixed with a 
pipettor.  Then, 2μL of 25% NaOMe/MeOH was added to each sample, mixed via pipettor, and 
allowed to react for 15min.  The reaction was quenched with 400μL of 0.1M HCl, frozen, and 
lyophilized. 
The crude product, along with NaCl salts, was dissolved in 75μL of 20% piperidine/NMP 
and allowed to react at room temperature for 36hrs.  The crude reaction was filtered, and injected 
as a single injection onto the analytical HPLC column for purification.  Fractions containing the 
desired product were identified by reinjection on the LCMS and lyophilized.  The samples were 
stored in the dark at 4˚C until needed. 
 
Synthesis of fluorescein labeled bivalent spin probes (26). 
 
Figure 63 Fluorescein labeled predicted bivalent spin probes (seq5-7). 
 
In 3 x 1.5mL microcentrifuge tubes, the coupling solutions were made by dissolving 
5.8mg (31.5μmol) of the 2,2,5,5-Tetramethyl-3-pyrrolin-1-oxyl-3-carboxylic Acid (Acros) and 
11.9mg of HATU (31.5μmol) in 165μL of 20% DCM/DMF.  These solutions were mixed using 
a micropipettor, after which 11.0μL (63.0μmol) of DIPEA was added to make the active ester 
and then after 10min, aliquoted to the resin seq5-7 as above, followed by washing, and a second 
coupling.  The resins were then washed 3 x 2min with DMF, the 3 x 1min ~5%piperidine/DMF, 
26 
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repeating these two washes 3x more.  Then the resins were extensively washed with DMF, IPA, 
DMF, IPA, DMF, MeOH, DCM, MeOH, DCM, MeOH, DCM, and then dried overnight, in 
vacuo. 
The scaffolds were cleaved in 0.75mL of 2.5% water, 2.5% triisopropylsilane in 
trifluoroacetic acid, with stirring for 2hour.  The solutions were drained and the beads were then 
washed with 2 x 2mL additional TFA.  The washes were pooled with the cleavage solutions in a 
13mm glass tube and the solvent was removed in a SpeedVac.   
The crude product was dissolved in 75μL of 20% piperidine/NMP and allowed to react at 
room temperature for 36hrs.  The crude reaction was filtered, and injected as a single injection 
onto the analytical HPLC column for purification.  Fractions containing the desired product were 
identified by reinjection on the LCMS and lyophilized.  The samples were stored in the dark at 
4˚C until needed. 
 
Synthesis of fluorescein labeled bivalent (-) control scaffold (27). 
 
Figure 64 Fluorescein labeled predicted bivalent (-) control (seq2). 
 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 6.2mg 
(31.5μmol) of the 3-methoxy-5-nitrobenzoic acid (7) and 11.9mg of HATU (31.5μmol) in 165μL 
of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 11.0μL 
(63.0μmol) of DIPEA was added to make the active ester and then after 10min, added to resin 
seq2 as above, followed by washing, and a second coupling.  The resin was then washed 3 x 
2min with DMF, the 3 x 1min ~5%piperidine/DMF, repeating these two washes 3x more.  Then 
the resins were extensively washed with DMF, IPA, DMF, IPA, DMF, MeOH, DCM, MeOH, 
DCM, MeOH, DCM, and then dried overnight, in vacuo. 
27 
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The scaffold was cleaved in 0.75mL of 2.5% water, 2.5% triisopropylsilane in 
trifluoroacetic acid, with stirring for 2hour.  The solution was drained and the beads were then 
washed with 2 x 2mL additional TFA.  The washes were pooled with the cleavage solutions in a 
13mm glass tube and the solvent was removed in a SpeedVac.  The sample was redissolved in 
0.5mL of 12.5% ACN in water with 0.5% formic acid and analyzed by LCMS.   
The crude product was dissolved in 75μL of 20% piperidine/NMP and allowed to react at 
room temperature for 36hrs.  The crude reaction was filtered, and injected as a single injection 
onto the analytical HPLC column for purification.  Fractions containing the desired product were 
identified by reinjection on the LCMS and lyophilized.  The samples were stored in the dark at 
4˚C until needed. 
 
Synthesis of predicted PEG-linker fluorescein labeled bivalent scaffold (28). 
 
Figure 65 Fluorescein labeled PEG-linked predicted bivalent ligand (seq5). 
 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 7.0mg 
(12.6μmol) of Fmoc-PEG-OH (Novabiochem) and 4.8mg of HATU (12.6μmol) in 75μL of 20% 
DCM/DMF.  This solution was mixed using a micropipettor, after which 4.4μL (25μmol) of 
DIPEA was added to make the active ester.  After 10min activation time, the solution was 
aliquoted to each resin, and allowed to react by argon mixing for 30min.  The resin was then 
washed 3 x 2min with DMF.  Double couplings allowed for quantitative acylation, as judged by 
subsequent Fmoc release in the same manner described above, followed by washing with DMF, 
isopropanol, DMF, isopropanol, DMF, for 2min each. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 7.1mg 
(12.6μmol) of the acetyl-protected ligand (12) and 4.8mg of HATU (12.6μmol) in 65μL of 20% 
DCM/DMF.  This solution was mixed using a micropipettor, after which 4.4μL (25.2μmol) of 
28 
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DIPEA was added to make the active ester and then after 10min, aliquoted to the resins as above, 
followed by washing, and a second coupling.  The resin was then washed 3 x 2min with DMF, 
the 3 x 1min ~5%piperidine/DMF, repeating these two washes 3x more.  Then the resin was 
extensively washed with DMF, IPA, DMF, IPA, DMF, MeOH, DCM, MeOH, DCM, MeOH, 
DCM, and then dried overnight, in vacuo. 
The scaffold was cleaved in 0.75mL of 2.5% water, 2.5% triisopropylsilane in 
trifluoroacetic acid, with stirring for 2hour.  The solution was drained and the beads were then 
washed with 2 x 2mL additional TFA.  The washes were pooled with the cleavage solutions in a 
13mm glass tube and the solvent was removed in a SpeedVac.   
The bivalent-acetylated ligand was dissolved in 200μL of methanol and mixed with a 
pipettor.  Then, 2μL of 25% NaOMe/MeOH was added to each sample, mixed via pipettor, and 
allowed to react for 15min.  The reaction was quenched with 400μL of 0.1M HCl, frozen, and 
lyophilized. 
The crude product, along with NaCl salts, was dissolved in 75μL of 20% piperidine/NMP 
and allowed to react at room temperature for 36hrs.  The crude reaction was filtered, and injected 
as a single injection onto the analytical HPLC column for purification.  Fractions containing the 
desired product were identified by reinjection on the LCMS and lyophilized.  The samples were 
stored in the dark at 4˚C until needed. 
 
Fluorescent Polarization (FP) Assay 
The FP assay was performed in a Corning Costar 384-well black square bottom microtiter plate 
(Fisher, 07-200-653).  The samples in each well were arranged in columns, consisting of 2 
columns of buffer, 2 columns of just FAM-ligand, and then 16 columns of 8 increasing protein 
concentration, ½ log difference between each (i.e. 6, 30, 60, 300, 600…).  The buffer was 50mM 
Tris-HCl (pH7.4), 200mM, 3 mM NaN3, 1 mM EDTA and 0.2mg/mL bovine gamma globulins 
and was used for all dilutions of protein or FAM-ligand.  Depending on the number of samples 
being analyzed at once, between 8-32 points duplicate points for protein concentration wee done.  
The protein dilutions, or just buffer were aliquoted using a multichannel pipettor, 25μL per well, 
with concentrations ranging from ~10nM to 300μM CTB depending on the sample.  Then the 
lights were turned out and the FAM-ligand was diluted to ~2-10nM, but usually 6nM.  Then, 
 74 
25μL of FAM-ligand or just buffer was aliquoted into each well, and mixed by pipette at least 
five times to give final FAM concentration of 3nM and CTB concentration of 3, 10, 30, 100, 
300, etc.  The microplate was covered with foil and allowed to sit at room temperature overnight.  
The plate was read on a LJL Analyst HT plate reader using the following settings: microplate 
format = Corning 384 Square Opaque PS, shake time = 10s, excitation filter = fluorescein 
485nm, emission filter = fluorescein 530 nm, beamsplitter = FL 505, detector counting = counts, 
one reading per well, integration time = 100000μs, attenuator mode off, Z height = 1.5mm, 
excitation polarizer filter = initial parallel, but dynamic, and emission polarizer filter = static. 
 
Boc-propargylamine (29). 
To an ice cooled 500mL round bottom containing 250mL distilled dichloromethane, 4.8mL of 
propargylamine (75.1mmol) was added and allowed to stir for 10min.  To this, 17.2g of Boc-
anhydride (78.8mmol) was added along with 21.1mL of triethylamine (150.1mmol).  The 
reaction was stirred for 12hrs under nitrogen.  The solvent was removed in vacuo.  The residue 
was dissolved in 300mL EtOAc, and washed 2 x 150mL 0.1M HCl, 2 x 100mL brine, and dried 
with sodium sulfate and filtered.  The solvent was removed in vacuo to yield the crude product, 
which was dissolved in 200mL hot hexanes.  The insolubles were filtered, and the product was 
allowed to crystallize at 4˚C for 36hrs.  The crystals were filtered and dried in vacuo to yield 
9.8g of product (84%).  1H NMR (300MHz, 25˚C, CDCl3) δ 4.68 (b, 1H), δ 3.91 (d, 2H, J = 
3.2Hz), δ 2.20 (t, 1H, J = 2.5Hz), δ 1.43 (s, 9H). 
 
meta-(Boc-amino-prop-1-ynyl)-benzoic acid methyl ester (30). 
To a flame-dried 250mL round bottom flask, 50mL of extra-dry acetonitrile was added, along 
with 2.2g Boc-propargylamine (14.2mmol), 5.0g meta-methyl-iodobenzoate (19.2mmol), 2.4mL 
triethylamine (17.7mmol), 45mg copper iodide (0.24mmol), and 140mg 
tetrakis(triphenylphosphine)palladium (0.12mmol).  Freeze-pump-thaw degassing cycles 
were conducted by freezing in liquid N2, pumped under vacuo, and warmed in a gloved hand.  
This was repeated at least 5 times, and the last the frozen sample was transferred to a stir 
plate, allowed to thaw, and stirred under nitrogen overnight.  15g of celite was then added 
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and the solvent removed in vacuo.  The celite was transferred to a loading cartridge.  The 
product was purified on a ~300g steel Isco column equilibrated in hexanes.  Separation was 
achieved with a gradient of hexanes to EtOAc:hexanes (3:2).  Fractions were pooled and the 
solvent removed in vacuo to yield 2.4g product (59%).  1H NMR (300MHz, 25˚C, CDCl3) δ 
8.05 (m, 1H), δ 7.95 (m, 1H), δ 7.55 (m, 1H), δ 7.36 (m, 1H), δ 4.80 (b, 1H), δ 4.13 (m, 2H), δ 
3.88 (s, 3H), δ 1.44 (s, 9H). 
 
meta-(amino-prop-1-ynyl)-benzoic acid methyl ester (31). 
To a 250mL round bottom flask, 2.4g of meta-methylbenzoate-Boc-propargylamine was added 
along with 150mL of TFA:DCM (2:5).  The reaction was stirred for 2hrs, and the solvent was 
removed in vacuo.  The crude product was dissolved in 10mL methanol and injected onto the 
120g RP-C18-Isco column and separated using a 5-45% ACN gradient using ACN (0.05% 
formic acid) and 95% water (0.1% formic acid).  Fractions containing pure product were 
identified by LCMS or HPLC and lyophilized to give 1.3g desired product (81%). 
 
Peracetyl-D-lactose (32). 
To a 500mL round bottom flask, 55mL of acetic anhydride (585mmol) was added, along with 
10g D-lactose (29.2mmol), 30mL of triethylamine (215mmol), and finally, 180mg 
dimethylaminopyridine (1.5mmol).  The reaction, initially a cloudy-white suspension, was stirred 
for 1hr, after which the solution was yellow, with all material now dissolved.  The reaction was 
cooled on ice, and 50mL of water was added to hydrolyze excess acetic anhydride.  300mL of 
water and 300mL of EtOAc were added and the mixture transferred to a separatory funnel.  The 
organic layer was set aside, and the aqueous layer extracted 2 x 150mL EtOAc.  The organic 
layers were pooled, and carefully washed with 6 x 100mL saturated sodium bicarbonate, which 
produced vigorous bubbling.  More washes may be needed until no further bubbling occurred.  
The organic layer wash then washed with 2 x 100mL water and 2 x 100mL brine, dried with 
sodium sulfate, and filtered.  The solvent was removed in vacuo to produce 19.1g product (97%).  
1H NMR (300MHz, 25˚C, CDCl3) δ 6.19 (d, 0.6H), δ 5.83 (d, 0.4H, J = 9.4Hz), δ 5.45 (t, 1H, J = 
8.8Hz), δ 5.34 (m, 1H), δ 5.07 (m, 2H), δ 4.94 (m, 1H), δ 4.83 (m, 1H), δ 4.45 (m, 1H), δ 4.24 




The peracetyllactose (19.1g, 28.2mmol) was dissolved in 50mL distilled dichloromethane in a 
250mL round bottom flask, and 50mL of hydrobromic acid in acetic acid (CAUTION) was 
carefully added over a few minutes.  The reaction was stirred for 3hr at room temperature.  The 
reaction was cooled on ice and 400mL of ice-water was slowly added over 10min.  Then 30g 
sodium bicarbonate, in ~2g scoops, with waiting until bubbling subsides.  300mL of EtOAc were 
added and the mixture transferred to a separatory funnel.  The organic was drained, and the 
aqueous layer was extracted 2 x 150mL of EtOAc.  The organic layers were pooled, washed with 
100mL of saturated sodium bicarbonate, then washed with 2 x 100mL water and 2 x 100mL 
brine, dried with sodium sulfate, and filtered.  The solvent was removed in vacuo to produce 
18.2g product (93%).  1H NMR (300MHz, 25˚C, CDCl3) δ 6.51 (d, 1H, J = 4.0Hz), δ 5.56 (t, 1H, 
J = 9.6Hz), δ 5.34 (d, 1H, J = 3.3Hz), δ 5.13 (dd, 1H, J = 7.9Hz, 10.3Hz) δ 4.96 (dd, 1H, J = 
3.4Hz, 10.4Hz) δ 4.76 (dd, 1H, J = 4.1Hz, 10.0Hz), δ 4.50 (m, 2H), δ 4.21 (m, 4H), δ 3.89 (m, 
2H), 2.14-1.94 (21H). 
 
Heptaacetyl-β-isothiocyanate-D-lactose (36). 
Extra-dry acetonitrile (300mL) was added to a flame-dried 500mL round bottom flask.  ~40g of 
activated molecular sieves (in microwave until red) were added with stirring for ~1hr.  Then, 
2.5g of tetrabutylammonium hydrogen sulfate (7.15mmol) followed by 2.1g of potassium 
thiocyanate (21.5mmol) were added, producing a red color change.  A condenser was attached 
and the suspension was refluxed under nitrogen for 2-3hr.  The suspension was allowed to cool 
to room temperature, and the lactose bromide was added and the reaction was stirred for 14hrs.  
The sieves were filtered using a Buchner funnel, and the flow-through collected into a 2L round 
bottom using an adaptor.  The sieves were washed extensively (5 x 150mL) with 
dichloromethane.  The solvent was removed in vacuo.  The crude product was adsorbed onto 20g 
celite.  The product was purified on a ~300g steel Isco column equilibrated in hexanes.  
Separation was achieved with a gradient of hexanes to EtOAc:hexanes (3:2).  Fractions were 
pooled and the solvent removed in vacuo to yield 3.0g product (66%).  1H NMR (300MHz, 
25˚C, CDCl3) δ 5.33 (d, 1H), δ 5.20 (m, 4H), δ 4.47 (m, 2H), δ 4.13 (m, 4H), δ 3.85 (m, 2H), δ 
3.65 (m, 1H), δ 2.13-1.92 (21H). 
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Meta-[[heptaacetyl-β-D-lactosamino]-4H-thiazol-(5Z)-ylidenemethyl]-benzoic acid methyl 
ester (38). 
To a 100mL round bottom flask containing 30mL distilled dichloromethane, 1.0g of the lactose-
isothiocyanate (1.48mmol) was added.  Then, 525mg of meta-methylbenzoate-propargylamine 
(2.22mmol) was added, followed by 1mL of diisopropylethylamine (2.96mmol).  The reaction 
was stirred for no more than 2hrs.  Acetic acid (6mL) was then added, and allowed to stir for 
~4hrs, after which the initial thiourea product was converted to the thiazoline.  The 
dichloromethane was removed in vacuo, and the crude product, in acetic acid, was loaded onto a 
120g-RP-C18-Isco column, equilibrated in 5% ACN (0.05% formic acid) / 95% water (0.1% 
formic acid).  A gradient from 5-95% ACN separated the mixture.  Product fractions were 
identified by reinjection onto an HPLC or LCMS and pooled, and the solvent was removed by 
lyophilization to yield about 900mg of product, usually in ~75% yield.  1H NMR (300MHz, 
25˚C, CDCl3) δ 7.86 (s, 1H), δ 7.82 (m, 1H), δ 7.38 (d, 2H), δ 6.53 (d, 1H), δ 5.30-4.82 (m, 8H), 
δ 4.44 (m, 2H), δ 4.12 (m, 2H), δ 3.88 (s, 3H), δ 3.81 (m, 3H), δ 2.10-1.91 (21H). 
 
Meta-[2[β-D-lactosamino]-thiazol-5-ylmethy]-benzoic acid (39/40). 
To the 900mg meta-[[heptaacetyl-β-D-lactosamino]-4H-thiazol-(5Z)-ylidenemethyl]-benzoic 
acid methyl ester (1.11mmol) in a 100mL round bottom flask, 50mL of methanol:0.5M aqueous 
LiOH (1:1) was added and the reaction was allowed to stir overnight for 12hrs.  The reaction was 
neutralized by addition of 1M HCl until ~pH7.  The methanol was carefully removed at ambient 
temperature in vacuo and injected onto the 40g-RP-C18-Isco and separated using a 5-30% ACN 
gradient using ACN (0.05% formic acid) and 95% water (0.1% formic acid).  Fractions 
containing pure product were identified by LCMS or HPLC and lyophilized to give ~300mg 
desired product (50%).  1H NMR (300MHz, 25˚C, d6-dimethylsulfoxide) ADD NMR PEAKS 
HERE. 
 
Meta-[2[β-D-lactosamino]-thiazol-5-ylmethy]-benzyl-glycine methyl ester 
To 10mg of meta-[2[β-D-lactosamino]-thiazol-5-ylmethy]-benzoic acid (17.9μmol) in a 1.5mL 
microcentrifuge tube, 200μL of DMF was added along with a stir bar.  To this, 5.5mg HOBt 
(35.8μmol) and 13.6mg HBTU (35.8μmol) were added, followed by 25μL of DIPEA 
(143.1μmol) and stirring for 5min.  Then 5.1mg of glycine methyl ester hydrochloride hydrate 
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(35.8μmol) was added and stirred for 2hrs.  The reaction was quenched by addition of 1mL 
12.5% ACN in water, 0.5% formic acid.  The crude reaction was purified on the preparative 
HPLC system, in four injections.  Fractions containing pure product were identified by LCMS 
reinjection.  Lyophilization gave the ~6mg of desired product (53%), which was confirmed by 
MS analysis 
 
Synthesis of the resin bound bivalent intermediate (41). 
 
 
Figure 66 Resin-bound scaffold used in the synthesis of 4 types of bivalent ligands. 
 
To a 50mL polypropylene solid phase peptide synthesis (SPPS) reaction vessel was 
added Rink Amide (NOT AM!) Resin (Novabiochem) (100mg, 60μmol loading).  The resin was 
swelled for 1hr in DMF.  The terminal Fmoc-protected amine was deprotected in 5mL of 20% 
piperidine/DMF for 40min.  By measuring the absorbance at 301nm of a 1/200 dilution, the 
number of moles of Fmoc removed was calculated by using ε = 7800 M-1 cm-1.  The resin was 
washed with DMF, isopropanol, DMF, isopropanol, DMF, for 2min each. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 61.2mg 
(120.0μmol) of Boc-protected pro4(2R4R)[17] building block and 45.6mg of HATU 
(120.0μmol) in 600μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after 
which 41.8μL (41.8μmol) of DIPEA was added to make the active ester.  After 10min activation 
time, the solution was added to the deprotected resin, and allowed to react by argon mixing for 
30min.  The resin was then washed 3 x 2min with DMF.  Double couplings allowed for 
quantitative acylation, as judged by subsequent Fmoc release in the same manner described 
above. 
This process of coupling/deprotection was repeated n (n=1-8) additional times. After 
each Fmoc deprotection, the resin was washed with DCM several times, and allowed to dry for 
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five minutes via aspiration.  The beads were now easily removed from the reactor and then 
weighed.  An appropriate weight fraction (i.e. 1/8th removed after 2nd building block was 
coupled, then 1/7th after third building block, etc.) was then removed, placed in a fresh 1.0mL 
reactor and stored in a desiccator.  The remaining resin was then swelled in DMF for 10 min.  
The process of coupling/deprotection/aliquot removed was repeated seven additional times, 
making 8 portions of equimolar amounts of 8 different lengths, 2-9 building blocks, with the 
final amine deblocked, yielding the sequence, resin-RR-(RR)n-free amine (n=1-8). 
Because the solid support was the ordinary Rink Amide resin, the Boc groups on the 
building blocks were removed using procedure from the Burgess lab.[42]  The beads were 
washed with DCM for 5min.  A solution of 20mL of 1M trimethylsilyl triflate (Aldrich-
TMSOTf-from a Schlenk bottle) and 1.5M 2,6-lutidine in DCM was prepared.  By adding 3 x 
0.75mL x 5min to each of the 8 resin lengths, with slight bubbling, the Boc groups were removed 
while still attached to the resin, with DCM washes in between.  After deprotection, the resin was 
washed vigorously with DCM, followed by 5 cycles of MeOH / DCM washes, ending up with 
swelling in DMF for 5min.  The DKPs were then closed on each resin using a stirred solution of 
0.5mL of 20% piperidine in NMP for 12hrs at 35˚C -40˚C. 
The resin was washed with DMF, isopropanol, DMF, isopropanol, DMF, for 2min each, 
then with DMF, MeOH, DCM, MeOH, DCM, MeOH, DCM, and then dried overnight, in vacuo.  
Each of the lengths n=1-8 was split into 4 equal portions to be used in the synthesis of the 4 
types of bivalent ligands described below.  The resins were stored in the desiccator until needed. 
 
Synthesis of the PEG-bivalent scaffolds (42). 
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Figure 67 PEG-bivalent scaffolds, of length 5-9 building blocks. 
 
The resin length portions n=4-8 were each swelled in DMF for 30min.  The estimated 
amount of material in each reactor was 60μmol / 8 / 4 = ~2μmol, with ~10μmol in total.  In a 
1.5mL microcentrifuge tube, the coupling solution was made by dissolving 27.9mg (50μmol) of 
Fmoc-PEG-OH (Novabiochem) and 19.0mg of HATU (50μmol) in 250μL of 20% DCM/DMF.  
This solution was mixed using a micropipettor, after which 8.7μL (100μmol) of DIPEA was 
added to make the active ester.  After 10min activation time, the solution was aliquoted to each 
resin, and allowed to react by argon mixing for 30min.  The resin was then washed 3 x 2min with 
DMF.  Double couplings allowed for quantitative acylation, as judged by subsequent Fmoc 
release in the same manner described above, followed by washing with DMF, isopropanol, 
DMF, isopropanol, DMF, for 2min each. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 22.4mg 
(40μmol) of the synthetic ligand (39/40), 6.1mg of HOBt (40μmol) and 15.2mg of HBTU 
(40μmol) in 400μL of 50% DMSO/DMF.  This solution was mixed using a micropipettor, after 
which 10.5μL (120μmol) of DIPEA was added to make the active ester and then after 10min, 
aliquoted as above, followed by washing, and a second coupling.  Then the resins were 
extensively washed with DMF, IPA, DMF, IPA, DMF, MeOH, DCM, MeOH, DCM, MeOH, 
DCM, and then dried overnight, in vacuo. 
The scaffolds were cleaved in 0.75mL of 2.5% water, 2.5% triisopropylsilane in 
trifluoroacetic acid, with stirring for 1hour (NO LONGER).  The solutions were drained and the 
beads were then washed with 2 x 2mL additional TFA.  The washes were pooled with the 
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cleavage solutions in a 13mm glass tube and the solvent was removed in a SpeedVac.  Each 
sample was redissolved in 0.5mL of 12.5% ACN in water with 0.5% formic acid and analyzed 
by LCMS.   
The final bivalent ligands of varying lengths (n=4-8) were purified on a preparative 
HPLC column, as a single injection.  All peaks were collected and re-injected on the LCMS to 
obtain the identity of the collected peak as well as the purity.  Using an HPLC calibration curve 
derived from the glycine methyl ester ligand (48), the total nmols of material in the pooled 
purified product were estimated, and aliquoted into ~10-30nmol portions, depending on the 
amount of material and the desired final concentration.  The microcentrifuge tubes were 
lyophilized and stored at 4˚C.  When the time came for binding measurements, a single tube was 
resuspended in 0.8mL buffer and the concentration was measured based on the extinction 
constant derived from the glycine methyl ester ligand (48). 
 
Synthesis of the βAla (1 or 2)-bivalent scaffolds (44/45). 
 
Figure 68 βAla (1 or 2)-bivalent scaffolds, of length 5-9 building blocks. 
 
Two sets of resin length portions n=4-8 were each swelled in DMF for 30min.  The 
estimated amount of material in each reactor was 60μmol / 8 / 4 = ~2μmol, with ~10μmol in 
each of the two length sets.  In 2 x 1.5mL microcentrifuge tube, the coupling solutions were 
made by dissolving 31.1mg (100μmol) of Fmoc-βAla-OH (Novabiochem) and 38.0mg of HATU 
(100μmol) in 500μL of 20% DCM/DMF.  These solution was mixed using a micropipettor, after 
which 34.8μL (200μmol) of DIPEA was added to each to make the active ester.  After 10min 
activation time, the solution was aliquoted to each resin, and allowed to react by argon mixing 
for 30min.  The resin was then washed 3 x 2min with DMF.  Double couplings allowed for 
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quantitative acylation, as judged by subsequent Fmoc release in the same manner described 
above, followed by washing with DMF, isopropanol, DMF, isopropanol, DMF, for 2min each. 
One set of 5 different lengths were ready for ligand coupling, but the other set needed 
another βAla.  By repeating the above steps of βAla double coupling followed by Fmoc removal, 
this sample was made ready for ligand incorporation. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 44.8mg 
(80μmol) of the synthetic ligand (39/40), 12.2mg of HOBt (80μmol) and 30.4mg of HBTU 
(80μmol) in 800 μL of 50% DMSO/DMF.  This solution was mixed using a micropipettor, after 
which 21.0μL (240μmol) of DIPEA was added to make the active ester and then after 10min, 
aliquoted into the 10 reactors, followed by washing, and a second coupling.  Then the resins 
were extensively washed with DMF, IPA, DMF, IPA, DMF, MeOH, DCM, MeOH, DCM, 
MeOH, DCM, and then dried overnight, in vacuo. 
The scaffolds were cleaved in 0.75mL of 2.5% water, 2.5% triisopropylsilane in 
trifluoroacetic acid, with stirring for 1hour (NO LONGER).  The solutions were drained and the 
beads were then washed with 2 x 2mL additional TFA.  The washes were pooled with the 
cleavage solutions in a 13mm glass tube and the solvent was removed in a SpeedVac.  Each 
sample was redissolved in 0.5mL of 12.5% ACN in water with 0.5% formic acid and analyzed 
by LCMS.   
The final bivalent ligands of varying lengths (n=4-8) were purified on a preparative 
HPLC column, as a single injection.  All peaks were collected and re-injected on the LCMS to 
obtain the identity of the collected peak as well as the purity.  Using an HPLC calibration curve 
derived from the glycine methyl ester ligand (48), the total nmols of material in the pooled 
purified product were estimated, and aliquoted into ~10-30nmol portions, depending on the 
amount of material and the desired final concentration.  The microcentrifuge tubes were 
lyophilized and stored at 4˚C.  When the time came for binding measurements, a single tube was 
resuspended in 0.8mL buffer and the concentration was measured based on the extinction 
constant derived from the glycine methyl ester ligand (48). 
 
Synthesis of bivalent scaffolds (46). 
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Figure 69 Βivalent scaffolds, of length 2-7 building blocks. 
 
The resin length portions n=1-6 were each swelled in DMF for 30min.  The estimated 
amount of material in each reactor was 60μmol / 8 / 4 = ~2μmol, with ~12μmol in total.  In a 
1.5mL microcentrifuge tube, the coupling solution was made by dissolving 22.4mg (40μmol) of 
the synthetic ligand (39/40), 6.1mg of HOBt (40μmol) and 15.2mg of HBTU (40μmol) in 400mL 
of 50% DMSO/DMF.  This solution was mixed using a micropipettor, after which 10.5μL 
(120μmol) of DIPEA was added to make the active.  After 10min activation time, the solution 
was aliquoted to each resin, and allowed to react by argon mixing for 30min.  The resin was then 
washed 3 x 2min with DMF, followed by a second coupling.  Then the resins were extensively 
washed with DMF, IPA, DMF, IPA, DMF, MeOH, DCM, MeOH, DCM, MeOH, DCM, and 
then dried overnight, in vacuo. 
The scaffolds were cleaved in 0.75mL of 2.5% water, 2.5% triisopropylsilane in 
trifluoroacetic acid, with stirring for 1hour (NO LONGER).  The solutions were drained and the 
beads were then washed with 2 x 2mL additional TFA.  The washes were pooled with the 
cleavage solutions in a 13mm glass tube and the solvent was removed in a SpeedVac.  Each 
sample was redissolved in 0.5mL of 12.5% ACN in water with 0.5% formic acid and analyzed 
by LCMS.   
The final bivalent ligands of varying lengths (n=1-6) were purified on a preparative 
HPLC column, as a single injection.  All peaks were collected and re-injected on the LCMS to 
obtain the identity of the collected peak as well as the purity.  Using an HPLC calibration curve 
derived from the glycine methyl ester ligand (48), the total nmols of material in the pooled 
purified product were estimated, and aliquoted into ~10-30nmol portions, depending on the 
amount of material and the desired final concentration.  The microcentrifuge tubes were 
lyophilized and stored at 4˚C.  When the time came for binding measurements, a single tube was 
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resuspended in 0.8mL buffer and the concentration was measured based on the extinction 
constant derived from the glycine methyl ester ligand (48). 
 
Synthesis of the monovalent scaffolds (47). 
 
Figure 70 Monovalent scaffolds, of length 2-7 building blocks. 
 
To a 15mL polypropylene solid phase peptide synthesis (SPPS) reaction vessel was 
added Rink Amide (NOT AM!) Resin (Novabiochem) (20mg, 12μmol loading).  The resin was 
swelled for 1hr in DMF.  The terminal Fmoc-protected amine was deprotected in 1mL of 20% 
piperidine/DMF for 40min.  By measuring the absorbance at 301nm of a 1/200 dilution, the 
number of moles of Fmoc removed was calculated by using ε = 7800 M-1 cm-1.  The resin was 
washed with DMF, isopropanol, DMF, isopropanol, DMF, for 2min each. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 12.2mg 
(24μmol) of Boc-protected pro4(2R4R)[17] building block and 9.1mg of HATU (24.0μmol) in 
120μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 8.4μL 
(48.0μmol) of DIPEA was added to make the active ester.  After 10min activation time, the 
solution was added to the deprotected resin, and allowed to react by argon mixing for 30min.  
The resin was then washed 3 x 2min with DMF.  Double couplings allowed for quantitative 
acylation, as judged by subsequent Fmoc release in the same manner described above. 
This process of coupling/deprotection was repeated n (n=1-6) additional times. After 
each Fmoc deprotection, the resin was washed with DCM several times, and allowed to dry for 
five minutes via aspiration.  The beads were now easily removed from the reactor and then 
weighed.  An appropriate weight fraction (i.e. 1/6th removed after 2nd building block was 
coupled, then 1/5th after third building block, etc.) was then removed, placed in a fresh 1.0 mL 
reactor and stored in a desiccator.  The remaining resin was then swelled in DMF for 10 min.  
The process of coupling/deprotection/aliquot removed was repeated six additional times, making 
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6 portions of equimolar amounts of 6 different lengths, 2-7 building blocks, with the final amine 
deblocked, yielding the sequence, resin-RR-(RR)n-free amine (n=1-6). 
The resin length portions n=1-6 were each swelled in DMF for 30min.  In a 1.5mL 
microcentrifuge tube, the coupling solution was made by dissolving 17.8mg (60.0μmol) of 
Fmoc-Gly-OH (Novabiochem) and 22.8mg of HATU (60.0μmol) in 300μL of 20% DCM/DMF.  
This solution was mixed using a micropipettor, after which 21.0μL (120.0μmol) of DIPEA was 
added to make the active ester.  After 10min activation time, the solution was aliquoted to each 
resin, and allowed to react by argon mixing for 30min.  The resin was then washed 3 x 2min with 
DMF and the coupling/washing was repeated. 
Because the solid support was the ordinary Rink Amide resin, the Boc groups on the 
building blocks were removed using procedure from the Burgess lab.[42]  The beads were 
washed with DCM for 5min.  A solution of 20mL of 1M trimethylsilyl triflate (Aldrich-
TMSOTf-from a Schlenk bottle) and 1.5M 2,6-lutidine in DCM was prepared.  By adding 3 x 
0.75mL x 5min to each of the 8 resin lengths, with slight bubbling, the Boc groups were removed 
while still attached to the resin, with DCM washes in between.  After deprotection, the resin was 
washed vigorously with DCM, followed by 5 cycles of MeOH / DCM washes, ending up with 
swelling in DMF for 5min.  The DKPs were then closed on each resin using a stirred solution of 
0.5mL of 20% piperidine in NMP for 12hrs at 35˚C -40˚C.  The resin was washed with DMF, 
isopropanol, DMF, isopropanol, DMF, for 2min each, then swelled in DMF again.   
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 13.5mg 
(24.0μmol) of the synthetic ligand (39/40), 3.7mg of HOBt (24.0μmol) and 9.1mg of HBTU 
(24.0μmol) in 240 μL of 50% DMSO/DMF.  This solution was mixed using a micropipettor, 
after which 4.2μL (48.0μmol) of DIPEA was added to make the active ester and then after 
10min, aliquoted as above, followed by washing, and a second coupling.  Then the resins were 
extensively washed with DMF, IPA, DMF, IPA, DMF, MeOH, DCM, MeOH, DCM, MeOH, 
DCM, and then dried overnight, in vacuo. 
The scaffolds were cleaved in 0.75mL of 2.5% water, 2.5% triisopropylsilane in 
trifluoroacetic acid, with stirring for 1hour (NO LONGER).  The solutions were drained and the 
beads were then washed with 2 x 2mL additional TFA.  The washes were pooled with the 
cleavage solutions in a 13mm glass tube and the solvent was removed in a SpeedVac.  Each 
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sample was redissolved in 0.5mL of 12.5% ACN in water with 0.5% formic acid and analyzed 
by LCMS.   
The final monovalent ligands of varying lengths (n=2-6) were purified on a preparative 
HPLC column, as a single injection.  All peaks were collected and re-injected on the LCMS to 
obtain the identity of the collected peak as well as the purity.  Using an HPLC calibration curve 
derived from the glycine methyl ester ligand (48), the total nmols of material in the pooled 
purified product were estimated, and aliquoted into ~10-30nmol portions, depending on the 
amount of material and the desired final concentration.  The microcentrifuge tubes were 
lyophilized and stored at 4˚C.  When the time came for binding measurements, a single tube was 
resuspended in 0.8mL buffer and the concentration was measured based on the extinction 
constant derived from the glycine methyl ester ligand (48). 
 
Synthesis of fluorescein containing bivalent scaffolds (51). 
 
Figure 71 Bivalent fluorescein labeled scaffolds, of length 2-7 building blocks. 
 
To a 15mL polypropylene solid phase peptide synthesis (SPPS) reaction vessel was 
added Rink Amide (NOT AM!) Resin (Novabiochem) (20mg, 12μmol loading).  The resin was 
swelled for 1hr in DMF.  The terminal Fmoc-protected amine was deprotected in 1mL of 20% 
piperidine/DMF for 40min.  By measuring the absorbance at 301nm of a 1/200 dilution, the 
number of moles of Fmoc removed was calculated by using ε = 7800 M-1 cm-1.  The resin was 
washed with DMF, isopropanol, DMF, isopropanol, DMF, for 2min each. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 32.8mg 
(60μmol) of Fmoc-L-Dab(ivDde)-OH (Novabiochem) and 22.8mg of HATU (60μmol) in 300μL 
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of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 20.9μL 
(120μmol) of DIPEA was added to make the active ester.  After 10min activation time, the 
solution was added to the deprotected resin, and allowed to react by argon mixing for 30min.  
The resin was then washed 3 x 2min with DMF.  Double couplings allowed for quantitative 
acylation, as judged by subsequent Fmoc release in the same manner described above. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 12.2mg 
(24μmol) of Boc-protected pro4(2R4R)[17] building block and 9.1mg of HATU (24.0μmol) in 
120μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 8.4μL 
(48.0μmol) of DIPEA was added to make the active ester, as above, followed by washing, a 
second coupling, washing, and Fmoc release.   
This process of coupling/deprotection was repeated n (n=1-6) additional times. After 
each Fmoc deprotection, the resin was washed with DCM several times, and allowed to dry for 
five minutes via aspiration.  The beads were now easily removed from the reactor and then 
weighed.  An appropriate weight fraction (i.e. 1/6th removed after 2nd building block was 
coupled, then 1/5th after third building block, etc.) was then removed, placed in a fresh 1.0 mL 
reactor and stored in a desiccator.  The remaining resin was then swelled in DMF for 10 min.  
The process of coupling/deprotection/aliquot removed was repeated six additional times, making 
6 portions of equimolar amounts of 6 different lengths, 2-7 building blocks, with the final amine 
deblocked, yielding the sequence, resin-RR-(RR)n-free amine (n=1-6). 
Because the solid support was the ordinary Rink Amide resin, the Boc groups on the 
building blocks were removed using procedure from the Burgess lab.[42]  The beads were 
washed with DCM for 5min.  A solution of 20mL of 1M trimethylsilyl triflate (Aldrich-
TMSOTf-from a Schlenk bottle) and 1.5M 2,6-lutidine in DCM was prepared.  By adding 3 x 
0.75mL x 5min to each of the 8 resin lengths, with slight bubbling, the Boc groups were removed 
while still attached to the resin, with DCM washes in between.  After deprotection, the resin was 
washed vigorously with DCM, followed by 5 cycles of MeOH / DCM washes, ending up with 
swelling in DMF for 5min.  The DKPs were then closed on each resin using a stirred solution of 
0.5mL of 20% piperidine in NMP for 12hrs at 35˚C -40˚C.  The resin was washed with DMF, 
isopropanol, DMF, isopropanol, DMF, for 2min each, then swelled in DMF again.   
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 26.9mg 
(48.0μmol) of the synthetic ligand (39/40), 7.3mg of HOBt (48.0μmol) and 18.2mg of HBTU 
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(48.0μmol) in 240 μL of 50% DMSO/DMF.  This solution was mixed using a micropipettor, 
after which 8.4μL (96.0μmol) of DIPEA was added to make the active ester and then after 
10min, aliquoted as above, followed by washing, and a second coupling.  Then the resins were 
extensively washed with DMF, IPA, DMF, IPA, and DMF. 
The Dab side chain protecting groups, ivDde, were removed using a solution of 4% 
hydrazine hydrate in DMF.  4 x 1mL, each reacting for about 3-5 minutes was sufficient to 
completely unmask the side chain.  Then the resins were extensively washed with DMF, IPA, 
DMF, IPA, and DMF. 
The resins were acylated with fluorescein-N-hydroxysuccinyl ester (56.8mg, 120.0mmol) 
in 600μL DMF with stirring in the dark for 72hrs. Then the resins were extensively washed with 
DMF, IPA, DMF, IPA, DMF, MeOH, DCM, MeOH, DCM, MeOH, DCM, and then dried 
overnight, in vacuo. 
The scaffolds were cleaved in 0.75mL of 2.5% water, 2.5% triisopropylsilane in 
trifluoroacetic acid, with stirring for 1hour (NO LONGER).  The solutions were drained and the 
beads were then washed with 2 x 2mL additional TFA.  The washes were pooled with the 
cleavage solutions in a 13mm glass tube and the solvent was removed in a SpeedVac.  Each 
sample was redissolved in 0.5mL of 12.5% ACN in water with 0.5% formic acid and analyzed 
by LCMS.   
The final fluorescently labeled ligands of varying lengths (n=2-6) were purified on an 
analytical HPLC column, as a single injection.  All peaks were collected and re-injected on the 
LCMS to obtain the identity of the collected peak as well as the purity.  The tubes were 
lyophilized and stored at 4˚C in the dark.   
 
Fluorescence Intensity (FI) Assay 
Two cuvettes were used for each titration (Semi-micro fluorometer cell, NSG Precision Cells, 
Type 517).  In the first, 500μL of FI buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl, 0.02% 
NaN3) was added, and in the second, 500μL of buffer along with CTB concentration = 100nM, 
250nM, or 500nM, depending on the ligand being tested.  The FI was measured using a Varian 
Cary Eclipse Fluorescence spectrophotometer with excitation at 282nm and the emission 
monitored from 300-400nm, with a scan rate of 100nm/min and 5 scans per point.  The voltage 
of the detector was adjusted to give ~200-400 of 1000, for the initial protein-only point.  Eight 
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incremental additions of a ligand stock solution were added using Hamilton syringes.  The 
background FI was averaged for each addition and then subtracted from each of the five scans, 
which were then averaged.  The 5-largest FI intensities between 330nm-360nm were then 
averaged to give the FI for each point.  The change in FI was calculated and plotted against the 
ligand concentration to get a sigmoidal curve.  Binding constants were derived either from a 







3. PHAGE DISPLAY ON AN ARTIFICIAL RECEPTOR 
3.1 INTRODUCTION 
The power of phage display lies in the expansive number of discrete peptide ligands which can 
be screened simultaneously.  Typically, in excess of 1 billion different peptide ligands can be 
tested for high-affinity interactions with a target.  The ligands which bind most tightly to the 
receptor are selectively retained, while the non-binders are washed away.  The strong binders are 
eluted, amplified, and again screened against the target receptor, this time with washing 
conditions designed to disrupt weaker interactions.  After repeated cycles of screening / 
amplification, it is possible to get enrichment on the order of several million, in going initially 
from 109 to much less than 102, but often near-complete enrichment to a few ligands is possible. 
Filamentous M13 phage are a member of the family of viruses which infect bacteria.  
Being a virus, phage are simply protein-coated DNA.  The DNA is found as a single circular 
strand consisting of a few thousand nucleotides encoding a few proteins.  Phage are long 
cylindrical particles with a diameter of about 50Ǻ, while the length is ten to a hundred times 
longer. The coat proteins of the phage are mainly pVIII, which, at copy levels of several 
thousand, makes up the entire outer barrel of the phage, while other proteins, like pIII, make up 
the tip of the phage, at copy numbers of five.[43] 
These two proteins are the main surrogates for insertion of small peptide libraries, 
although all coat proteins have been tried, but by far the most success has been achieved with 
pVIII and pIII.  The question of the desired copy number and size of the peptide are important 
when deciding which coat protein to chose.  Commercially available phage libraries mainly use 
pIII, although pVIII has much promise and will likely be commercialized in the future.  Several 
features of pIII make it useful, such as its tolerance of large inserts, beyond the length scale of a 
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simple peptide, as well as the likelihood for monovalent interactions between ligand and 
receptors.   
The selection process, between a phage-peptide library and the target receptor, is 
conceptually very simple: the phage library is incubated with an immobilized target, then non-
binders are washed away, binders are eluted and amplified, and the process repeated, normally 
two more times, or until sufficient enrichment is achieved.  The conditions used for elution are 
diverse, ranging from low pH (~2),[44] to denaturants (6M urea),[45] to displacement with 
specific ligands,[46] or, alternatively, direct infection without elution.[47] 
The incredible power of selection is the driving force behind the utility of phage display, 
but there is also an dark side to the selective pressure.  It has been said before that “one gets what 
one is selecting for.”  In the absence of the desired strong, productive interaction between 
peptide and receptor, selection rears it other side by selecting for plastic binder or streptavidin 
binders.  Alternatively, “freaks” can be selected for, such that internal duplication results in the 
display of additive weakly interacting peptides which amount to a stronger binder.  Additional, 
unnecessary rounds of selection and amplification result in the selection for a growth advantage, 
or in the case of trace contamination, wild-type phage not burdened by the additional peptide 
insert. 
Since phage display was first described over 20 twenty years ago,[44] there have been 
tens of thousands of published examples exploiting the powers of affinity selection and 
amplification.  A 12 residue peptide was found that modulates the fluorescent properties of the 
dye, Texas-Red.[48]  A taxol binding peptide was found to be of a sequence similar to anti-
apoptotic human protein Bcl-2, demonstrating that peptides displayed on the surface of 
bacteriophage particles can mimic the ligand-binding properties of disordered regions of 
proteins.[49]  A non-RGD containing peptide ligand was found that selectively bound to the 
integrin v 6 with 20nM affinity.[50]  Remarkably, a peptide was found which binds to a range 
of inorganic semiconductor surfaces with high specificity, depending on the crystallographic 
orientation and composition of the surface.[51]  A molecule consisting of multiple copies of a 
peptide discovered by phage display, covalently linked to a flexible backbone, prevented 
assembly of the anthrax toxin complex in vitro and blocked toxin action in an animal model.[52]  
Phage display has been done in vivo, where the phage library was injected into mice and peptides 
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involved in localization to specific organs were identified.[53]  The utility of phage display is 
limited only by the researcher’s creativity. 
One area of science that could benefit from the power of phage display is the area of 
synthetic receptors.  To date, no one has found a peptide that binds inside of a totally-synthetic 
receptor.  The ability to synthesize a molecule that folds into a pocket and presents functional 
groups in specific orientations in three dimensional space has not been possible.   
Using a building-block approach to make rigid, functionalized molecules which are 
potentially able to fold and form a cavity, presents an opportunity for phage display to select and 
identify a short peptide ligand capable of binding to an artificial receptor.  This would be the first 
example of an artificial antibody and would represent a major step forward for the field of 
artificial biological receptors.   
3.2 RESULTS AND DISCUSSION 
Initial studies using molecular modeling on sequences of building blocks potentially able to fold 
and form a pocket settled on the alternating sequence of pro4(2S4S), RR, SS, RR, SS, RR as 
fitting this requirement.  Modeling suggests that this sequence forms a tight turn, bringing both 
ends into close proximity (Figure 72).  A tryptophan at the trailing end will serve as the UV 
chromophore and a Dpr at the leading end will terminate one chain by forming a DKP, and 
deprotection of the orthogonal side chain protecting group will initiate a new chain.   
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Figure 72 MOE structure (Amber 94 minimized) of LEFT- Trp-SS-RR-SS-RR-SS-RR-Dpr, RIGHT- Trp-SS-RR-
SS-RR-SS-RR-Dpr-SS-RR-SS-RR-SS-RR-Dpr (BLUE sphere = Resin amide nitrogen, RED sphere = second chain, 
first building block amide oxygen). 
 
The second Dpr would be functionalized with a linker, facilitatating attachment to a 
surface.  Polystyrene functionalized with various groups such as a maleimide, an amine, or a 
carboxy-N-hydroxysuccinimide were all commercially available through Corning Life Science.  
All of the above were suitable means for covalent attachment of a scaffold receptor to 
polystyrene for affinity selection with a phage library.  However, biotin-streptavidin is a 
ubiquitous method for immobilizing molecules on a surface, whereas the covalent means may be 
a slightly over-engineered system, especially as a first attempt.  The design of the scaffold and 
the solid-phase methods would easily allow for any mode of attachment to be employed, as the 
tether was the last thing attached and be orthogonal to all other functionality in the molecule.   
Biotin-streptavidin was chosen for it simplicity and for the strength of the interaction.  
The biotinylating molecule consisted of the biotin, linked through its carboxylic acid to a diPEG 
spacer, and finally, a carboxylic acid which could be coupled cleanly and selectively to the last 
amine on the resin bound scaffold, right before cleavage.  Half of the material was left 
unfunctionalized to provide a scaffold without biotin, used to competitively elute the bound 
phage from the immobilized, biotinylated receptor.  Presumably this would not elute phage 
which were interacting with the plastic or streptavidin.  Low pH was not employed, as this would 
likely disrupt all phage interactions. Specific elution techniques were thought to be more desired 
than non-specific elution.  Perhaps this naively passed over because it was reasoned that low pH 
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would likely disrupt electrostatic interactions, while neglecting hydrogen bonds, hydrophobic 
interactions or van der Waals interaction.  Although this seemed plausible, the function of the 
low pH likely serves to denature the streptavidin, or even peel off everything that was initially 
bound to the plastic.  In retrospect low pH should have been investigated as a means for elution, 
because, depending on the off-rate of any phage bound to the receptor, strongly bound phage 
may have been de-selected by using a competitive elution pathway. 
The synthesis of the first scaffold receptor on the Rink Amide resin (Figure 73), 
proceeded first by attachment of Trp(Boc), then an alternating series of six pro4(2S4S) and 
pro4(2R4R).  The eighth residue was the weak acid cleavable, orthogonally protected methytrityl 
diaminopropionic acid (Dpr).  Removal of the Fmoc quickly resulted in attack upon the methyl 
ester of the previous building block, consuming all of the amine to form a diketopiperazine 
(DKP), thus serving to terminate the chain.  Removal of the methytrityl with 1%TFA proceeded 
quantitatively to allow for initiation of a new chain.  Next a second series of six alternating SS 
and RR building blocks were attached as before.  Finally, another Dpr(Mtt) served to terminate 
the second chain and, upon deprotection, served as the attachment point for the PEG-linked 
biotin (52).  Half of the resin was capped with biotin, while the other half was unmodified for the 
purpose of competitive elution.  Cleavage with 95% TFA afforded the Boc-deprotected scaffold, 
in yields between 10-20% (a typical yield).  Also seen was the fact that the carbon dioxide 
remnants of the Boc group remain attached to the indole of tryptophan (M+44).  Multiple 
lyophilizations from aqueous solutions is the standard treatment to remove this, however it was 





Figure 73 Figure illustrating the solid phase synthesis of the phage display receptor. 
 
 
Figure 74 Acylation of 52 with biotin, followed by cleavage and failed DKPS closure. 
 
Normal incubation of the scaffolds, with or without biotin, in 20% piperidine/ NMP for 
48hrs failed to go to completion, as judged by LCMS (Figure 74).  Although it was difficult to 
estimate the incomplete reaction yield by LC, it did appear that there was significantly less 
material than was initially present, as judged by the tryptophan 278nm LC absorbance.  
Additional time of up to one week, or elevated temperature of 50˚C, had no effect on the closure.  
So, not only did the DKP closure reaction fail to go to completion, but material seemed to 
disappear as well.  This exact sequence was abandoned and the second version would be 
truncated by one building block on both chains.   
This observation of loss of material and incompletion of the DKP closure has been seen 






repeats.  The current working hypothesis rationalizes these observations as being due to 
intramolecular, complementary, hydrogen bonding interactions (Figure 75).  As the DKPs close, 
the hydrogen bonding interactions in one molecule become complimentary to that in another 
molecule, possibly producing a three-dimensional lattice with different solubility properties.  
Future studies are underway to potentially exploit this event via self-assembly or suppress the H-
bonding using denaturants, capable of forming both H-bond acceptors and H-bond donors. 
 
Figure 75 MOE picture, Amber 94 minimized, of SS-RR-SS-RR-SS-RR illustrating the repeating ordered nature of 
the DKP pattern. 
 
A second set of potential receptors was synthesized with only 2.5 SS-RR repeats.  This 
new sequence, resin-Trp-SS-RR-SS-RR-SS-Dpr, was made in the same fashion as illustrated in 
Figure 76.  When it came time to initiate the second chain of five building blocks, the resin was 
split into two portions (53, in Figure 76).  The difference in what was built off of these two 
portions consisted of two choices: -SS-RR-SS-RR-SS, as on the first chain, or its enantiomer, -
RR-SS-RR-SS-RR, both being capped with another Dpr.  Each of these two sequences was again 
split into two portions at the end, to be consisted of with or without biotin. 
Cleavage yielded the product, which was subsequently closed in 20% piperidine/ NMP.  
After the normal 48hrs, it was apparent that the reaction was progressing sluggishly.  The desired 
product was the major peak (~80%), but additional time of 1-3 days was necessary to drive the 
DKP closure to completion.  In spite of the prolonged exposure to highly basic conditions, no 
evidence of epimerization, such as multiple peaks with the same mass or distinct shoulders, were 
seen in the chromatogram.  The two receptors (labeled as RR (54) or SS (55) for the first point of 
divergence), with or without biotin were easily purified to homogeneity by preparative HPLC.  
Using the Trp (Σ = 5600), the concentration was determined, with a final yield in the range of 5-
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10%.  Two biotinylated receptors and the corresponding free receptors were successfully 
synthesized and purified, and would be screened for binding with a phage display library. 
 
Figure 76 Solid-phase synthesis of biotinylated scaffold with DKPs that do close. 
 







Figure 78  LC trace, MS trace and structure of the "RR-receptor." 
 
The exact phage display procedures, modified from the NEB recommended procedure, 
are explicitly detailed in the experimental section, so a brief account of what was done and what 
the results were will be detailed here.  The choice of the library was the NEB-12mer peptide-
phage library, based on the fact that we were unsure how large of a peptide could potentially 
bind to the scaffold receptor.  With a stated diversity of over 2 billion unique sequences of 
peptides, present at copy number of about 4 copies, this 12mer library would allow the scanning 
of only 1 of every 20,000 of all possible 12mers (2012 / 2x10e9 / 100).  In retrospect, the 
inadequacy of the sequence coverage should have trumped any concerns about sufficient length 
of the peptide, but the 12mer peptide was chosen nonetheless. 
Screening of the two receptors, as well as the streptavidin control, against the 12mer 
phage library was carried out for three rounds and two amplifications.  The phage were eluted 
with free receptor or with 100μM biotin.  Titers of 104 to 105 phage were eluted and subsequent 
amplification produced titers of 1011-1012 after the first round.  Similar titers were seen after the 
second round.  The final round of selection produced titers in the range of 101-103.  Numerous 
plaques were chosen for amplification and sequencing.  For the positive control phage, the 
streptavidin binding sequence, HPQ, was found numerous times, so the phage display selection 
process was successful.  Out of 6 clones sequenced from the RR-receptor selection, one sequence 
55 
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showed up twice.  This peptide sequence was synthesized, with a fluorescein attached at the N-
terminus.  Using fluorescence polarization, (not shown) the binding constant was not below the 
5μM limit of detection. 
 
Figure 79 Protein sequence of DNA sequenced clones. Left, (+) control, Right, RR-receptor, eluting with free 
receptor. 
The conclusion from this first attempt at phage display was that the experiment was done 
properly, as judged by the presence of the HPQ sequence.  However, more information was 
required from the experiment, because synthesizing every peptide sequence would be 
impractical.  Interrogation of the individual phage clones was necessary to assess the binding 
affinity and binding properties.  An Enzyme-Linked Immunosorbent Assay (ELISA) would be 
performed to confirm the binding properties of each phage, in a manner redundant to the phage 
display selection.  Controls would be set up to test for plastic binders[54] and to confirm that the 
phage were directly interacting with the scaffold receptor.  Only after this secondary inference of 
binding would sequencing be done, followed by peptide synthesis and solution phase binding 
assessment. 
Following this approach, additional receptors were synthesized, this time with variation 
in the length of the linking diamino acid between the two scaffold segments, in the hopes that the 
ability of the two C-shapes to fold onto each other would be enhanced with added flexibility in 
the hinge region.  Lysine (57) and ornithine (56) containing receptors were synthesized in an 
identical manner to the SS-receptor containing Dpr above.  Again, incubation for at least 60hrs in 
piperidine/ NMP was needed to fully close the DKP.  Subsequent preparative HPLC purification 
of the biotinylated and free receptors afforded the desired products seen in Figures 80 and 81, 
again with yields ranging from 5-10%. The solubility of the purified scaffolds without biotin in 
water was insufficient for phage elution.  This was unexpected, and frankly, difficult to explain, 
but could be remedied in the future by attaching the identical commercially available PEG linker 
to the free-receptor, just omitting the biotin. 
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Figure 80 LC trace, MS trace and structure of the "Orn-receptor." 
 
Figure 81 LC trace, MS trace and structure of the "Lys-receptor." 
 
The second attempt at phage display was much more ambitious, as three receptors were 
being screened against three different libraries, for a total of 12 separate selection experiments, 




as constrained 7mer library consisting of a 7mer flanked by a pair of cysteines.  Incidentally, 
both of these 7mer libraries should have contained 100% of all possible 7-residue peptides.  The 
Dpr(SS) receptor was eluted with free receptor, while the Lys and Orn receptors were eluted with 
100mM biotin, because the free receptor was inexplicably insoluble in buffer.  Typically, 103-104 
phage were eluted during the first and second selections, while amplification of this eluent 
resulted in 1011-1012 phage.  After the final selection, 103-105 phage were eluted.  Of these 
plaques, ~10 clones from each positive control and ~30 clones from each of the receptors and 
phage library were amplified in 1mL of media in 3 x 96-deep-well plate.  Again, sequencing of 
the positive control binding phage validated them as HPQ-streptavidin binders.  The crude 
supernatant contained ample phage for subsequent analysis by ELISA.  Analysis of each clone in 
the presence and absence of biotinylated receptor showed no difference in ELISA signal 
intensity.  The conclusion was that the phage were either plastic binders or binding to something 
else besides the receptor.  The inference was that there was insufficient selective pressure 
directing the phage to bind to the receptor because the receptor was not ordered enough.  More 
rigidity was required of the scaffold receptor, which would be accomplished by exploring 
possible cyclization conditions. 
Synthesis of the next version of a scaffold receptor utilized several modifications.  First, 
four alternating building blocks were used instead of five, because of the difficulties in closing 
all of the DKPs in a timely manner.  Second, by coupling an orthogonally protected Dab(ivDde) 
as the second residue, versatility in subsequent choice of cyclization partner was afforded.  
Third, by using Cbz-protected building blocks for the two trailing ends of the two scaffold 
sequences, which were not able to form DKPs, it was possible to attach a carboxylic acid 
cyclization partner in solution after the DKPs were closed.  Finally, by coupling the amino acid 
cyclization partner last, versatility was increased.   
 




We first attempted to close a macrocycle via a thioether.  The synthesis of thioether 
cyclized peptides are versatile and chemoselective.[55, 56]  Cysteine is available with numerous 
protecting groups which are cleavable using a wide range of conditions, from 1% TFA 
(methoxytrityl), 95% TFA (trityl), triflic acid (tert-butyl), transition metal (acetamido), and 
reduction with phosphines or thiols (S-tert-butyl).  Difficulties were had on previous attempts to 
remove an acetamido using silver salts.  Therefore, we chose the S-tert-butyl as this could be 
deprotected at the very end of the sequence by treatment with tributylphosphine.  Starting from 
the intermediate in Figure 83 (58), Fmoc-Cys(StBu) was attached to the leading end (Figure 84), 
the Fmoc removed, and acetylated, the ivDde was removed, the scaffold was cleaved, the DKPs 
closed, and the product was treated with bromoacetic anhydride (59), with a selective reaction 
facilitated by the presence of the Cbz groups in blue in Figure 84.  Purification gave the desired 
product, which was dissolved in 20%ACN/water and treated with 10mg/mL tris-carboxyethyl 
phosphine (TCEP), a water soluble phosphine reducing agent.  Exposure to this reagent failed to 









At this point, a paper documenting an on-resin, head-to-tail cyclodimerization utilizing 
the Huisgens cyclization between an alkyne and an azide was found.[57]  Finn and coworkers 
synthesized a C-terminal propargyl glycine followed by a >10 residue peptide, culminating with 
azidovaleric acid.  In the presence of copper(I) and base, the peptide was cleanly cyclodimerized.  
No starting material or cyclomonomer were found.  Modifying the resin bound intermediate 58 
with propargyl glycine and azidovaleric acid[58] (61) (Figure 84) produced a substrate similar to 
that of Finn, although the locations of the azide and alkyne were reversed.  Subjecting this azido-
alkyne containing scaffold to the conditions used by Finn produced a new peak 60 with the same 
mass, as would be expected. 
 









Figure 85 First attempt at Huisgens cyclization, producing cyclized product in low overall yield. 
 
The two peaks were purified using preparative HPLC.  The low-res MS (Figure 85) of 
both peaks after purification look similar, with the noticeable absence of charge states indicative 
of a cyclodimer, such as (2M+3)/3 or (2M+5)/5, where M = mass of the monomer.  Additionally, 
close inspection of the (M+1)/1 reveals an isotope pattern differing by integer mass units, not ½ 
as would be expected for a dimer.  Both isolated peaks were subjected to typical DKP closing 
conditions.  The starting material peak closed in 36hrs, while the product triazole peak appeared 
to stall with 1 open DKP.  The interpretation was complicated by the Cbz groups (shown in blue 
in Figure 84), which masked the amines and reducing the MS signal.  Removal of the Cbz 
groups with triflic acid, after cyclization, produced triflate salts that also complicated 
interpretation.  The purpose of the Cbz groups was to allow a selective reaction in solution with 
bromoacetic anhydride in the sequence of forming a thioether, which was not a requirement for 
the Huisgens cyclization.  The thioether would be shelved and this copper catalyzed cyclization 
further explored. 
Free of the need to use Cbz groups, the next proposed macrocycle would contain an extra 
“arm” that could fold on top of the macrocycle to shield the pocket (Figure 86).  A Dab(ivDde) 
would serve as a future attachment point for the PEG-linked biotin.  The synthesis of this 
shielded macrocycle started with Dab, then propargyl glycine and Dpr(Mtt).  The UV tag, 
nitrophenylalanine, was attached after a series of three alternating building blocks.  The Mtt was 
then removed and an additional four alternating building blocks were added.  Another Dpr(Mtt) 
followed by azidovaleric acid (61) completed the synthesis (62).   
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Figure 86 Synthesis outline of a "shielded" macrocycle. 
 
 This molecule 62 was subjected to the on-resin copper(I) cyclization conditions, followed 
by cleavage to produce the desired product (63) as the major peak, as seen in Figure 87.   Again, 
the mass spectrum was consistent with a cyclomonomer.  Treatment of the product with 






Figure 87 Shielded macrocycle (major peak), cleavage product. 
 
The crude cleavage product 63 was subjected to 20% piperidine/NMP for 36hrs to 
produce 64.  This time there was no ambiguity in this cyclization result, as the final product still 
contained one open DKP (Figure 88).  There was a total absence of fully closed product, even 
after an additional two days.  This result along with the lack of a reaction with phosphines imply 
that the copper catalyzed cyclization was clean and efficient, however the resulting ring was too 
strained to be able to close all of the DKPs.  The consensus now is that the DKPs of a 
cyclomonomer are difficult to close fully, perhaps because of strain or sterics.  The solution is to 
close the DKPs first, and then subject that product to macrocyclization conditions. 
63 
MS of 63 
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Figure 88 Shielded macrocycle (major peak), DKP final product 64 (1 DKP still open). 
 
At this in time I had recently discovered conditions for removing the Boc groups on a 
Rink Amide resin.  These conditions were developed and optimized to break a bottleneck in the 
synthesis of the bivalent ligand described in the previous chapter.  This system also would 
benefit greatly from mild Boc deprotection conditions, allowing for the closure of the DKPs on 
the resin in only 12hrs at 37˚C.  Then, after the DKPs were closed, various macrocyclization 
conditions could be evaluated.  The synthesis of a versatile intermediate 65 ensued (Figure 89), 
using a similar sequence as previously, consisting of the sequence, resin-Trp-Dab(ivDde)-SS-
RR-SS-RR-Dpr-SS-RR-SS-RR-Dpr.  This resin was split into ~10 portions.  Three cyclizations 
would be attempted using a thioether, a Huisgens reaction, and a Heck reaction, involving an 




Figure 89 Versatile intermediate used for subsequent cyclization tests 
 
The intermediate was readied for cyclization by the following steps (Figure 90).  First, 
the Fmoc-amino acid was attached to the leading-end amine.  Next, the Boc groups were 
removed using trimethylsilyl triflate (TMSOTf) and 2,6-lutidine in DCM.[42]  The DKPs were 
closed in 12hrs at 37˚C.  At this point, the 3 remaining amines, and also the Trp indole needed to 
be protected or masked.  Initial trials were done by acetylation, however, this lead to difficulties 
in MS interpretation.  A superior solution was to re-protects the amine with Boc-anhydride and 
base.  The ivDde was then removed and the carboxylic acid cyclization partner was attached to 
form 66.  Cyclization conditions followed by cleavage yielded the final product which was 




Figure 90 General synthetic scheme for the synthesis of the cyclization substrate. 
 
For the synthesis of the thioether macrocycle (R2 = bromoacetyl), the cysteine derivative 
Fmoc-Cys(Trt)-OH (R1) was chosen because this was the only protecting group that had been 
successfully and reliably deprotected in the past.  The final Cys protecting group was actually 
unknown, as it was uncertain whether the Boc-deprotection conditions would also remove the 
~50% TFA cleavable Trt group.  If it was removed it would surely be re-protected with a Boc 
group, which would also be labile to the 95% TFA final cleavage solution.[59]  Either way, the 
final DKP closed product would contain a bromoacetyl and a free thiol, all ready for the 





Figure 91 Successful synthesis of a thioether substrate (the second peak). 
 
The desired product was synthesized, containing the free thiol and bromoacetyl.  
Additional peaks were identified corresponding to incorporation of an extra bromoacetyl.  This 
likely was due to incomplete Boc protection.  This could be remedied by washing the beads 
down that may have stuck to the sides of the reactor during the protection, followed by another 
Boc protection.  Incubation of the crude substrate in 10%ACN/water for 1 week resulted in no 
formation of thioether macrocycle.  Bray and coworkers were able to cyclize a 5-residue peptide 
using acidic or basic conditions in a variety of solvents.[55]  It would appear from the literature 
that the formation of a thioether is robust, however we cannot explain why thioether formation 
does not occur in our molecule. 
Synthesis of the Huisgens substrate proceeded as described in Figure 90 by coupling 
Fmoc-propargyl glycine (R1 in Figure 90) and azidovaleric acid (R2 in Figure 90).  Subjection 
this to the copper(I) cyclization conditions similar to that used in Figure 86 should have afforded 
the desired macrocycle upon cleavage.  However, interpretation of this result was complicated by 
the fact the cleavage product before and after alleged cyclization had identical retention times.  
Treatment of the expected product with phosphines resuled in no change in mass or retention 
67 
MS of 67 (product peak) 
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time, however this is a negative result and we can not be certain about the cyclization.  The best 
that can be said about the Huisgens cyclization is that further testing and optimization is needed. 
An alternative cyclization procedure involving the palladium catalyzed Heck reaction 
between an olefin and aromatic iodide was found in the literature, and seemed robust and high-
yielding.[60]  Preparation of the cyclization substrate was described in Figure 90.  Treatment 
with 0.4eq Pd(OAc)2, PPh3, and Bu4NCl in DMF:water:Et3N (20:2:1) for 12hrs at room 
temperature, followed by cleavage yielded the final cyclized product 68  (Figure 92, 93).   
 
Figure 92 Heck macrocyclization, followed by cleavage. 
 
Figure 93 LCMS confirmation of a successful Heck macrocyclization. 
 
This reaction went to >95% completion based on absence of aryl iodide substrate, and 




involved in the synthesis of the cyclized scaffold, based on an HPLC calibration curve, appear to 
be typical (~10%).  Again, the major impurities were cyclized products with multiple acrylic 
acids, derived from incomplete Boc re-protection, and could easily be prevented in the future.  It 
should be noted that the Heck reaction worked the first time, and three subsequent times, all 
going to completion in less than 12hr at room temperature.  Also, the Heck reaction was tolerant 
to water and was run open to the atmosphere, proving to be a particularly easy reaction with no 
optimization.  The Heck reaction has been successfully implemented for making cyclic scaffolds, 
having all DKPs closed, and warrants further development as a promising tool for making 
molecules that can act as receptors, ligands, or sensors. 
3.3 CONCLUSIONS 
Although the search for a peptide that binds to a synthetic receptor has been unsuccessful thus 
far, there is a great deal of promise for the future of this project.  The techniques and methods of 
phage display have proven to be easy to master, as judged by the successful selection of the HPQ 
phage for streptavidin.  We believe that the first two attempts at phage display failed because the 
receptors were too flexible or floppy. Because of the inadequacies of the first generations of 
scaffold receptors, conditions for making large cyclic scaffolds have been explored, and the 
Heck reaction has been identified as an excellent way to macrocyclize a rigidified scaffold, 
having all DKPs closed.  Large cyclic scaffolds capable of folding and forming a pocket should 
now be possible, so the potential exists that a specific peptide could be recognized by this 
scaffold receptor, thus propelling the field of artificial antibodies forward. 
3.4 EXPERIMENTAL 
General: Dichloromethane was distilled from CaH2.  All other reagents were used as received, 
unless stated otherwise.  Column chromatography was performed using ICN Silitech 32-63 D 
(60 Ǻ) grade silica gel and TLC analysis was performed on EM Science Silica Gel 60 F254 plates 
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(250μm thickness).  NMR spectroscopy was performed using a Bruker 300 MHz instruments.  
Chemical shifts were reported in parts per million downfield relative to trimethylsilane and 
categorized as br = broad, s = singlet, d = doublet, dd = doublet of doublet, ddd = doublet of 
doublet of doublet, t = triplet, q = quartet, and m = multiplet.  Solid phase synthesis was 
performed in a 1.5mL disposable polypropylene reaction column, connected to a three-way valve 
equipped with vacuum and argon for mixing.  Dichloromethane (DCM) used in coupling 
reactions was distilled over calcium hydride.  Dry grade of dimethylformamide (DMF) from 
Aldrich was used for coupling.  N,N-diisopropylethylamine (DIPEA) was distilled under 
nitrogen sequentially from ninhydrin and potassium hydroxide and stored over molecular sieves.  
O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorphospate (HATU) was 
obtained from Acros.  O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorphospate 
(HBTU) and N-Hydroxybenzotriazole hydrate (HOBt) were obtained from Novabiochem.  All 
solid phase reactions were mixed by bubbling argon up through reactor, allowing for mixing and 
an inert atmosphere over the reaction.  HPLC-MS analysis was performed on a Hewlett-Packard 
Series 1050 instrument equipped with a Waters Xterra MS C18 column (3.5μm packing, 4.6 mm 
x 150 mm) and a diode-array detector, while the MSD-ESI was Series 1100.  Preparative 
purification was done using a Varian Prostar 500 equipped with a Waters Xterra Prep MS-C18 
column (5μm packing, 10 mm x 100 mm), equipped with a dual wavelength detector. 
 
Solid phase synthesis of receptor Version 1 (SS,RR,SS,RR,SS,RR)2 (52). 
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Figure 94 Biotin labeled receptor, containing two 6-building block sections 
 
To a 50mL polypropylene solid phase peptide synthesis (SPPS) reaction vessel was 
added Rink Amide AM Resin (Novabiochem) (40mg, 25.2μmol loading).  The resin was swollen 
for 1hr in DMF.  The terminal Fmoc-protected amine was deprotected in 2mL of 20% 
piperidine/DMF for 40min.  By measuring the absorbance at 301nm of a 1/100 dilution, the 
number of moles of Fmoc removed was calculated by using ε = 7800 M-1 cm-1.  The resin was 
washed with DMF, isopropanol, DMF, isopropanol, DMF, for 2min each. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 66.4mg 
(126μmol) of Fmoc-L-Trp(Boc)-OH (Novabiochem)  and 47.9mg of HATU (126μmol) in 630μL 
of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 43.9μL 
(252μmol) of DIPEA was added to make the active ester.  After 10min activation time, the 
solution was added to the deprotected resin, and allowed to react by argon mixing for 30min.  
The resin was then washed 3x 2min with DMF.  Double couplings allowed for quantitative 
acylation, as judged by subsequent Fmoc release in the same manner described above. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 25.7mg 
(50.4μmol) of Boc-protected pro4(2S4S) building block[17] and 19.2mg of HATU (50.4μmol) in 
252μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 17.6μL 
(100.8μmol) of DIPEA was added to make the active ester, as above, followed by washing, a 
second coupling, washing, and Fmoc release.  This process of coupling/deprotection was 
52 
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repeated five additional times, by alternating between Boc-protected pro4(2S4S) building block 
and Boc-protected pro4(2R4R) building block, yielding the sequence, resin-Trp-SS-RR-SS-RR-
SS-RR-free amine. 
In a 1.5 mL microcentrifuge tube, the coupling solution was made by dissolving 73.4mg 
(126μmol) of Fmoc-L-Dpr(Mtt)-OH (Novabiochem) and 47.9mg of HATU (126μmol) in 630μL 
of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 21.9μL 
(252μmol) of DIPEA was added to make the active ester, as above, followed by washing, a 
second coupling, washing, and Fmoc release.  The final Fmoc-deprotection was allowed to go 
for 2hr instead of 40min.  This ensured that diketopiperazine formation was complete, thus all 
free amine was converted to an amide. 
The resin was swelled in DCM with slight bubbling for 30min.  The Dpr side chain 
protecting group, methytrityl, was removed using a 1% trifluoroacetic acid, 5% triisopropylsilane 
solution in DCM.  10 x 1mL, each reacting for about 2-3 minutes was sufficient to completely 
unmask the side chain amine.  Neutralization with 2 x 0.5mL of 5% DIPEA in DCM followed by 
swelling in DMF readied the resin for acylation.   
The second arm of the receptor was made in same manner as the first, consisting of 
alternating between Boc-protected pro4(2S4S) building block and Boc-protected pro4(2R4R) 
building block, yielding the sequence, resin-Trp-SS-RR-SS-RR-SS-RR-Dpr-SS-RR-SS-RR-SS-
RR-free amine, followed by coupling of Fmoc-Dpr(Mtt)-OH, removal of Fmoc for 2hr, removal 
of Mtt with 1% TFA, and neutralization with 5% DIPEA, as above. 
The resin was then portioned into halves.  Half was prepared for cleavage and half was 
acylated with biotin.  The resin was swelled in DMF for 30min.  In a 1.5 mL microcentrifuge 
tube, the coupling solution was made by dissolving 35.3mg (63.0μmol) of N-Biotinyl-NH-
(PEG)2-COOH (Novabiochem)and 24.0mg of HATU (63.0μmol) in 315μL of 20% DCM/DMF.  
This solution was mixed using a micropipettor, after which 11.0μL (126μmol) of DIPEA was 
added to make the active ester, as above, followed by washing, a second coupling, washing, and 
Fmoc release.  Both halves of the resin were extensively washed with DMF, IPA, DMF, IPA, 
DMF, MeOH, DCM, MeOH, DCM, MeOH, DCM, and then dried overnight, in vacuo. 
The scaffolds, with and without biotin, were cleaved in 2mL of 2.5% water, 2.5% 
triisopropylsilane in trifluoroacetic acid, with stirring for 2hours.  The solutions were drained and 
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the beads were then washed with 2 x 2mL additional TFA.  The cleavage solutions were pooled 
into a 13mm glass tube and the solvent was removed in a SpeedVac. 
The diketopiperazines were closed by incubation for 48hr in 0.5mL of 20% piperidine in 
NMP.  In this case, it was concluded by LCMS that the product was not fully closed, so the 
reaction was incubated at 60˚C for 3 days.  Then, the product was dripped into 10 volumes ether, 
which was then spun at 3000rpm in a benchtop centrifuge.  The pellet was washed with fresh 
ether and centrifuged again.  The pellet was allowed to dry for an hour, before being dissolved in 
25% ACN in water with 0.5% formic acid and analyzed by LCMS. 
 
Solid phase synthesis of receptor Version 2 (SS,RR,SS,RR,SS)-(SS,RR,SS,RR,SS) (54) or 
(SS,RR,SS,RR,SS)-(RR,SS,RR,SS,RR) (55). 
 
Figure 95 Biotin labeled receptor, containing two 5-building block sections, with different stereochemistries. 
 
To a 50mL polypropylene solid phase peptide synthesis (SPPS) reaction vessel was 
added Rink Amide AM Resin (Novabiochem) (80mg, 50.4μmol loading).  The resin was swollen 
for 1hr in DMF.  The terminal Fmoc-protected amine was deprotected in 4mL of 20% 
piperidine/DMF for 40min.  By measuring the absorbance at 301nm of a 1/200 dilution, the 
number of moles of Fmoc removed was calculated by using ε = 7800 M-1 cm-1.  The resin was 
washed with DMF, isopropanol, DMF, isopropanol, DMF, for 2min each. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 132.8mg 
(252μmol) of Fmoc-L-Trp(Boc)-OH (Novabiochem) and 95.8mg of HATU (252μmol) in 
1260μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 87.8μL 
(504μmol) of DIPEA was added to make the active ester.  After 10min activation time, the 
solution was added to the deprotected resin, and allowed to react by argon mixing for 30min.  
The resin was then washed 3x 2min with DMF.  Double couplings allowed for quantitative 
acylation, as judged by subsequent Fmoc release in the same manner described above. 
54 55 
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In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 51.4mg 
(100.8μmol) of Boc-protected pro4(2S4S) building block and 38.4mg of HATU (100.8μmol) in 
504μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 35.1μL 
(201.6μmol) of DIPEA was added to make the active ester, as above, followed by washing, a 
second coupling, washing, and Fmoc release.  This process of coupling/deprotection was 
repeated four additional times, by alternating between Boc-protected pro4(2S4S) building block 
and Boc-protected pro4(2R4R) building block, yielding the sequence, resin-Trp-SS-RR-SS-RR-
SS- free amine. 
In a 1.5 mL microcentrifuge tube, the coupling solution was made by dissolving 146.8mg 
(252μmol) of Fmoc-L-Dpr(Mtt)-OH (Novabiochem) and 95.8mg of HATU (252μmol) in 
1260μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 87.8μL 
(504μmol) of DIPEA was added to make the active ester, as above, followed by washing, a 
second coupling, washing, and Fmoc release.  The final Fmoc-deprotection was allowed to go 
for 2hr instead of 40min.  This ensured that diketopiperazine formation was complete, thus all 
free amine was converted to an amide. 
The resin was swelled in DCM with slight bubbling for 30min.  The Dpr side chain 
protecting group, methytrityl, was removed using a 1% trifluoroacetic acid, 5% triisopropylsilane 
solution in DCM.  10 x 1mL, each reacting for about 2-3 minutes was sufficient to completely 
unmask the side chain amine.  Neutralization with 2 x 0.5mL of 5% DIPEA in DCM followed by 
swelling in DMF readied the resin for acylation.   
The resin was split into halves.  The difference between the two was whether the 6th 
building block was Boc-protected pro4(2S4S) or Boc-protected pro4(2R4R).  This produced 
resin-Trp-SS-RR-SS-RR-SS-Dpr-SS-RR-SS-RR-SS-free amine or resin-Trp-SS-RR-SS-RR-SS-
Dpr-RR-SS-RR-SS-RR-free amine, followed by coupling of Fmoc-Dpr(Mtt)-OH, removal of 
Fmoc for 2hr, removal of Mtt with 1% TFA, and neutralization with 5% DIPEA, as above. 
Each resin was then again portioned into halves.  Half was prepared for cleavage and half 
was acylated with biotin.  The resin was swelled in DMF for 30min.  In 2 x 1.5 mL 
microcentrifuge tube (for each of the two receptors), the coupling solution was made by 
dissolving 35.3mg (63.0μmol) of N-Biotinyl-NH-(PEG)2-COOH (Novabiochem)and 24.0mg of 
HATU (63.0μmol) in 315μL of 20% DCM/DMF.  This solution was mixed using a 
micropipettor, after which 11.0μL (126μmol) of DIPEA was added to make the active ester, as 
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above, followed by washing, a second coupling, washing, and Fmoc release.  Both halves of the 
resin were extensively washed with DMF, IPA, DMF, IPA, DMF, MeOH, DCM, MeOH, DCM, 
MeOH, DCM, and then dried overnight, in vacuo. 
The scaffolds, with and without biotin, were cleaved in 2mL of 2.5% water, 2.5% 
triisopropylsilane in trifluoroacetic acid, with stirring for 2hours.  The solutions were drained and 
the beads were then washed with 2 x 2mL additional TFA.  The cleavage solutions were pooled 
into a 13mm glass tube and the solvent was removed in a SpeedVac. 
The diketopiperazines were closed by incubation for 36hr in 0.5mL of 20% piperidine in 
NMP.  Then, the product was dripped into 10 volumes ether, which was then spun at 3000rpm in 
a benchtop centrifuge.  The pellet was washed with fresh ether and centrifuged again.  The pellet 
was allowed to dry for an hour, before being dissolved in 25% ACN in water with 0.5% formic 
acid.  The final products (with and without biotin) were purified on a preparative HPLC column, 
as a single injection.  All peaks were collected and re-injected on the LCMS to obtain the identity 
of the collected peak as well as the purity.  Fractions containing product were pooled, 
lyophilized, and resuspended in tris-buffered saline (TBS).  From the absorbance of the Trp, the 
concentration was calculated (ε = 5600 M-1 cm-1).  The stock solutions were stored at 4˚C. 
 
 
Solid phase synthesis of receptor Version 3 (SS,RR,SS,RR,SS)-X-(SS,RR,SS,RR,SS), 
X=Orn (56) or Lys (57). 
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Figure 96 Biotin labeled receptor, containing two 5-building block sections, with Orn or Lys spacer. 
 
To a 50mL polypropylene solid phase peptide synthesis (SPPS) reaction vessel was 
added Rink Amide AM Resin (Novabiochem) (80mg, 50.4μmol loading).  The resin was swollen 
for 1hr in DMF.  The terminal Fmoc-protected amine was deprotected in 4mL of 20% 
piperidine/DMF for 40min.  By measuring the absorbance at 301nm of a 1/200 dilution, the 
number of moles of Fmoc removed was calculated by using ε = 7800 M-1 cm-1.  The resin was 
washed with DMF, isopropanol, DMF, isopropanol, DMF, for 2min each. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 132.8mg 
(252μmol) of Fmoc-L-Trp(Boc)-OH (Novabiochem) and 95.8mg of HATU (252μmol) in 
1260μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 87.8μL 
(504μmol) of DIPEA was added to make the active ester.  After 10min activation time, the 
solution was added to the deprotected resin, and allowed to react by argon mixing for 30min.  
The resin was then washed 3x 2min with DMF.  Double couplings allowed for quantitative 
acylation, as judged by subsequent Fmoc release in the same manner described above. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 51.4mg 
(100.8μmol) of Boc-protected pro4(2S4S) building block and 38.4mg of HATU (100.8μmol) in 
504μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 35.1μL 
57 56 
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(201.6μmol) of DIPEA was added to make the active ester, as above, followed by washing, a 
second coupling, washing, and Fmoc release.  This process of coupling/deprotection was 
repeated four additional times, by alternating between Boc-protected pro4(2S4S) building block 
and Boc-protected pro4(2R4R) building block, yielding the sequence, resin-Trp-SS-RR-SS-RR-
SS- free amine. 
The resin was split into halves.  The difference between the two was whether the bridging 
amino acid was Fmoc-Orn(Mtt)-OH or Fmoc-Lys(Mtt)-OH.  In a 1.5 mL microcentrifuge tube, 
the coupling solution was made by dissolving 76.9mg of Orn or 78.7mg of Lys (126μmol) of 
Fmoc-L-AA(Mtt)-OH (Novabiochem) and 47.9mg of HATU (126μmol) in 630μL of 20% 
DCM/DMF.  This solution was mixed using a micropipettor, after which 43.9μL (252μmol) of 
DIPEA was added to make the active ester, as above, followed by washing, a second coupling, 
washing, and Fmoc release.  The final Fmoc-deprotection was allowed to go for 2hr instead of 
40min.  This ensured that diketopiperazine formation was complete, thus all free amine was 
converted to an amide. 
The resin was swelled in DCM with slight bubbling for 30min.  The Dpr side chain 
protecting group, methytrityl, was removed using a 1% trifluoroacetic acid, 5% triisopropylsilane 
solution in DCM.  10 x 1mL, each reacting for about 2-3 minutes was sufficient to completely 
unmask the side chain amine.  Neutralization with 2 x 0.5mL of 5% DIPEA in DCM followed by 
swelling in DMF readied the resin for acylation.   
The two resins were then elongated with five alternating building blocks  This produced 
resin-Trp-SS-RR-SS-RR-SS-Orn-SS-RR-SS-RR-SS-free amine or resin-Trp-SS-RR-SS-RR-SS-
Lys-SS-RR-SS-RR-SS-free amine, followed by coupling of Fmoc-Dpr(Mtt)-OH, removal of 
Fmoc for 2hr, removal of Mtt with 1% TFA, and neutralization with 5% DIPEA, similar to 
above. 
Each resin was then again portioned into halves.  Half was prepared for cleavage and half 
was acylated with biotin.  The resin was swelled in DMF for 30min.  In 2 x 1.5 mL 
microcentrifuge tube (for each of the two receptors), the coupling solution was made by 
dissolving 35.3mg (63.0μmol) of N-Biotinyl-NH-(PEG)2-COOH (Novabiochem)and 24.0mg of 
HATU (63.0μmol) in 315μL of 20% DCM/DMF.  This solution was mixed using a 
micropipettor, after which 11.0μL (126μmol) of DIPEA was added to make the active ester, as 
above, followed by washing, a second coupling, washing, and Fmoc release.  Both halves of the 
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resin were extensively washed with DMF, IPA, DMF, IPA, DMF, MeOH, DCM, MeOH, DCM, 
MeOH, DCM, and then dried overnight, in vacuo. 
The scaffolds, with and without biotin, were cleaved in 2mL of 2.5% water, 2.5% 
triisopropylsilane in trifluoroacetic acid, with stirring for 2hours.  The solutions were drained and 
the beads were then washed with 2 x 2mL additional TFA.  The cleavage solutions were pooled 
into a 13mm glass tube and the solvent was removed in a SpeedVac. 
The diketopiperazines were closed by incubation for 36hr in 0.5mL of 20% piperidine in 
NMP.  Then, the product was dripped into 10 volumes ether, which was then spun at 3000rpm in 
a benchtop centrifuge.  The pellet was washed with fresh ether and centrifuged again.  The pellet 
was allowed to dry for an hour, before being dissolved in 25% ACN in water with 0.5% formic 
acid.  The final products (with and without biotin) were purified on a preparative HPLC column, 
as a single injection.  All peaks were collected and re-injected on the LCMS to obtain the identity 
of the collected peak as well as the purity.  Fractions containing product were pooled, 
lyophilized, and resuspended in tris-buffered saline (TBS).  From the absorbance of the Trp, the 
concentration was calculated (ε = 5600 M-1 cm-1).  The stock solutions were stored at 4˚C. 
 
Solid phase synthesis of receptor Version 4, macrocyclization via thioether or Huisgens 
cyclization (58). 
 
Figure 97 Common intermediate for macrocycle synthesis 
 
To a 10mL polypropylene solid phase peptide synthesis (SPPS) reaction vessel was 
added Rink Amide AM Resin (Novabiochem) (20mg, 12.6μmol loading).  The resin was swollen 
for 1hr in DMF.  The terminal Fmoc-protected amine was deprotected in 1mL of 20% 
58 
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piperidine/DMF for 40min.  By measuring the absorbance at 301nm of a 1/200 dilution, the 
number of moles of Fmoc removed was calculated by using ε = 7800 M-1 cm-1.  The resin was 
washed with DMF, isopropanol, DMF, isopropanol, DMF, for 2min each. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 33.2mg 
(63μmol) of Fmoc-L-Trp(Boc)-OH (Novabiochem) and 24.0mg of HATU (63μmol) in 315μL of 
20% DCM/DMF.  This solution was mixed using a micropipettor, after which 21.9μL (126μmol) 
of DIPEA was added to make the active ester.  After 10min activation time, the solution was 
added to the deprotected resin, and allowed to react by argon mixing for 30min.  The resin was 
then washed 3 x 2min with DMF.  Double couplings allowed for quantitative acylation, as 
judged by subsequent Fmoc release in the same manner described above. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 34.4mg 
(63μmol) of Fmoc-L-Dab(ivDde)-OH (Novabiochem) and 24.0mg of HATU (63μmol) in 315μL 
of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 21.9μL 
(126μmol) of DIPEA was added to make the active ester, as above, followed by washing, a 
second coupling, washing, and Fmoc release.   
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 13.2mg 
(25.2μmol) of Cbz-protected pro4(2R4R) building block and 9.6mg of HATU (25.2μmol) in 
126μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 8.8μL 
(50.4μmol) of DIPEA was added to make the active ester, as above, followed by washing, a 
second coupling, washing, and Fmoc release.  This process of coupling/deprotection was 
repeated three additional times, by alternating between Boc-protected pro4(2S4S) building block 
and Boc-protected pro4(2R4R) building block, yielding the sequence, resin-Trp-RR(Cbz)-SS-
RR-SS- free amine. 
In a 1.5 mL microcentrifuge tube, the coupling solution was made by dissolving 18.4mg 
(31.5μmol) of Fmoc-L-Dpr(Mtt)-OH (Novabiochem) and 12.0mg of HATU (31.5μmol) in 
160μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 5.5μL 
(63.0μmol) of DIPEA was added to make the active ester, as above, followed by washing, a 
second coupling, washing, and Fmoc release.  The final Fmoc-deprotection was allowed to go 
for 2hr instead of 40min.  This ensured that diketopiperazine formation was complete, thus all 
free amine was converted to an amide. 
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The resin was swelled in DCM with slight bubbling for 30min.  The Dpr side chain 
protecting group, methytrityl, was removed using a 1% trifluoroacetic acid, 5% triisopropylsilane 
solution in DCM.  10 x 1mL, each reacting for about 2-3 minutes was sufficient to completely 
unmask the side chain amine.  Neutralization with 2 x 0.5mL of 5% DIPEA in DCM followed by 
swelling in DMF readied the resin for acylation.   
The resin was then elongated with five alternating building blocks, as described above.  
This produced resin-Trp-Dab-RR(Cbz)-SS-RR-SS-Dpr-RR(Cbz)-SS-RR-SS-free amine, 
followed by coupling of Fmoc-Dpr(Mtt)-OH, removal of Fmoc for 2hr, removal of Mtt with 1% 
TFA, and neutralization with 5% DIPEA, similar to above. 
The resin was extensively washed with DMF, IPA, DMF, IPA, DMF, MeOH, DCM, 
MeOH, DCM, MeOH, DCM, and then dried overnight, in vacuo, and then stored in the 
desiccator. 
Synthesis of thioether macrocycles (68). 
 
Figure 98 Bromoacetylated scaffold, with the cysteine still protected. 
 
A few (~3mg) beads were placed in a 1mL polypropylene solid phase peptide synthesis  
reaction vessel.  After being swelled in DMF for 30min, a solution of activated ester, consisting 
of estimated 20eq Fmoc-Cys(StBu)-OH (Novabiochem), 20eq HATU, 40eq DIPEA at 0.2M in 
DMF, was added and allowed to react for.  The beads were washed 3 x 2min with DMF, and the 
coupling was repeated.  The Fmoc was removed, and the free amine was capped with acetic 
anhydride: DMF: DIPEA (100:400:20).  The Dab side chain protecting group, ivDde, was 
removed using a solution of 4% hydrazine hydrate in DMF.  4 x 1mL, each reacting for about 3-
59 
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5 minutes was sufficient to completely unmask the side chain.  The resin was extensively washed 
with DMF, IPA, DMF, IPA, DMF, MeOH, DCM, MeOH, DCM, MeOH, DCM, and then dried 
overnight, in vacuo. 
The scaffold was cleaved in 2mL of 2.5% water, 2.5% triisopropylsilane in trifluoroacetic 
acid, with stirring for 2hours.  The solutions were drained and the beads were then washed with 2 
x 2mL additional TFA.  The cleavage solutions were pooled into a 13mm glass tube and the 
solvent was removed in a SpeedVac. 
The diketopiperazines were closed by incubation for 36hr in 0.5mL of 20% piperidine in 
NMP.  Then, the product was dripped into 10 volumes ether, which was then spun at 3000rpm in 
a benchtop centrifuge.  The pellet was washed with fresh ether and centrifuged again.  The pellet 
was allowed to dry for an hour, before being dissolved in 25% ACN in water with 0.5% formic 
acid and analyzed by LCMS. 
The bromoacetyl group was attached to the only free amine by dissolving 10mg 
bromoacetic anhydride (Aldrich) in 200μL DMF, and adding to the ether precipitated pellet.  The 
reaction was stirred for 30min, and precipitated into ether as described above.  The dried pellet 
was dissolved in 25% ACN in water, 0.5% formic acid and analyzed by LCMS. 
 
Synthesis of Huisgens macrocycle (60). 
 




methyl 5-azidovalerate[58] (Caution—low molecular weight azides are potentially 
EXPLOSIVE) 
To a stirred solution of 1.15g (6.0mmol) of methyl 5-bromovalerate (Aldrich) in 20mL of DMF 
in a 50mL round bottom, 430mg (6.6mmol) of sodium azide was added, and the solution was 
stirred under dry nitrogen overnight.  The solution was then poured into 200mL of water, and 
extracted with 3 x 100mL EtOAc.  The organic layers were pooled, washed with 2 x50mL brine, 
and dried over sodium sulfate.  The solvent was removed in vacuo, and dried in vacuo for 2hrs 
(product is volatile).  The resulting product (720mg, 76% yield) was a colorless oil and was used 
without further purification. 
 
5-azidovaleric acid (61). [58] 
The substrate (700mg, 3.7mmol) was dissolved in 5mL MeOH and 5mL of 0.5M LiOH was 
added, and the reaction was stirred for 4hrs.  The reaction was quenched with 3mL of 1M HCl, 
and extracted with 3 x 50mL EtOAc.  The pooled organic layers were washed with 2 x 20mL 
brine and dried over sodium sulfate.  The solvent was removed in vacuo to yield 610mg product 
(94%) as a colorless oil.  The product was dissolved in 5mL dry dichloromethane and stored like 
this to minimize explosive conditions.  1H NMR (300MHz, 25˚C, CDCl3) δ 11.2 (br, 1H), 3.28 
(t, 2H), 2.38 (t, 2H), 1.65 (m, 4H). 
 
A few (~3mg) beads were placed in a 1mL polypropylene solid phase peptide synthesis  
reaction vessel.  After being swelled in DMF for 30min, a solution of activated ester, consisting 
of estimated 20eq Fmoc-L-propargyl glycine-OH (Fluka), 20eq HATU, 40eq DIPEA at 0.2M in 
DMF, was added and allowed to react for 30min.  The beads were washed 3 x 2min with DMF, 
and the coupling was repeated.  The Fmoc was removed, and the free amine was capped with 
acetic anhydride: DMF: DIPEA (100:400:20) for 10min.  The Dab side chain protecting group, 
ivDde, was removed using a solution of 4% hydrazine hydrate in DMF.  4 x 1mL, each reacting 
for about 3-5 minutes was sufficient to completely unmask the side chain.  A solution of ~8eq 5-
azidovaleric acid, 8eq HATU, 16eq DIPEA at 0.2M in DMF, was added and allowed to react for 
30min.  The beads were washed 3 x 2min with DMF, and the coupling was repeated.   
The on-resin macrocyclization conditions were similar to those used by Finn for an on-
resin head-to-tail, cyclodimerization.[57]  Solutions of 4.8mg CuI (Avacodo) in 2.5mL of 20% 
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DMSO in ACN and 12.5mg of sodium ascorbate (Aldrich) in 0.25mL water were prepared, as 
well as 12μL of 2,6-lutidine.  A volume fraction of each, based on the number of moles of Fmoc 
released from the propargyl glycine (Ppg), divided by the number of moles used in the paper 
(50μmol), was used to compute the volumes of CuI, NaAsc, and lutidine that were needed.  The 
CuI was added first, followed by the lutidine and finally the NaAsc.  The reaction and beads 
were stirred for 16hrs at room temperature.  Following this, the beads were washed extensively 
with acetonitrile and DMF, then water and 0.1M EDTA, and acetonitrile and DMF again, 
repeated at least three times.  Then, the resin was extensively washed with DMF, IPA, DMF, 
IPA, DMF, MeOH, DCM, MeOH, DCM, MeOH, DCM, and then dried overnight, in vacuo. 
The scaffold was cleaved in 2mL of 2.5% water, 2.5% triisopropylsilane in trifluoroacetic 
acid, with stirring for 2hours.  The solutions were drained and the beads were then washed with 2 
x 2mL additional TFA.  The cleavage solutions were pooled into a 13mm glass tube and the 
solvent was removed in a SpeedVac. 
The diketopiperazines were closed by incubation for 36hr in 0.5mL of 20% piperidine in 
NMP.  Then, the product was dripped into 10 volumes ether, which was then spun at 3000rpm in 
a benchtop centrifuge.  The pellet was washed with fresh ether and centrifuged again.  The pellet 
was allowed to dry for an hour, before being dissolved in 25% ACN in water with 0.5% formic 
acid and analyzed by LCMS. 
 
Solid phase synthesis of receptor Version 5, Huisgens macrocycle (63). 
 




To a 10mL polypropylene solid phase peptide synthesis (SPPS) reaction vessel was 
added Rink Amide AM Resin (Novabiochem) (10mg, 6.3μmol loading).  The resin was swollen 
for 1hr in DMF.  The terminal Fmoc-protected amine was deprotected in 1mL of 20% 
piperidine/DMF for 40min.  By measuring the absorbance at 301nm of a 1/100 dilution, the 
number of moles of Fmoc removed was calculated by using ε = 7800 M-1 cm-1.  The resin was 
washed with DMF, isopropanol, DMF, isopropanol, DMF, for 2min each. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 10.3mg 
(18.9μmol) of Fmoc-L-Dab(ivDde)-OH (Novabiochem) and 7.2mg of HATU (18.9μmol) in 
100μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 6.6μL 
(37.8μmol) of DIPEA was added to make the active ester.  After 10min activation time, the 
solution was added to the deprotected resin, and allowed to react by argon mixing for 30min.  
The resin was then washed 3 x 2min with DMF.  Double couplings allowed for quantitative 
acylation, as judged by subsequent Fmoc release in the same manner described above. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 6.3mg 
(18.9μmol) of Fmoc-L-Ppg-OH (Novabiochem) and 7.2mg of HATU (18.9μmol) in 100μL of 
20% DCM/DMF.  This solution was mixed using a micropipettor, after which 6.6μL (37.8μmol) 
of DIPEA was added to make the active ester, as above, followed by washing, a second coupling, 
washing, and Fmoc release.   
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 11.0mg 
(18.9μmol) of Fmoc-L-Dpr(Mtt)-OH (Novabiochem) and 7.2mg of HATU (18.9μmol) in 100μL 
of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 6.6μL 
(37.8μmol) of DIPEA was added to make the active ester, as above, followed by washing, a 
second coupling, washing, and Fmoc release.   
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 6.4mg 
(12.6μmol) of Boc-protected pro4(2R4R) building block and 4.8mg of HATU (12.6μmol) in 
75μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 4.4μL 
(25.2μmol) of DIPEA was added to make the active ester, as above, followed by washing, a 
second coupling, washing, and Fmoc release.  This process of coupling/deprotection was 
repeated two additional times, by alternating between Boc-protected pro4(2R4R) building block 
and Boc-protected pro4(2S4S) building block, yielding the sequence, resin-Dab-Ppg-Dpr-RR-
SS-RR-free amine. 
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In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 16.6mg 
(31.5μmol) of Fmoc-L-4-Nitrophenylalanine-OH (Novabiochem) and 12.0mg of HATU 
(31.5μmol) in 160μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after 
which 11.0μL (63μmol) of DIPEA was added to make the active ester, as above, followed by 
washing, a second coupling, washing, and Fmoc release.  The final Fmoc-deprotection was 
allowed to go for 2hr instead of 40min.  This ensured that diketopiperazine formation was 
complete, thus all free amine was converted to an amide. 
The resin was swelled in DCM with slight bubbling for 30min.  The Dpr side chain 
protecting group, methytrityl, was removed using a 1% trifluoroacetic acid, 5% triisopropylsilane 
solution in DCM.  10 x 1mL, each reacting for about 2-3 minutes was sufficient to completely 
unmask the side chain amine.  Neutralization with 2 x 0.5mL of 5% DIPEA in DCM followed by 
swelling in DMF readied the resin for acylation.   
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 6.4mg 
(12.6μmol) of Boc-protected pro4(2S4S) building block and 4.8mg of HATU (12.6μmol) in 
75μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 4.4μL 
(25.2μmol) of DIPEA was added to make the active ester, as above, followed by washing, a 
second coupling, washing, and Fmoc release.  This process of coupling/deprotection was 
repeated three additional times, by alternating between Boc-protected pro4(2S4S) building block 
and Boc-protected pro4(2R4R) building block, yielding the sequence, resin-Dab-Ppg-Dpr-(-RR-
SS-RR-SR-free amine)-SS-RR-SS-NO2Phe. 
In a 1.5 mL microcentrifuge tube, the coupling solution was made by dissolving 11.0mg 
(18.9μmol) of Fmoc-L-Dpr(Mtt)-OH (Novabiochem) and 7.2mg of HATU (12.6μmol) in 100μL 
of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 6.6μL 
(37.8μmol) of DIPEA was added to make the active ester, as above, followed by washing, a 
second coupling, washing, and Fmoc release.  The final Fmoc-deprotection was allowed to go 
for 2hr instead of 40min.  This ensured that diketopiperazine formation was complete, thus all 
free amine was converted to an amide. 
The resin was swelled in DCM with slight bubbling for 30min.  The Dpr side chain 
protecting group, methytrityl, was removed using a 1% trifluoroacetic acid, 5% triisopropylsilane 
solution in DCM.  10 x 1mL, each reacting for about 2-3 minutes was sufficient to completely 
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unmask the side chain amine.  Neutralization with 2 x 0.5mL of 5% DIPEA in DCM followed by 
swelling in DMF readied the resin for acylation. 
In a 1.5 mL microcentrifuge tube, the coupling solution was made by dissolving 4.5mg 
(31.5μmol) of 5-azidovaleric acid and 12.0mg of HATU (31.5μmol) in 160μL of 20% 
DCM/DMF.  This solution was mixed using a micropipettor, after which 11.0μL (63.0μmol) of 
DIPEA was added to make the active ester, as above, followed by washing, a second coupling, 
and washing. 
The on-resin macrocyclization conditions were similar to those used by Finn for an on-
resin head-to-tail, cyclodimerization.[57]  Solutions of 4.8mg CuI (Avacodo) in 2.5mL of 20% 
DMSO in ACN and 12.5mg of sodium ascorbate (Aldrich) in 0.25mL water were prepared, as 
well as 12μL of 2,6-lutidine.  A volume fraction of each, based on the number of moles of Fmoc 
released from the propargyl glycine (Ppg), divided by the number of moles used in the paper 
(50μmol), was used to compute the volumes of CuI, NaAsc, and lutidine that were needed.  The 
CuI was added first, followed by the lutidine and finally the NaAsc.  The reaction and beads 
were stirred for 16hrs at room temperature.  Following this, the beads were washed extensively 
with acetonitrile and DMF, then water and 0.1M EDTA, and acetonitrile and DMF again, 
repeated at least three times.  Then, the resin was extensively washed with DMF, IPA, DMF, 
IPA, DMF, MeOH, DCM, MeOH, DCM, MeOH, DCM, and then dried overnight, in vacuo. 
The scaffold was cleaved in 2mL of 2.5% water, 2.5% triisopropylsilane in trifluoroacetic 
acid, with stirring for 2hours.  The solutions were drained and the beads were then washed with 2 
x 2mL additional TFA.  The cleavage solutions were pooled into a 13mm glass tube and the 
solvent was removed in a SpeedVac. 
The diketopiperazines were closed by incubation for 36hr in 0.5mL of 20% piperidine in 
NMP.  Then, the product was dripped into 10 volumes ether, which was then spun at 3000rpm in 
a benchtop centrifuge.  The pellet was washed with fresh ether and centrifuged again.  The pellet 
was allowed to dry for an hour, before being dissolved in 25% ACN in water with 0.5% formic 
acid and analyzed by LCMS. 
 
Solid phase synthesis of receptor Version 6, macrocyclization via thioether, Huisgens 
cyclization, or Heck reaction (65). 
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Figure 101 Common intermediate for testing of multiple macrocyclization conditions. 
 
To a 10mL polypropylene solid phase peptide synthesis (SPPS) reaction vessel was 
added Rink Amide (NOT AM!) Resin (Novabiochem) (30mg, 18μmol loading).  The resin was 
swollen for 1hr in DMF.  The terminal Fmoc-protected amine was deprotected in 2mL of 20% 
piperidine/DMF for 40min.  By measuring the absorbance at 301nm of a 1/200 dilution, the 
number of moles of Fmoc removed was calculated by using ε = 7800 M-1 cm-1.  The resin was 
washed with DMF, isopropanol, DMF, isopropanol, DMF, for 2min each. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 47.4mg 
(90μmol) of Fmoc-L-Trp(Boc)-OH (Novabiochem) and 34.2mg of HATU (90μmol) in 450μL of 
20% DCM/DMF.  This solution was mixed using a micropipettor, after which 31.4μL (180μmol) 
of DIPEA was added to make the active ester.  After 10min activation time, the solution was 
added to the deprotected resin, and allowed to react by argon mixing for 30min.  The resin was 
then washed 3 x 2min with DMF.  Double couplings allowed for quantitative acylation, as 
judged by subsequent Fmoc release in the same manner described above. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 49.2mg 
(90μmol) of Fmoc-L-Dab(ivDde)-OH (Novabiochem) and 34.2mg of HATU (90μmol) in 450μL 
of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 31.4μL 
(180μmol) of DIPEA was added to make the active ester, as above, followed by washing, a 
second coupling, washing, and Fmoc release.   
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 18.4mg 
(36.0μmol) of Boc-protected pro4(2S4S) building block and 13.7mg of HATU (36.0μmol) in 
180μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 12.5μL 
(72.0μmol) of DIPEA was added to make the active ester, as above, followed by washing, a 
second coupling, washing, and Fmoc release.  This process of coupling/deprotection was 
65 
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repeated three additional times, by alternating between Boc-protected pro4(2S4S) building block 
and Boc-protected pro4(2R4R) building block, yielding the sequence, resin-Trp-SS-RR-SS-RR-
free amine. 
In a 1.5 mL microcentrifuge tube, the coupling solution was made by dissolving 31.5mg 
(54.0μmol) of Fmoc-L-Dpr(Mtt)-OH (Novabiochem) and 20.5mg of HATU (54.0μmol) in 
270μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 18.8μL 
(108μmol) of DIPEA was added to make the active ester, as above, followed by washing, a 
second coupling, washing, and Fmoc release.  The final Fmoc-deprotection was allowed to go 
for 2hr instead of 40min.  This ensured that diketopiperazine formation was complete, thus all 
free amine was converted to an amide. 
The resin was swelled in DCM with slight bubbling for 30min.  The Dpr side chain 
protecting group, methytrityl, was removed using a 1% trifluoroacetic acid, 5% triisopropylsilane 
solution in DCM.  10 x 1mL, each reacting for about 2-3 minutes was sufficient to completely 
unmask the side chain amine.  Neutralization with 2 x 0.5mL of 5% DIPEA in DCM followed by 
swelling in DMF readied the resin for acylation.   
The resin was then elongated with four alternating building blocks, as described above.  
This produced resin-Trp-Dab-SS-RR-SS-RR-Dpr-SS-RR-SS-RR-free amine, followed by 
coupling of Fmoc-Dpr(Mtt)-OH, removal of Fmoc for 2hr, removal of Mtt with 1% TFA, and 
neutralization with 5% DIPEA, similar to above. 
The resin was extensively washed with DMF, IPA, DMF, IPA, DMF, MeOH, DCM, 
MeOH, DCM, MeOH, DCM, and then dried overnight, in vacuo, and then stored in the 
desiccator. 
 
Synthesis of Macrocycle via a Heck reaction (68). 
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Figure 102 Macrocycle made with a Heck reaction 
 
A few beads (~3mgs) of resin were swelled in DMF for 30min.  In a 1.5 mL 
microcentrifuge tube, the coupling solution was made by dissolving 10eq of Fmoc-L-4-
Iodophenylalanine-OH (Synthetech) and 10eq of HATU at 0.2M of 20% DCM/DMF.  This 
solution was mixed using a micropipettor, after which 20eq of DIPEA was added and allowed to 
react for 30min.  The beads were washed 3 x 2min with DMF, and the coupling was repeated.  
The Fmoc was removed and washed with DMF, IPA, DMF, IPA, DCM, IPA, and DCM. 
Because the solid support was the ordinary Rink Amide resin, the Boc groups on the 
building blocks were removed using procedure from the Burgess lab.[42]  The beads were 
washed with DCM for 5min.  A solution of 5mL of 1M trimethylsilyl triflate (Aldrich-TMSOTf-
from a Schlenk bottle) and 1.5M 2,6-lutidine in DCM was prepared.  By adding 3 x 0.75mL x 
5min, with slight bubbling, the Boc groups were removed while still attached to the resin, with 
DCM washes in between.  After deprotection, the resin was washed vigorously with DCM, 
followed by 5 cycles of MeOH / DCM washes, ending up with swelling in DMF for 5min.  The 
DKPs were then closed on the resin using a stirred solution of 0.5mL of 20% piperidine in NMP 
for 12hrs at 35˚C -40˚C. 
68 
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The Boc groups were then reattached to the 2 trailing end amines and N-terminus using a 
solution of ~10mg of Boc-anhydride in DCM with 30μL of DIPEA, with stirring overnight.  The 
resin was then washed with DCM, MeOH, DCM, IPA, DMF, IPA, DMF, and DMF. 
The Dab side chain protecting group, ivDde, was removed using a solution of 4% 
hydrazine hydrate in DMF.  4 x 1mL, each reacting for about 3-5 minutes was sufficient to 
completely unmask the side chain.  A solution of ~20eq acrylic acid, 20eq HATU, 40eq DIPEA 
at 0.2M in DMF, was added and allowed to react for 30min.  The beads were washed 3 x 2min 
with DMF, and the coupling was repeated.   
A solution of 5mg Pd(OAc)2 (Aldrich), 3mg tetrabutylammonium chloride (Aldrich) and 
6mg of triphenylphospine (Aldrich) in 2mL of DMF: water: triethylamine (20:2:1) was prepared 
(all reagents are 0.4eq).  The volume fraction of the Heck reagents was calculated, based on the 
number of moles of Fmoc released from the Iodophenylalanine (Iph), divided by the 
concentration, which was 36μL per μmol of Fmoc released, similar to the conditions used by 
others.[60]  The reaction was allowed to stir for 12hrs at room temperature.  It was then washed 
extensively with DMF, IPA, DMF, IPA, DMF, MeOH, DCM, MeOH, DCM, MeOH, DCM, and 
then dried overnight, in vacuo. 
 The scaffold was cleaved in 2mL of 2.5% water, 2.5% triisopropylsilane in 
trifluoroacetic acid, with stirring for 2hours.  The solutions were drained and the beads were then 
washed with 2 x 2mL additional TFA.  The cleavage solutions were pooled into a 13mm glass 
tube and the solvent was removed in a SpeedVac. 
 
Synthesis of Macrocycle via a thioether (67). 
 134 
 
Figure 103 Thioether substrate used for attempted thioether synthesis 
 
  A few beads (~3mgs) of resin were swelled in DMF for 30min.  In a 1.5 mL 
microcentrifuge tube, the coupling solution was made by dissolving 10eq of Fmoc-L-Cys(Trt)-
OH (Novabiochem) and 10eq of HATU at 0.2M of 20% DCM/DMF.  This solution was mixed 
using a micropipettor, after which 20eq of DIPEA was added and allowed to react for 30min.  
The beads were washed 3 x 2min with DMF, and the coupling was repeated.  The Fmoc was 
removed and washed with DMF, IPA, DMF, IPA, DCM, IPA, and DCM. 
The Boc groups on the building blocks were removed using procedure from the Burgess 
lab.[42]  The beads were washed with DCM for 5min.  A solution of 5mL of 1M trimethylsilyl 
triflate (Aldrich-TMSOTf-from a Schlenk bottle) and 1.5M 2,6-lutidine in DCM was prepared.  
By adding 3 x 0.75mL x 5min, with slight bubbling, the Boc groups were removed from the 
resin, with DCM washes in between.  After deprotection, the resin was washed vigorously with 
DCM, followed by 5 cycles of MeOH / DCM washes, ending up with swelling in DMF for 5min.  
The DKPs were then closed on the resin using a stirred solution of 0.5mL of 20% piperidine in 
NMP for 12hrs at 35˚C -40˚C. 
The Boc groups were then reattached to the 2 trailing end amines and N-terminus, and, 
likely, the cysteine sulfur as well, using a solution of ~10mg of Boc-anhydride in DCM with 
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30μL of DIPEA, with stirring overnight.  The resin was then washed with DCM, MeOH, DCM, 
IPA, DMF, IPA, DMF, and DMF. 
The Dab side chain protecting group, ivDde, was removed using a solution of 4% 
hydrazine hydrate in DMF.  4 x 1mL, each reacting for about 3-5 minutes was sufficient to 
completely unmask the side chain.  A solution of ~10mg bromoacetic anhydride in 200μL of 
DMF was added and allowed to react for 30min.  The beads were washed 3 x 2min with DMF, 
and the coupling was repeated.  The beads were then washed extensively with DMF, IPA, DMF, 
IPA, DMF, MeOH, DCM, MeOH, DCM, MeOH, DCM, and then dried overnight, in vacuo. 
 The scaffold was cleaved in 2mL of 2.5% water, 2.5% triisopropylsilane in 
trifluoroacetic acid, with stirring for 2hours.  The solutions were drained and the beads were then 
washed with 2 x 2mL additional TFA.  The cleavage solutions were pooled into a 13mm glass 
tube and the solvent was removed in a SpeedVac. 
 
Synthesis of Macrocycle via a Huisgens cyclization 
 
Figure 104 Macrocycle made with a Huisgen cycloaddition. 
 
  A few beads (~3mgs) of resin were swelled in DMF for 30min.  In a 1.5 mL 
microcentrifuge tube, the coupling solution was made by dissolving 10eq of Fmoc-L-Propargyl 
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glycine-OH (Fluka) and 10eq of HATU at 0.2M of 20% DCM/DMF.  This solution was mixed 
using a micropipettor, after which 20eq of DIPEA was added and allowed to react for 30min.  
The beads were washed 3 x 2min with DMF, and the coupling was repeated.  The Fmoc was 
removed and washed with DMF, IPA, DMF, IPA, DCM, IPA, and DCM. 
The Boc groups on the building blocks were removed using procedure from the Burgess 
lab.[42]  The beads were washed with DCM for 5min.  A solution of 5mL of 1M trimethylsilyl 
triflate (Aldrich-TMSOTf-from a Schlenk bottle) and 1.5M 2,6-lutidine in DCM was prepared.  
By adding 3 x 0.75mL x 5min, with slight bubbling, the Boc groups were removed from the 
resin, with DCM washes in between.  After deprotection, the resin was washed vigorously with 
DCM, followed by 5 cycles of MeOH / DCM washes, ending up with swelling in DMF for 5min.  
The DKPs were then closed on the resin using a stirred solution of 0.5mL of 20% piperidine in 
NMP for 12hrs at 35˚C -40˚C. 
The Boc groups were then reattached to the 2 trailing end amines and N-terminus, using a 
solution of ~10mg of Boc-anhydride in DCM with 30μL of DIPEA, with stirring overnight.  The 
resin was then washed with DCM, MeOH, DCM, IPA, DMF, IPA, DMF, and DMF. 
The Dab side chain protecting group, ivDde, was removed using a solution of 4% 
hydrazine hydrate in DMF.  4 x 1mL, each reacting for about 3-5 minutes was sufficient to 
completely unmask the side chain.  A solution of ~20eq 5-azidovaleric acid, 20eq HATU, 40eq 
DIPEA at 0.2M in DMF, was added and allowed to react for 30min.  The beads were washed 3 x 
2min with DMF, and the coupling was repeated.   
The on-resin macrocyclization conditions were similar to those used by Finn for an on-
resin head-to-tail, cyclodimerization.[57]  Solutions of 4.8mg CuI (Avacodo) in 2.5mL of 20% 
DMSO in ACN and 12.5mg of sodium ascorbate (Aldrich) in 0.25mL water were prepared, as 
well as 12μL of 2,6-lutidine.  A volume fraction of each, based on the number of moles of Fmoc 
released from the propargyl glycine (Ppg), divided by the number of moles used in the paper 
(50μmol), was used to compute the volumes of CuI, NaAsc, and lutidine that were needed.  The 
CuI was added first, followed by the lutidine and finally the NaAsc.  The reaction and beads 
were stirred for 16hrs at room temperature.  Following this, the beads were washed extensively 
with acetonitrile and DMF, then water and 0.1M EDTA, and acetonitrile and DMF again, 
repeated at least three times.  Then, the resin was extensively washed with DMF, IPA, DMF, 
IPA, DMF, MeOH, DCM, MeOH, DCM, MeOH, DCM, and then dried overnight, in vacuo. 
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The scaffold was cleaved in 2mL of 2.5% water, 2.5% triisopropylsilane in trifluoroacetic 
acid, with stirring for 2hours.  The solutions were drained and the beads were then washed with 2 
x 2mL additional TFA.  The cleavage solutions were pooled into a 13mm glass tube and the 
solvent was removed in a SpeedVac. 
  
 Phage Display Procedure 
 
 The phage display experiments were done using a kit from New England Biolabs (NEB).  
The procedures used were similar to that found in the Phage Display Peptide Library Kit Manual, 
available at www.neb.com /nebecomm/products/productE8110.asp.  However, some changes 
were made, and the amended procedure is found below. 
  
Media and Solutions: 
LB Medium: Per liter: 10 g Bacto-Tryptone, 5 g yeast extract, 5 g NaCl. Aliquot into many 25mL 
or a few 10mL portions in 50mL Falcon tubes, cap loosely.  Autoclave, tighten cap, store at 
room temperature. 
LB/IPTG/Xgal Plates: LB medium + 15 g/L agar. Autoclave, cool to < 70°C, add 1 ml 
IPTG/Xgal (Mix 1.25 g IPTG (isopropyl -D-thiogalactoside) and 1 g Xgal (5-Bromo-4-chloro-3-
indolyl-D-galactoside) in 25 ml DMF. Solution can be stored at ¬20°C in the dark) and pour, 
20mL per plate. Store plates at 4°C in the dark. 
LB-Tet Plates: LB medium + 15 g/l Agar. Autoclave, cool to <70°C, add 20mg Tetracycline and 
pour, 20mL per plate. Store plates at 4°C in the dark. Do not use plates if brown or black. 
Agarose Top: Per liter: 10 g Bacto-Tryptone, 5 g yeast extract, 5 g NaCl, 1 g MgCl2•6H2O, 7 g 
agarose. Dispense into 100 ml aliquots in orange-cap bottles. Autoclave only on the morning of 
the experiments, retrieve hot, and store in water bath, set at 45°C, until needed. 
Blocking buffer: 0.1 M NaHCO3(pH 8.6), 5 mg/ml BSA, 0.02% NaN3. Filter sterilize, store at 
4°C. The blocking buffer should contain 0.1 µg/ml streptavidin in order to complex any  
biotin in the BSA. 
TBS: 50 mM Tris-HCl (pH 7.5), 150 mM NaCl (make at least 10 liters). Autoclave, store at room 
temperature. 
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PEG/NaCl: 20% (w/v) polyethylene glycol¬8000, 2.5 M NaCl (difficult to dissolve-may even be 
cloudy after heating). Autoclave, store at room temperature. 
Streptavidin Stock Solution: Dissolve 1.5 mg Lyophilized Streptavidin (supplied) in 1 ml 10 mM 
sodium phosphate (pH 7.2), 100 mM NaCl, 0.02% NaN3. Store at 4°C. 
 
Strain Maintenance 
1. The supplied E. coli host strain ER2738 is a robust F+strain with a rapid growth rate and is 
particularly well-suited for M13 propagation.  
2. Since M13 is a male-specific phage, it is recommended that all cultures for M13 propagation 
be inoculated from colonies grown on media selective for presence of the F-factor, rather than 
directly from the supplied glycerol culture. The F-factor of ER2738 contains a mini-transposon 
which confers tetracycline resistance, so cells harboring the F-factor can be selected by plating 
and propagating on tetracycline- containing media. 
3. Streak out ER2738 from the included glycerol culture onto an LB-Tet plate. Invert and 
incubate at 37°C overnight and store wrapped with parafilm at 4°C in the dark for a maximum of 
1 week. 
4. ER2738 cultures for infection can be grown either in LB or LB-Tet media. Loss of F-factor in 
nonselective media is insignificant as long as cultures are not serially diluted repeatedly. 
 
Avoiding Phage Contamination 
The M13 coat protein pIII mediates infectivity by binding to the F-pilus of the recipient 
bacterium. Display of foreign peptides as N-terminal fusions to pIII appears to attenuate 
infectivity of the library phage relative to wild-type M13. As a result, there is a strong in vivo 
selection for any contaminating wild-type phage during the amplification steps between rounds 
of panning. In the absence of a correspondingly strong in vitro binding selection, even 
vanishingly small levels of contamination can result in a majority of the phage pool being wild-
type phage after three rounds of panning.  
1. The potential for contamination with environmental bacteriophage can be minimized by using 
aerosol-resistant pipette tips for all protocols described in the Manual. 
2. Since the library phage are derived from the common cloning vector M13mp19, which carries 
the lacZ gene, phage plaques appear blue when plated on media containing Xgal and IPTG. 
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Environmental filamentous phage will typically yield white plaques when plated on the same 
media. These plaques are also larger and "fuzzier" than the library phage plaques. We strongly 
recommend plating on LB/IPTG/Xgal plates for all titering steps and, if white plaques are 
evident, picking ONLY blue plaques for sequencing.  
 
Phage Titering  
The number of plaques will increase linearly with added phage only when the multiplicity of 
infection (MOI) is much less than 1 (i.e.,, cells are in excess). For this reason, it is recommended 
that phage stocks be titered by diluting prior to infection, rather than by diluting cells infected at 
a high MOI. Plating at low MOI will also ensure that each plaque contains only one DNA 
sequence. 
1. Inoculate 5-10 ml of LB-TET with a single colony of ER2738 and incubate with shaking until 
mid-log phase (OD600~ 0.5; about 12hrs). 
2. Once cells are growing, autoclave Agarose Top, remove hot, and store in water bath at 45°C 
until ready for use. 
3. Pre-warm LB/IPTG/Xgal plate per expected dilution at 37°C until ready for use. 
4. Prepare 10-fold serial dilutions of phage in LB.  Suggested dilution ranges: for amplified 
phage culture supernatants, 108 to 1011; for unamplified panning eluents, 101-104. Use a fresh 
pipette tip for each dilution.  
5. Once culture has reached mid-log phase, dispense 200 µl culture into 15mL conical tubes, 1 
for each phage dilution. 
6. Add 10 µl of each dilution to each tube, vortex quickly, and incubate at room temperature for 
1¬5 minutes. 
7. After this time, remove 5 caps at a time, and transfer 3mL of Top-Agar to each tube, quickly 
cap and vortex and quickly pour onto a pre-warmed LB/IPTG/Xgal plate. Spread Top-Agar 
evenly by tilting plate. 
8. Allow plates to cool 5 minutes, invert and incubate overnight at 37°C. 
9. Inspect plates and count plaques on plates having ~102plaques. Multiply each number by the 
dilution factor for that plate to get phage titer in plaque forming units (pfu) per 10 µl. 
 
Control Panning Experiment 
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Follow the below procedure using streptavidin as the target adding 0.1 µg /ml streptavidin to the 
blocking solution to complex to any biotin in the BSA. Elute bound phage with 0.1 mM biotin in 
TBS for at least 30 minutes. After 3 rounds of enrichment/amplification, the consensus sequence  
for streptavidin-binding peptides should contain the motif His-Pro-Gln (HPQ). 
 
Day One 
Panning is carried out in a 96-well microtiter plates (ReactiBind, Pierce #15042).  Alternatively, 
pre-coated streptavidin plates could be used (Sigma #M5432).   
1. Prepare a solution of 100 µg/ml of streptavidin in 0.1 M NaHCO3 (pH 8.6).  
2. Add 150 µl to each well.  
3. Incubate overnight at 4°C in a humidified container (e.g., a sealable plastic box lined with 
damp paper towels). Store plates at 4°C in humidified container until needed. 
 
Day Two 
4. Inoculate 10 ml LB medium (add Tet) with streaked-plate ER2738 (plating culture for 
titering).  Incubate 37°C for 8-10hrs with vigorous shaking. 
5. Pour off the coating solution from the microplate and firmly slap it face down onto a clean 
paper towel to remove residual solution. Fill each plate or well completely with Blocking Buffer. 
Incubate at least 1 hour at 4°C. 
6. Discard the blocking solution as in step 5. Wash each plate rapidly 6X with TBST (TBS + 
0.1% [v/v] Tween-20). Coat bottom and sides of plate or well by swirling, pour off the solution, 
and slap the plate face down on a clean paper towel each time. Work quickly to avoid drying out 
the plates. 
7a. While plates are blocking, pre-complex phage with biotinylated target. Combine in 
microfuge tube 0.1-10 µg biotinylated target (depending on amount available) and 1.5 x 1011 
pfu of the input phage (=10 µl of original library) in 400 µl TBST. Incubate at room temperature 
for 60 minutes. 
7b. Add phage-target solution to the washed blocked plate. Incubate at room temperature for 30 
minutes. 
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7c. Add biotin to a final concentration of 0.1 mM (to displace potential HPQ phage) and incubate 
an additional 5 minutes.  The off rate for the biotinylated target is sufficiently slow that the target 
will not be displaced by the biotin. 
8. Discard nonbinding phage by pouring off and slapping plate face-down onto a clean paper 
towel. 
9. Wash plates 10 times with TBST as in step 6. Use a clean section of paper towel each time to 
prevent cross-contamination. 
10. Elute bound phage with 100 µl of a solution of the "biotin-less" ligand (~100 µg/ml in TBS) 
to compete the bound phage away from the immobilized target on the plate. Rock gently for 60 
minutes at room temperature. Pipette eluent into a sterile microcentrifuge tube. 
10a. Alternatively, a general buffer for nonspecific disruption of binding interactions (likely lifts 
everything off of the plate or totally denatures the streptavidin) is 150 µl of 0.2 M Glycine-HCl 
(pH 2.2), 1 mg/ml BSA. Rock gently for no more than 10 minutes. Pipette eluent into a 
microcentrifuge tube. Neutralize with 150 µl (15 µl for microtiter wells) 1 M Tris-HCl (pH 9.1).  
The pH neutralization here is absolutely critical. 
11. Titer a small amount (~1 µl) of the eluent as described in General M13 Methods, above. The 
remaining eluent can be stored overnight at 4°C at this point and amplified the next day.  
12. Set up an overnight culture of ER2738 (from streaked plate) in LB-Tet. 
 
Day Three 
13. The next day dilute the overnight culture 1:100 in 20 ml LB-TET in a 250 ml Erlenmeyer 
flask and add ½ the volume unamplified eluent (store the rest at 4°C in case of emergency). 
Incubate at 37°C with vigorous shaking for 4.5 hours (time critical here). 
14. Transfer the culture to a centrifuge tube and spin 10 minutes at 5,000 rpm in large, floor-
centrifuge at 4°C. Transfer the supernatant to a fresh tube and re-spin to ensure all cells removed 
(SAVE SUPERNATANT-phage is in the liquid layer).  
15. Pipette the upper 80% of the supernatant to a fresh tube (purple cap=higher strength) and add 
1/6 volume of PEG/NaCl. Allow phage to precipitate at 4°C for at least 2hrs. 
16. Spin PEG precipitation 15 minutes at 10,000 rpm at 4°C. Decant supernatant, re-spin briefly, 
and remove residual supernatant with a pipette. 
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17. Suspend the pellet in 1 ml TBS. Transfer the suspension to a microcentrifuge tube and spin 
for 5 minutes at 4°C to pellet residual cells. 
18. Transfer the supernatant to a fresh microcentrifuge tube and re-precipitate with 1/6 volume of 
PEG/NaCl. Incubate on ice 30 minutes. Microcentrifuge for 10 minutes at 4°C. Discard 
supernatant, re-spin briefly, and remove residual supernatant with a micropipette. 
19. Suspend the pellet in 200 µl TBS, 0.02% NaN3. Microcentrifuge for 1 minute to pellet any 
remaining insoluble matter. Transfer the supernatant to a fresh tube. This is the amplified eluent. 
20. Titer the amplified eluent as described in General M13 Method on LB/IPTG/Xgal plates. 
Store at 4°C. 
21. Coat a plate for the second round of panning, as in day one. 
 
Days Four and Five 
22. Count blue plaques and determine phage titer. Use this value to calculate an input volume 
corresponding to 1-2 x 1011pfu. If the titer is too low, succeeding rounds of panning can be 
carried out with as little as 109pfu of input phage. 
23. Carry out a second round of panning: repeat steps 4-12 and raising the Tween concentration 
in the wash steps to 0.5% (v/v). 
24. Titer the resulting second round amplified eluent on LB/IPTG/Xgal plates.  Amplify ½ the 
volume eluent and precipitate phage as in steps 13-20. 
25. Coat a plate for the third round of panning, as in day one. 
 
Days Six 
22. Count blue plaques and determine phage titer. Use this value to calculate an input volume 
corresponding to 1-2 x 1011pfu. If the titer is too low, succeeding rounds of panning can be 
carried out with as little as 109pfu of input phage. 
23. Carry out a second round of panning: repeat steps 4-12 and raising the Tween concentration 
in the wash steps to 0.5% (v/v). 
24. Titer the resulting second round amplified eluent on LB/IPTG/Xgal plates.  Plaques from this 
titering can be used for sequencing or ELISA assays: time the procedure so that plates are 
incubated no longer than 18 hours, as deletions may occur if plates are grown longer. Store the 
remaining eluent at 4°C. 
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Assaying titered phage for binding to receptor by ELISA 
1. The night before ELISA is to be done, inoculate 20 ml of LB-Tet medium with streaked 
ER2738 and incubate at 37°C overnight.  Also coat two plates (FisherBrand 21-377-204) for 
every deep-welled plate with 100µl of 100 µg/ml of streptavidin in 0.1 M NaHCO3 (pH 8.6). 
Incubate at 4°C overnight in an air-tight humidified box (e.g., a sealable plastic box lined with 
wet paper towels). 
2. The amplified crude, phage-containing supernatant can be used for the ELISA assay.  For the 
highest throughput, use a deep-welled (2mL, VWR-47749-874) 96-well plate to amplify the 
titered 3rd elution plaques from the last step, step 24.  Dilute the overnight culture, 1:100 with 
fresh LB-Tet, and, use a flame-sterilized metal wire cell-picker to barely touch the tip to a blue 
colony and transfer to 1mL of 1:100 diluted cell culture.  More explicitly, flame sterilize the tip, 
pierce the agar to cool, then immediately touch the tip to a colony, which was numbered using a 
marker to write on the petri dish (don't "sweep" the colony- need to conserve for multiple uses, 
potentially).  Repeat many times.  At least 50-200 colonies should be investigated, per library, 
per receptor.   
3. Incubate deep-well plate at incubate at 37°C with vigorous aeration for 4 1/2 hours, although 
be careful to secure the plate to the shaker, and be sure not to shake too hard and get cross-talk 
between wells. 
4. After 4.5 hrs transfer plate to benchtop centrifuge and use the 96-well plate rotor to pellet cells 
at 2000rpm for 20-30min at 4°C. 
5. While the phage is amplifying, shake out excess streptavidin solution and slap plate face-down 
onto a paper towel. Fill each well completely with Blocking Buffer. Additionally, a second 
microtiter plate/per deep-welled plate should also be blocked in order to test for binding of each 
selected sequence to BSA-coated plastic.  Incubate at 4°C, 1-2 hours.   
6. Shake out the blocking buffer and wash each plate 6 times with TTBS (the percentage of 
Tween should be the same as the concentration used in the panning wash steps), slapping the 
plate face-down onto a clean section of paper towel each time.  
7. At this point there are three blocked plate.  One has only been blocked and will be used to test 
for BSA-plastic binding.  Two others have been coated with streptavidin and blocked.  One will 
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be used to test for streptavidin binding, by omitting the biotinylated-receptor, and the other plate 
will be the actual experiment, containing all important components. 
8. Add 50 µl of phage supernatant from the deep-well amplification plate to each of the three 
blocked microtiter plates, using the multichannel pipettor.  Then add biotinylated receptor, 0.1 
µg in 50 µl TTBS, to each well of the experimental plate.  Add 50 µl TTBS to the other two 
plates (BSA/phage only and BSA-streptavidin/phage only).  Incubate at room temperature for 1-
2 hours with agitation. 
9. Wash plate 6 times with 1X TBS/Tween as in step 6. 
10. Dilute HRP-conjugated anti-M13 antibody (Pharmacia # 27-9411-01) 1:5,000 in blocking 
buffer. Add 200 µl of diluted conjugate to each well and incubate at room temperature for 1 hour 
with agitation. 
11. Wash 6 times with 1X TBS/Tween as in step 6. 
12. Prepare the HRP substrate solution as follows: a stock solution of ABTS can be prepared in 
advance by dissolving 22 mg ABTS (Sigma #A1888) in 100 ml of 50 mM sodium citrate, pH 
4.0. Filter sterilize and store at 4°C. Immediately prior to the detection step, add 36 µl 30% 
H2O2 to 21 ml of ABTS stock solution per plate to be analyzed. 
13. Add 200 µl substrate solution to each well, incubate at room temperature for 10-60 minutes. 
14. Read plates using a microplate reader set at 405-415 nm. 
 
Plaque amplification 
1. The night before, inoculate 20 ml of LB-Tet medium with streaked ER2738 and incubate at 
37°C overnight.   
2. Dilute the ER2738 overnight culture 1:100 in LB-Tet. Dispense 2 ml diluted culture into a 
15mL falcon culture tubes with the clear caps that rest or snap, one for each clone to be 
characterized. 
3. Using a sterile metal cell-picker, touch a blue plaque and transfer to a tube containing diluted 
culture. Important: pick plaques from plates having  
no more than ~100 plaques. This will ensure that each plaque contains a single DNA sequence. 
4. Incubate tubes at 37°C with shaking for 4.5¬5 hours. 
5. Snap caps and centrifuge cultures for 20 min, 3000rpm at 4°C. Transfer the upper 80% of the 
supernatant (1.6 mL) to a fresh tube. This is the amplified phage stock and can be stored at 4°C 
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for several weeks with little loss of titer. For long-term storage, dilute 1:1 with sterile glycerol 
and store at -20°C. 
6. Add 300 µl PEG/NaCl. Invert to mix, and let stand at room temperature 10 minutes. 
7. Centrifuge 10 minutes, discard supernatant. 
8. Re-spin briefly. Carefully pipette away any remaining supernatant. 
9. Suspend pellet thoroughly in 100 µl Iodide Buffer and add 250 µl ethanol. Incubate 10 
minutes at room temperature. Short incubation at room  
temperature will preferentially precipitate single-stranded phage DNA, leaving most phage 
protein in solution. 
10. Spin 10 minutes, discard supernatant. Wash pellet in 70% ethanol, dry briefly under vacuum. 
7. Suspend pellet in 30 µl deionized water (DO NOT USE TE buffer-EDTA bad for sequencing 
enzymes) 
11. 10 µl of the resuspended template + 3pmol of -96 primer (for automated sequencing) in fresh 
1.5mL tube.  Label with template name, Schafmeister, tube number, starting with 1 (will 
correspond to number on order form to be faxed over before 9am the next day- see website for 
more info http://www.pitt.edu/~rsup/DNAstaticSplash.html).  That night, deliver to fridge 
marked DNA sequencing, found in hallway of 11th floor outside room W1105 BSTWR, in the 
service corridor. 
 
FYI -- The sequence being read corresponds to the anticodon strand of the template. Download 
BioEdit (free program found on web, also on scratch drive, Bird folder) and download 
(http://www.neb.com/nebecomm/tech_reference/restriction_enzymes/sequences/m13ke.txt)  the 
M13KE vector nucleotide sequence from NEB. Open the text file in BioEdit, transform into 
complimentary strand then use the Sequence and Map from the PhD manual to search for 
sequence found in the figure in the manual.  Alternatively, a file on the scratch drive, Bird folder, 
filename "gIII 12mer DNA sequence complement 5-3" contains the sequence of the primer and 
the sequence, as it is extended.  The M and N nucleotides correspond to the nucleotides encoding 
the 12mer peptide.  Delete the appropriate number of nucleotides if using shorter peptides.  
Actual sequence can be opened and overlaid for comparison, such that the constant regions on 
both sides of the peptide nucleotides are identical (it may be necessary to delete or insert 
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nucleotides to get the flanking regions to perfectly overlap.  Take the reverse-complement for the 
coding strand and translate for the peptide sequence. 
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4. STUDIES OF BIVALENT INTERACTIONS:  MATCHED AND MISMATCHED 
BIVALENT PAIRS 
4.1 INTRODUCTION 
The interaction between vancomycin and D-Ala-D-Ala is one of the most well studied and 
characterized non-protein receptor-ligand interactions.  This is because of the importance of 
vancomycin in the treatment of post-operative patients infected with particularly virulent strains 
of Staphylococcus aureas and enterococci, which are often resistant to all other antibiotics.  
Vancomycin and other glycopeptide antibiotics act against gram-positive bacteria, having an 
outer peptidoglycan cell-wall layer, while inactivity in gram-negative stems from the ability of 
glycopeptides to cross the lipopolysachharide layer outside of the peptidoglycan cell-wall. 
 The mechanism of action of vancomycin differs from that of other antibiotics like 
penicillin that also target the cell-wall (Figure 105).  Whereas penicillin binds and inhibits the 
transglycosidase/transpeptidase (TG/TP) involved in the cell-wall cross-linking, vancomycin 
binds to the substrate of the TG/TP.   
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Figure 105 Mechanism of cell-wall formation.  Yellow indicates D-Ala-D-Ala ligand for vancomycin. 
The terminal D-Ala-D-Ala dipeptide of the parent pentapeptide linked to the lipo-
disaccharide membrane anchor is the ligand for vancomycin, while the terminal D-Ala is the 
leaving group resulting from the intermolecular cross-linking of adjacent L-Lys and penultimate 
D-Ala.  The steric bulk of the vancomycin bound to D-Ala-D-Ala prevents the TG/TP from 
binding to its D-Ala substrate.[61]  This leads to incomplete cell-wall cross-linking, causing 
holes to form which end up bursting the cell from the osmotic pressure inside the cell.   
The poly-aromatic backbone of vancomycin serves to precisely pre-arrange the peptide 
backbone of vancomycin (69) for hydrogen bonding interactions with the terminal D-Ala-D-Ala 
as seen in Figure 106.  There exists considerable uncertainty as to the exact function of the 
disaccharide portion of vancomycin.  Affinity can be modulated by adding or subtracting 
substituents to the disaccharide, (results suggest that this affinity modulation occurs through 
alternate pathways, perhaps dimerization) from interaction with the cross-linked oligosaccharide 
cell-wall layer, or through interaction with TG/TP.[62, 63] 
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Figure 106 Hydrogen bonding interactions in the vancomycin D-Ala-D-Ala complex. 
 
These hydrogen bonding interactions are crucial for high affinity and specificity in the 
complex.  For example, when a single H-bond is lost, in the case of mutating the D-Ala-D-Ala 
amide linkage to a D-Ala-D-lactate ester linkage, the cost is 3 orders of magnitude in binding 
affinity.  This is the most common mechanism of resistance to vancomycin.[64]  Two things are 
apparent when looking at the crystal structure of the complex (Figure 107).  First, the proximity 
and geometry between the atoms involved in the recognition network of hydrogen bonds is very 
well-defined.  Second, the way in which the vancomycin folds over the D-Ala-D-Ala allows for 




Figure 107 Crystal structure of a vancomycin (ball & stick)-D-Ala-D-Ala (space filling) complex. 
 
 The numerous analogues of vancomycin have been made, but the effects on activity and 
binding affinity are outside of the relevance of this discussion, except for Whitesides’ tris-Van 
(70) / tris-D-Ala-D-Ala (71) system (Figure 108).[22, 25]  Compared to the monovalent Kd 
(1μM), the trivalent system has a Kd of 4 x 10-17, as measured by HPLC via a competition with 
monovalent D-Ala-D-Ala.  The magnitude of the strength of this interaction is almost difficult to 
comprehend: it is 25 times stronger than the benchmark for high affinity, avidin-biotin.  
Whitesides remarks that the trivalent Kd only differs from the monovalent (Kd)3 by a factor of 40, 
which is likely due to the fact there is little loss of conformational entropy from the linker and 
the vancomycin itself, as both were initially described as relatively rigid.[25]   
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Figure 108 Trivalent vancomycin and trivalent D-Ala-D-Ala structures. 
 
However, Whitesides concluded that there was indeed entropy loss of 13.3 kcal/mol upon 
binding, due to the 9 rotatable bonds in the 3-Van and the 18 rotatable bonds in the 3-D-Ala that 
had to be frozen before complexation.[22]  Jencks estimated the entropic cost of each rotatable 
bond to be ~1.2 kcal/mol.[21]  Whitesides states that the difference in his calculated values and 
the value using Jencks’ formula arise from the difference due the different types of rotatable 
bonds being frozen, both between Jencks’ and Whitesides’ systems, and within Whitesides’ 
system.  [22] 
There are brilliant contributions being made to improving the affinity and antibiotic 
activity of vancomycin.  However, there are other features of this interaction that can be 
exploited.  Using a building block approach to make rigid linkers of varying lengths which hold 
two ligands or two receptors a given distance apart will usher in a new field of applied bivalent 




between the ligand (D) and receptor (V) are either matched or mismatched would be a novel 
application of bivalent interactions and building block approaches towards functional, nanoscale 
molecules.  Matched pairs of D2 and V2 would have complimentary distances between each 
other, while mismatched pairs of D2 and V2 would have distances that were either too long or too 
short to interact as strongly as a matched pair.  As a result, one would expect that a matched pair 
of D2 and V2 would bind to each other, even in the presence of D2 and V2 whose spacing was not 
similar to the matched pair of D2 and V2.  Additionally, if there were two or more matched pairs 
in solution, one would expect that those pairs that were of similar spacing would preferentially 
interact with each other, resulting in multiple matched bivalent pairs.  
 
Figure 109 Two sets of two complimentary pairs should preferentially interact with each other. 
  
This may have application in separation of complex mixtures.  For instance, one could 
imagine a mixture of compounds, each individually fused to a bivalent ligand of having differing 
spacing between the ligands (Figure 110).  Using immobilized bivalent receptors of differing 
length, each individually attached to a resin that was confined in a “tea bag” or lantern of 
differing color, one could separate the mixture of compounds by allowing the different bivalent 
pairs to commingle.  After sufficient time for equilibration, the mixture could be separated, or at 
least enriched, by using the preferred interactions between matched bivalent pairs having similar 





Figure 110 Illustration of proposed mixture separation (A) mixture of "stars" attached to bivalent ligands of 
differing length (B) bivalent receptors of differing lengths, immobilized on “colored beads” (C) complexation of 
mixture of ligands with immobilized receptors, after equilibration (D) visual segregation of colored beads facilitates 
separation of the initial mixture. 
4.2 RESULTS AND DISCUSSION 
The goal of this project was to synthesize bivalent D-Ala-D-Ala and bivalent vancomycin bis-
amino acid scaffold spacers varying from short to long.  The first part of this discussion will 
address the synthesis of D-Ala-D-Ala component and subsequent incorporation into a scaffold.  
The second part will deal with the synthesis of the bivalent vancomycin-containing scaffolds, 
from commercially available vancomycin. 
A series of reactions were necessary to synthesize the D-Ala-D-Ala component needed 
for solid-phase incorporation into bivalent D-Ala-D-Ala molecules.  Using commercially 
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available protected amino acids, a solution phase coupling reaction was utilized to assemble the 
protected dipeptide, followed by deprotection at the N-terminus.  The liberated amine was then 
used to ring open an anhydride to yield a carboxy-terminating linker attached to D-Ala-D-Ala-
OtBu, ready for incorporation into a scaffold on the solid-phase. 
Initial attempts utilized the Fmoc-D-Ala as the coupling partner (Figure 111).  This group 
was chosen initially based previous experiences with it and because it contains a very bright 
chromophore which facilitates ease of purification.  The first step, making the dipeptide, 
proceeded cleanly on a gram-scale using HOBt/HBTU in DMF.  A slight excess of the D-Ala-
OtBu and HOBt/HBTU was used to ensure that all Fmoc-D-Ala was consumed, resulting in only 
one species containing an Fmoc group (72).  After reaction was complete, as judged by LC/MS, 
the contents were poured in 20 volumes of water.  This served multiple purposes.  First, it served 
to stop the reaction, and second, it served to remove the DMF.  Most helpful though, the HOBt 
related species were highly water soluble, while the fully protected dipeptide had zero water 
solubility.  Filtration served to isolate the product away from the coupling reagents and the DMF.  
The product was then dried in vacuo, and loaded onto celite for purification on the Isco.  A 
gradient of hexanes-to-EtOAc was used to remove any slight impurities. 
 
Figure 111 Synthesis of D-Ala-D-Ala using Fmoc-D-Ala 
 
 The assembly of the dipeptide proved to be easily accomplished, however problems were 
encountered in subsequent steps.  Removal of the Fmoc group was done using 4% piperidine in 
acetonitrile, for 30min (73).  After LCMS confirmed completion, the solvent was removed in 
vacuo to yield a white powder, which was then dried overnight in vacuo, at 45˚C.  The dried 
powder was then used to ring open an anhydride, in this case phthalic anhydride.  Problems were 
encountered because it was difficult to remove all of the piperidine from the previous reaction.  
The piperidine-fullvene adduct which is stable in a solution of piperidine likely reverted back to 
piperidine and fullvene via an elimination reaction.  This liberated piperidine or any trace 
piperidine reacted on a similar time-scale to the desired D-Ala-D-Ala-OtBu substrate to consume 
the anhydride which was used sparingly.  In order to get complete reaction to form the desired 
product, excess of the anhydride was required.  This resulted in a number of carboxylic acid-
72 73 
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containing products being formed (Figure 112), all of which eluted on an HPLC chromatogram 
within two minutes of each other.  It is known that mixtures of carboxylic acids are very difficult 
to separate, either on normal or reversed phase, owing to the carboxylic acid being the polarity 
dictating functional group.   
 
Figure 112 Multiple products formed because piperidine is needed to remove the Fmoc group 
 
 An alternative synthesis (Figure 113) was easily implemented, simply by replacing the 
Fmoc-D-Ala with Cbz-D-Ala.  The dipeptide 75 was synthesized in an identical fashion, only the 
purification was slightly challenged by the fact the Cbz absorbs UV light more than 1,000 times 
less at 254nm.  Using a smaller column (40g as opposed to 330g) allowed for clean separation 
and a lower flow rate, thus increasing the sensitivity.  Removal of the Cbz group was easily 
accomplished using palladium-on-charcoal and a hydrogen balloon, with the chosen solvent 
being EtOAc.  Previous experiences had shown that hydrogenations proceed cleanly in 12hrs 
when EtOAc is the solvent.  Although it was known that protic solvents systems, especially 
AcOH:MeOH:water, drastically accelerate the reaction, this would have caused the formation of 
salts upon removal of the protecting groups.  Additionally, acetic acid should be avoided in any 
step near the end of a synthetic product destined for incorporation onto the solid-phase, as even 
trace amounts of acetic acid will react very quickly with the amine, to the detriment of the 
desired product.  However, because clean hydrogenolysis in EtOAc occurred, no acceleration 
was needed.  Since the biproducts were CO2 and toluene, pure product 73 was afforded by 
removal of the solvent in vacuo, yielding an oil used without further purification.  Reaction of 
the amine and the anhydride (0.85 equivalents, relative to the amine) in distilled dichloromethane 
occurred within 2hours to form the desired product (74) quantitatively, which was purified using 





Figure 113 Synthesis of desired phthalate-D-Ala-D-Ala. 
 
A second anhydride (diglycolic anhydride) was used to form an amide of the form, 
HO2C-CH2-O-CH2-CONH-.  However, this linker was deemed less useful, because of the lack of 
a chromophore from which an accurate concentration could be measured.   
 With the ortho-phthalate-D-alanine-D-alanine-tert-butyl ester ligand in hand, the next 
step was the synthesis of the scaffolds of varying length.  It was important to have rigidity, 
resulting from DKPs at both ends of this bivalent scaffold.  A DKP at the leading end is easy to 
accomplish: remove the Fmoc of an amino acid that follows a building block and DKP 
immediately forms.  However, no one in our group had been able to form a DKP at the trailing 
end (Figure 114).  In order to accomplish this, a few things are required.  First a carboxylic acid 
at the trailing end needs to be present.  Many resins produce a free acid after cleavage.  Second 
the resin would need to be cleaved with dilute acid to produce a fully protected scaffold, 
containing a free acid.  Then the free acid could be selectively methylated with TMSCHN2, 
while all other sensitive functionality remained protected.  The trityl resin was chosen, as it met 
all of the above requirements.  After formation of the methyl ester at the trailing end, all 
protecting could then be removed, and the DKPs closed, including the trailing end DKP between 
the first building block and the newly formed methyl ester.  This proposed scheme was validated 
on a model substrate and found to work exactly as planned.  It was then broadly applied to the 
synthesis of both the bis-vancomycin and the bis-D-Ala-D-Ala bivalent molecules. 
 






 The chlorotrityl chloride resin was the solid-support for the synthesis of a series of 
different length scaffolds, having a D-Ala-D-Ala at either end.  The orthogonal protecting group 
isovaleryl-dimethyl-dioxocyclohexylidene (ivDde), cleavable by 2% hydrazine in DMF, was 
chosen for diaminobutanoic acid (Dab) side chain.  One cannot use the diaminopropionic acid 
because it was known to be susceptible to intramolecular migration of the ivDde group when the 
Fmoc was removed, from the N-β to N-α.   
 
Figure 115 Solid phase synthesis of the intermediate used to make bivalent D-Ala-D-Ala. 
 
This first residue was attached to the trityl resin (Figure 115) by deprotonation of the 
carboxyl with DIPEA and then subsequent nucleophilic attack on the triphenylmethyl position of 
the resin.  Attachment of the first building block, pro4(2S4S) with HATU followed by Fmoc 
removal with piperidine served to elongate the chain of building blocks.  After each Fmoc 
removal, an appropriately sized portion of resin would have to be removed so that the varying 
lengths could be made.  By washing the resin with DCM, followed by drying with aspiration for 
5min, this allowed for removal of the dried resin from the reactor and placement in a weigh boat.  
75 
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Removal of a fraction of the resin (first = 1/6th, second = 1/5th, third = 1/4th, etc.) allowed for a 
series of equimolar amounts of varying lengths to made produced.  After completion of the series 
of lengths of 1-6 building blocks, the final Fmoc-Dab(ivDde) was attached using HATU and the 
Fmoc removal was allowed to go for 2hrs to ensure complete closure.  After this, the ivDde was 
removed with hydrazine to give the resin-bound intermediate 75. 
At this point the resins were each split into 3 equal portions, with one portion being set 
aside in the desiccator in case anything went wrong.  The first portion was to contain a β-Ala 
linker between the ligand and scaffold.  This was done in order to evaluate the effect that added 
flexibility may have on the formation of matched bivalent pairs.  This was done by first coupling 
Fmoc-β-Ala to 75, followed by Fmoc removal (Figure 116).  Next the ortho-phthalate-D-
alanine-D-alanine-tert-butyl ester (74) was attached to the resin using HATU.   
 
Figure 116 Synthesis and cleavage of bivalent-β-Ala-D-Ala-D-Ala.  Bivalent D-Ala-D-Ala was made using the 
same steps, except omission of the β-Ala coupling and Fmoc removal step. 
 
The second portion had the initial β-Ala coupling step omitted followed by coupling of 





Figure 117 Synthetic steps of methyl esterification, acid-labile deprotection, and DKP closure to yield final bivalent 
D-Ala-D-Ala molecules 78.  
 
Figure 118 Synthetic steps of methyl esterification, acid-labile deprotection, and DKP closure to yield final bivalent 
β-Ala-D-Ala-D-Ala molecules.  Analogous steps were used to synthesize the bivalent D-Ala-D-Ala molecules. 
 
Cleavage was carried out in 0.5mL of AcOH:trifluorethanol:DCM (1:1:3) for 2hrs, and 
then the resin beads were again treated with 0.5mL of fresh cleavage cocktail, for 3 x 20min 
additional time to give 77/81. The cleavage solutions were pooled and the solvent was removed 
in a SpeedVac.  Addition of DCM:hexanes (3:1) to the oily residue followed by removal of the 
solvent in the SpeedVac, and repeating this two more times, the oily residue turned into a white 
pellet.  This indicated that all of the AcOH had been removed, which would prove to be 
important for the success of the next step.   
Dissolving the pellet in MeOH and treatment of the pellet with 25eq (based on initial 









conversion of the carboxylic acid to the methyl ester 78/82 (Figure 117/118), with no apparent 
side reactions.  Quenching of the excess TMSCHN2 with TFA, followed by removal of the 
solvent in the SpeedVac resulted in an oil that was subsequently treated with TFA:DCM (1:1) to 
remove the Boc groups (79/83).  Solvent was again removed in the SpeedVac.  Closure of the 
diketopiperazines was carried out in 200μL of 20% piperidine in N-methyl pyrrolidone (NMP) at 
room temperature for 36hrs.  Precipitation into ether, centrifugation, ether wash and 
centrifugation gave the final product 80/84, which was resuspended in 0.5mL of 12.5% ACN, 
water with 0.25% formic acid.   
 
Figure 119 Representative HPLC chromatograms of 1mer-DA-DA (A) free acid, cleavage product (B) methyl ester 
product (C) TFA deprotection product (D) final crude DKP product. 
 
Each of the 12 samples 80/84 was purified on the preparative HPLC, as a single injection.  
Fractions suspected of containing the desired product were reinjected onto the LCMS.  In all 
cases, the desired product was obtained in acceptable amounts and in purity in excess of 90% 
(Figure 120/121).  Fractions containing product were lyophilized, and resuspended in 0.5mL 
25% ACN in water.  5μL was injected onto the analytical HPLC in order to quantify the amount 
of the bivalent D-Ala-D-Ala molecules, as described below.  The samples were again lyophilized 




Quantitation of the amounts of material was done using an HPLC calibration curve made 
by injection of known amounts of a phthalic diamide.  Phthalic anhydride was ring opened by 
glycine methyl ester, and another equivalent of glycine methyl ester was used to acylate the 
liberated free acid.  The phthalic diamide was purified to homogeneity using the preparative 
HPLC.  Appropriate fractions were pooled, lyophilized, and weighed to make a standard solution 
of known concentration.    
 










Figure 121 Final purified bivalent-β-Ala-D-Ala-D-Ala, 1-6mers 
 
After analysis of the crude cleavage product by HPLC (Figure119-A), it became clear 
that there was a problem with the removal of the ivDde groups.  But after careful inspection, it 
was obvious that the difference in peak height was not a direct measurement of the relative 
amounts.  This is because the ivDde chromophore has a much larger extinction coefficient that 
the substituted benzene ring of the phthalic diamide, although no experiments were done to 
identify the molar absorptivity of the ivDde.  Previous experiences with the ivDde suggest that it 
is difficult to totally remove this protecting group.  This suggests that the peaks corresponding to 
ivDde protected amines were minor contaminants.  In subsequent experiments involving other 
projects, it was found that the ivDde could be more completely removed by increasing the 
hydrazine concentration from 2% to 4%.  Also, some amount of product that failed to be acylated 
by the D-Ala-D-Ala can be identified throughout the series of manipulations.  This is surprising, 
as an excess of D-Ala-D-Ala 74 and coupling reagent were used.  However, this coupling 
reaction which failed to go to completion may be an anomaly, as the amount of unreacted amine 
in most of the other 11 sequences is much less or nonexistent.  Nevertheless, the desired products 








could stand to be improved, this was more than enough material for subsequent analysis of 
binding by capillary electrophoresis.   
Synthesis of the bis-vancomycin scaffolds also required some development.  Coupling 
reactions involving the carboxylic acid of the vancomycin and an external amine have been 
utilized by Whitesides in his synthesis of his bivalent and trivalent vancomycin derivatives,[22, 
25, 66] by Griffin in his synthesis of vancomycin carboxamide derivatives and vancomycin 
dimmers,[67, 68] and by Williams, who also studied vancomycin dimers.[69, 70]  The general 
consensus of the various approaches is that when a mild coupling reagent, like HOBt/HBTU is 
used, reaction between the vancomycin carboxylic acid and a primary amine is favored, while in 
the case of more reactive coupling reagents, like PyBOP (benzotriazol-1-
yloxy)tripyrrolidinophosphonium hexafluorophosphate) or PyBrOP (bromo-
tripyrrolidinophosphonium hexafluorophosphate), the secondary amine and neopentyl amine of 
vancomycin become involved as possible sites of acylation.  So, HOBt/HBTU was obviously the 
reagent of choice to accomplish a selective coupling between the scaffold diamine and two 
separate vancomycin molecules.  Additionally, carrying out the coupling reaction in an ice bath 
will increase the selectivity for only the most reactive amines, improving the yield of desired 
product. 
Initial tests of the efficacy of coupling vancomycin with HOBt/HBTU to a derivatized 
Rink amide resin proved to be successful, however upon cleavage with 95% TFA, total de-
glycosylation occurred to produce the undesired vancomycin aglycone, as anticipated.  The sugar 
portion of vancomycin is not directly involved in the recognition of the D-Ala-D-Ala, although it 
surely provides added water solubility to polyaromatic core.  We decided to first try other 
approaches for incorporation of the vancomycin into a scaffold, with solid-phase synthesis of 
aglycone-scaffolds as a backup plan.   
Some conclusions from initial experiments on possible ways to attach vancomycin to a 
scaffold on a weak-acid cleavage resin follows.  First, vancomycin failed to react with the first 
amino acid attached to the trityl resin.  Diaminobutanoic acid was attached to the trityl resin and 
its side chain was deprotected.  The vancomycin failed to acylate that amine, while tyrosine 
succeeded.  This was interpreted as failure due to the steric clash of the bulky trityl resin with the 
equally bulky vancomycin.  Secondly, a polymer-bound-HOBt was tested for its ability to be 
acylated with activated vancomycin, and then transfer that vancomycin to an amine in solution.  
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This approach failed primarily due to difficulties in completely washing away vancomycin which 
was not initially attached to the resin bound HOBt.  Because these two approaches failed, the 
only to cleanly attach vancomycin to our scaffolds would be a solution-phase coupling.  On that 
thought, one final test involved the feasibility of a post-reaction scavenging.  The ability of the 
chloro-trityl chloride resin to scavenge excess carboxylic acid was tested with vancomycin.  This 
was found to be possible, however times in excess of two day were needed to removed only 50% 
of the vancomycin.  This may be useful in the future, but for now, a simple solution phase 
coupling reaction between the scaffold diamine and vancomycin was approach we would take.   
The synthesis of the diamine scaffolds, of length 1-6 building blocks, proceeded using an 
approach similar to scaffold backbone of the bis-D-Ala-D-Ala, however, there were a few 
differences.  Since there would be no on-resin derivatization of the side chain of the terminal 
amino acids, the shorter, diaminopropionic acid (Dpr) would be used instead of Dab.  Also, the 
side chains needed to remain protected for the selective methyl ester formation with TMSCHN2, 
so the Boc group was chosen as the side chain protecting group for Dpr.   
It should be noted that an alternative approach employing Dab(ivDde) was attempted.  
This approach envisioned that the steps would involve cleavage, TMSCHN2, then removal of 
ivDde using hydrazine, followed by coupling of vancomycin.  It was hypothesized that the 
presence of the Boc groups on the building blocks would aid in the purification of the bis-
vancomycin product away from vancomycin, as the polarity difference would be larger due to 
the non-polarity of the tert-butyl protecting groups.  This attempt failed because the hydrazine 
was not easily removed from the reaction mixture.  When the deprotection mixture was added to 
ether, in an attempt to precipitate the product, it was found that the hydrazine was not miscible 
with the ether.  So, the hydrazine was removed in the SpeedVac.  High temperatures (50˚C) and 
long times (20hr) were needed to totally remove the high-boiling hydrazine.  These conditions 
caused extensive epimerization of the oligomer, as judged by LCMS (Figure 122). 
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Figure 122 Extracted ion chromatogram illustrating the epimerization of the scaffold during removal of hydrazine 
after a solution-phase ivDde deprotection. 
 
The second difference in the scaffold synthesis was that the leading-end Fmoc group was 
left on, because there were no hydrazine treatments at the end of this synthesis.  Also this was the 
only intense chromophore in the molecule and facilitated characterization of all species, until the 
second-to-last step, when the DKPs were closed.  When the Fmoc was removed, quantifying the 
amount of material in solution was achieved by using an HPLC calibration curve.  This accuracy 
in measuring the concentration of diamine for the vancomycin coupling step ensured that 
precisely 5eq of vancomycin, relative to diamine, were used, greatly facilitating purification of 
the final bis-vancomycin product.  
The final approach for the synthesis of bis-vancomycin scaffolds utilized, first the solid-
phase synthesis of a scaffold diamine (Figure 122), followed by the solution-phase incorporation 
of vancomycin using HOBt/HBTU.  The diamine was synthesized on the trityl resin, by first 
reacting the carboxylate salt of Fmoc-Dpr(Boc)-OH with the resin in DCM.  Fmoc removal 
resulted in an amine that was acylated with pro4(2S4S) building block and HATU.  After Fmoc 
removal, the resin was appropriately portioned, and the process of acylation, Fmoc removal, and 
portioning was repeated, resulting in six equimolar amounts of scaffolds containing a resin-
bound Dpr(Boc), followed by one to six building blocks, all terminating in a deprotected amine.  
These amines were then acylated with Fmoc-Dpr(Boc)-OH and HATU, to yield the final product 




Figure 123  Solid phase synthesis of the scaffold diamines used to make bivalent vancomycins. 
 
After cleavage (Figure124, 86), the liberated trailing end carboxylic acid was esterified 
with TMSCHN2 to form 87.  The Boc groups were then removed using TFA in DCM to yield 88.  
Each of the six sequences was then aliquoted into 4 equal volumes, and the solvent removed in 
the SpeedVac, and stored in a desiccator, until needed.  When a vancomycin was to be attached, 
first the DKPs were closed in 200μL of 20% piperidine in NMP (89).  It was especially 
important to use small volumes for this step, so that precipitation could be done into a minimum 
volume of ether (~1.5mL).  In the case of the shorter sequences, the insolubility in ether was not 
as pronounced as the longer sequences, due to smaller mass and smaller numbers of amide 
bonds.  In order to recover the desired product from the ether precipitations, it was therefore 
critical to use small volumes of piperidine/NMP and correspondingly small volumes of ether.  
The resulting pellet was washed at least twice with fresh ether in order to remove as much 




Figure 124 Synthesis of scaffold diamine and coupling of two vancomycins. 
 
As mentioned above, the LCMS chromatogram used to confirm that all DKPs were 
closed also was used to quantify the amount of fullvene and corresponding diamine.  Of course, 
this assumes complete recovery in the ether precipitation.   Amounts of vancomycin, HOBt, and 
HBTU, which could be accurately weighed (at least 5mg), were used and the coupling reagents 
and vancomycin were put in separate microcentrifuge tubes, and placed in an ice bath.  To each 
tube, DMF:DMSO (1:1) was added, and sonication was used to solubilize the reagents.  
Vancomycin required particular attention to totally dissolve all material, although better results 
were seen when the DMSO was added first, followed by sonication, and then addition of the 
DMF.  Appropriate volumes containing 5eq of each reagent were then added to the diamine 
pellet in an ice bath.  Cycles of a few seconds of sonication followed by a minute in the ice bath 
served to solubilize the pellet and mix it with the reagents while keeping the temperature low.  
Addition of base started the coupling reaction, which was monitored by LCMS every 30min 
(Figure 125).  Not much difference was seen between t=30min and t=60min, so the reaction was 
deemed to be complete.  Diamine was visible by LCMS, although it was not possible to 
quantitate, beyond saying it was still present.  Additionally, the presence of a scaffold containing 
only one vancomycin was identified by MS, but not deemed to be significant by LC. 
86 87 88 




Figure 125 HPLC chromatograms illustrating the importance of time and temperature on the synthesis of a bis-
vancomycin, 3mer. 
 
The ease of isolation of the desired product could be improved by addition of a 
hydrophobic amine which would react with excess vancomycin to form a more nonpolar 
vancomycin amide.  Initially, octadecylamine (C18) was employed, but it was found to be 
insoluble in DMF:DMSO.  Octylamine was settled on, as it was readily soluble in DMF and, 
being a liquid, it was easily added to the reaction.  Simply adding the amine to the reaction after 
one hour served to “scavenge” excess vancomycin (Figure 126/127) and convert it to a product 
that was much more nonpolar, and therefore, easier to isolate away from the desired product.  In 
spite of addition of excess amine, it was not possible to remove all of the vancomycin.  This was 
thought to be due to the partial consumption of the active ester-vancomycin adduct, by 
advantageous water in the solvent or, more likely, water of hydration of the vancomycin starting 
material.  Addition of more coupling reagent when the amine was added was considered, but it 
was deemed to be too risky, as the desired product was present, and any further perturbation of it 




Figure 126 HPLC chromatograms illustrating the effective scavenging of excess vancomycin by octylamine. 
 





After completion of the scavenging reaction (30 additional minutes) the reaction was 
quenched by adding 10 volumes of water, 10% ACN, 0.5% formic acid.  This was then filtered 
and purified as a single injection on the preparative HPLC.  Again all peaks were collected, and 
saved until reinjection on the LCMS confirmed the identity of each.  Tubes containing product 
were pooled and lyophilized (some representative chromatograms are listed below in Figures 
128- 132).  The product was then redissolved in 0.5mL water, 10% acetonitrile, and a small 
injection of this on the analytical HPLC facilitated quantification using a calibration curve from 
known amounts of vancomycin.  Lyophilizing again yielded the final product, which was stored 
at 4˚C. 
 
Figure 128 HPLC chromatogram of the crude bis-vancomycin, 2mer product (the mass listed above is the calculate 
M+1H, derived from the various multiply charged species). 
 





Figure 130 HPLC chromatograms illustrating the importance of time and temperature on the synthesis of a bis-
vancomycin, 4mer (the mass listed above is the calculate M+1H, derived from the various multiply charged species). 
 






Figure 132 Final purified bis-Van, 1-6mer oligomers. 
 
The synthesis and purification of the varying lengths of scaffolds, bis-vancomycin 
derivatives were, for the most part, successful, although some improvements could be made.  
Namely, the amount of material initially present was, frankly, miniscule.  Nanomoles of scaffold 
were present, so trace water and minor impurities were more of any issue than would be the case 
if the scale were larger.  Nevertheless, five of six bis-vancomycin scaffolds were made in 
acceptable yield and good to excellent purity.  In these cases, the products were free of any other 
contaminating byproducts containing vancomycin, which was an absolute requirement for 
studies of bivalent molecules.  In the only other sample, the desired product was the major 









The synthesis of a series of bis-vancomycin and bis-D-Ala-D-Ala bivalent molecules has been 
successfully completed.  Capillary electrophoresis is currently being employed to measure the 
binding constants of each individual bis-D-Ala-D-Ala with each individual bis-vancomycin, 
according to procedures and methods outlined by Whitesides.[66, 71-73]  After this initial work 
is done, competition experiments are planned, where a single bis-vancomycin can choose 
multiple bis-D-Ala-D-Ala in which to bind.  Finally, multiple bis-vancomycin and multiple bis-
D-Ala-D-Ala pairs will be analyzed to assess the extent of selectivity as matched bivalent pairs. 
4.4 EXPERIMENTAL 
General: Dichloromethane was distilled from CaH2.  All other reagents were used as received, 
unless stated otherwise.  Column chromatography was performed using ICN Silitech 32-63 D 
(60 Ǻ) grade silica gel and TLC analysis was performed on EM Science Silica Gel 60 F254 plates 
(250μm thickness).  NMR spectroscopy was performed using a Bruker 300 MHz instruments.  
Chemical shifts were reported in parts per million downfield relative to trimethylsilane and 
categorized as br = broad, s = singlet, d = doublet, dd = doublet of doublet, ddd = doublet of 
doublet of doublet, t = triplet, q = quartet, and m = multiplet.  Gradient normal phase 
chromatography was done on the Isco Combiflash Companion, with detection at 254nm.  Solid 
phase synthesis was performed in a 1.5mL disposable polypropylene reaction column, connected 
to a three-way valve equipped with vacuum and argon for mixing.  Dichloromethane (DCM) 
used in coupling reactions was distilled over calcium hydride.  Dry grade of dimethylformamide 
(DMF) from Aldrich was used for coupling.  Diisopropylamine (DIPEA) was distilled under 
nitrogen sequentially from ninhydrin and potassium hydroxide and stored over molecular sieves.  
O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorphospate (HATU) was 
obtained from Acros.  O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorphospate 
(HBTU) and N-Hydroxybenzotriazole hydrate (HOBt) were obtained from Novabiochem.  All 
solid phase reactions were mixed by bubbling argon up through reactor, allowing for mixing and 
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an inert atmosphere over the reaction.  HPLC-MS analysis was performed on a Hewlett-Packard 
Series 1050 instrument equipped with a Waters Xterra MS C18 column (3.5μm packing, 4.6 mm 
x 150 mm) and a diode-array detector, while the MSD-ESI was Series 1100.  Preparative 
purification was done using a Varian Prostar 500 equipped with a Waters Xterra Prep MS-C18 
column (5μm packing, 10 mm x 100 mm), equipped with a dual wavelength detector. 
 
N-α-Carbobenzyloxy-D-alanine-D-alanine-tert-butyl ester (75). 
A solution of N-α-Carbobenzyloxy-D-alanine free acid (mmol) HOBt (mmol) and HBTU 
(mmol) in dry DMF was stirred for 5min in a 100mL round-bottom flask.  DIPEA (mmol) was 
then added, producing a yellow color characteristic of an OBt active ester.  The amine, alanine-
tert-butyl ester (mmol) was then added, and the mixture was stirred for 2hrs.  The reaction 
mixture was then poured into 20 volumes of ice water, producing a dense precipitate, which was 
collected using a suction filter.  The precipitate was then dried in vacuo for 3hrs, then dissolved 
in chloroform and transferred to a 250mL round-bottom flask.  20g celite was then added and the 
solvent removed using a rotovap.  The water bath was then turned to 50C, and rotovapping 
continued for 30min to remove residual solvent.  The celite was easily transferred to an Isco 
loading cartridge.  Automated flash chromatography using an automated Isco Companion and a 
custom-built steel column containing ~300g silica was then performed using 3:2 ethyl 
acetate:hexanes.  The fully protected dipeptide was obtained in good yield (%). 1H NMR 
NH2-D-alanine-D-alanine-tert-butyl ester (73). 
The Cbz protected dipeptide (mmol) was dissolved in distilled EtOAc in a 100mL round bottom 
flask.  Palladium-on-charcoal (mmol) was added, along with a stir bar.  A double-balloon of 
hydrogen was connected to the flask using a three-way valve, and the side-arm of the valve was 
connected to an aspirator.  At least five cycles of aspiration (until boiling) and H2 backfill were 
performed to fully degas the solvent as well as charge the palladium with hydrogen.  The 
reaction was allowed to stir overnight.  Upon completion, the Pd/C was removed by filtration, 
followed by washing with 3 x 30mL of EtOAc.  The filtrates were combined and the solvent was 
removed in vacuo.  The free base was obtained in good yield (%).  1H NMR (300MHz, 25˚C, 
CDCl3) δ 7.7 (br, 1H), 4.39-4.44 (m, 1H), 3.45-3.52 (q, 1H), 2.77 (s, 1H), 1.60 (br, s, 2H), 1.44 
(s, 9H), 1.30-1.36 (dd, 6H) 
ortho-phthalate-D-alanine-D-alanine-tert-butyl ester (74). 
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The free base (mmol) was dissolved in dichloromethane, and stirred in a 50mL conical flask.  
The phthalic anhydride (mmol) as the limiting reagent was added and stirred for 1hr.  Removal 
of the solvent in vacuo afforded an oil.  The crude product was dissolved in 5mL chloroform and 
taken up in a syringe and injected onto an Isco column containing 40g of silica, equilibrated in 
chloroform.  A gradient of chloroform to 10% MeOH in chloroform, performed on the Isco 
Companion served to purify the final product, and removal of the solvent in vacuo produced the 
final product in good yield (%).  1H NMR (300MHz, 25˚C, CDCl3) δ 10.0 (br, 1H), δ 7.9 (d, 1H, 
J = 7.6Hz), δ 7.5 (m, 4H), δ 7.3 (d, 1H, 7.3Hz), δ 4.8 (m, 1H), δ 4.5 (m, 1H), δ 1.5 (d, 3H, J = 
7.0), δ 1.4 (s, 9H),  δ 1.4 (d, 3H, J = 7.2Hz), 
 
Solid-phase synthesis of resin-Dab-(ivDde)-pro4-(2S4S)n-Dab-(ivDde), end-DKP (n=1-6) 
(76). 
 
Figure 133 Synthesis of resin bound intermediate for bis-D-Ala-D-Ala molecules. 
 
To a 10mL polypropylene solid phase peptide synthesis (SPPS) reaction vessel was added 
chlorotrityl chloride Resin (Novabiochem) (30mg, 36μmol loading).  The bottom on the reactor 
was capped and a small stir bar was added.  A solution of Fmoc-L-Dab(ivDde)-OH 
(Novabiochem) (99 mg, 180 μmol) in 900 μL of distilled DCM and 94 μL of DIPEA (540 μmol) 
was prepared in a 1.5 mL microcentrifuge tube and then added to the reactor and stirred for 2hrs.  
The stir bar and cap were removed, the solution drained and the beads were washed 5x with 
DCM, and then washed with DMF, 2x.  The Fmoc-protected amine was deprotected in 2mL of 
20% piperidine/DMF for 40min.  By measuring the absorbance at 301nm of a 1/100 dilution, the 
number of moles of Fmoc removed was calculated by using ε = 7800 M-1 cm-1.  The resin was 
washed with DMF, isopropanol, DMF, isopropanol, DMF, for 2min each. 
76 
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In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 39.2 mg 
(72 μmol) of Boc-protected pro4(2S4S) building block[17] and 27.4 mg of HATU (72 μmol) in 
360 μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 25.1 μL 
(144 μmol) of DIPEA was added to make the active ester.  After 10min activation time, the 
solution was added to the deprotected resin, and allowed to react for 30min.  The resin was then 
washed 3 x 2min with DMF.  Double couplings allowed for quantitative acylation, as judged by 
subsequent Fmoc release.  After the Fmoc deprotection, the resin was washed with DCM several 
times, and allowed to dry for five minutes via aspiration.  The beads were now easily removed 
from the reactor and then weighed.  An appropriate weight fraction (i.e. 1/6th removed after 1st 
building block was coupled, then 1/5th after second building block, etc.) was then removed, 
placed in a fresh 1.0 mL reactor and stored in a desiccator.  The resin was then swelled in DMF 
for 10 min.  The process of coupling/deprotection/aliquot removed was repeated five additional 
times, making 6 portions of equimolar amounts of 6 different lengths, 1-6 building blocks, with 
the final amine deblocked 
In a 1.5 mL microcentrifuge tube, the final coupling solution was made by dissolving 
39.3 mg (108 μmol) of Fmoc-L-Dab(ivDde)-OH (Novabiochem) and 41.1 mg of HATU (108 
μmol) in 540 μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after 
which 37.6 μL (216 μmol) of N,N-diisopropylethylamine (DIPEA) was added to make the active 
ester.  After 10min activation time, the solution was added, in six equal portions to the 6 resins of 
varying lengths, and allowed to react by argon mixing for 30min.  The resin was then washed 3 x 
2min with DMF, and the coupling was repeated.  The final Fmoc-deprotection was allowed to go 
for 2hr instead of 40min.  This ensured that diketopiperazine formation was complete, thus all 
free amine was converted to an amide. 
The resin was swelled in DMF for 30min.  The Diaminobutanoic acid side chain 
protecting group, ivDde, was removed using a solution of 4% hydrazine hydrate in DMF.  4 x 
1mL, each reacting for about 3-5 minutes was sufficient to completely unmask the two side chain 
amines.  After deprotection, the resin was washed with DMF, IPA, DMF, IPA, DCM, DCM, 
DCM, and allowed to dry under aspiration for 5min.  The deprotected resins of varying numbers 
of building blocks was split into 3 equal portions, with one being stored in the desiccator and the 
other two being used for subsequent conversion into the two types of bivalent D-Ala-D-Ala. 
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Synthesis of bivalent D-Ala-D-Ala of lengths n=1-6 (80). 
 
Figure 134 Bivalent D-Ala-D-Ala scaffolds. 
 
The 6 resins of differing lengths, consisting of approximately 6 x 2μmol deprotected 
scaffold (6 x 4μmol free amines), were swelled in DMF for 30min.  During which, ortho-
phthalate-D-alanine-D-alanine-tert-butyl ester (26.2 mg, 72 μmol) and HATU (27.4 mg, 72 
μmol) was dissolved in 720 μL 20% DCM/DMF, and then, after addition of 25.1 μL of DIPEA 
(144 μmol), the mixture was allowed to sit for ten minutes.  The preactivated substrate was then 
added to the resins in 6 equal portions, and allowed to react with argon bubbling for 30min.  The 
beads were then washed with DMF, 3x, and the coupling reaction was repeated again, followed 
by an extensive washing with DMF, IPA, DMF, IPA, DMF, MeOH, DCM, MeOH, DCM, 
MeOH, DCM, and then overnight drying, in vacuo. 
The 6 reactors were then cleaved in 1mL of 20% AcOH, 20% trifluoroethanol, in DCM, 
with stirring for 2hrs.  This was then drained and 3 x 1mL additional cleavage cocktail with 
stirring for 3 x 15min served to remove any residual product.  The pooled cleavage solutions 
were transferred into a 13mm glass tube, and the solvent was removed in a SpeedVac.  An 
additional ~4mL of DCM and ~2mL hexanes served to azeotropically distill off residual acetic 
acid, and was repeated an additional three times, resulting in a dry white powder. 
The white powder was dissolved in 1mL of dry MeOH, a stir bar was added and ~25eq 
trimethylsilyldiazomethane (TMSCHN2), as a 2M solution in ether was added dropwise.  Slight 
bubbling and yellow color resulted.  The reaction was stopped after 10min by addition of an 
identical volume of trifluoroacetic acid, also dropwise.  More bubbling was apparent and the 
color disappeared.  The solvent was again removed in the SpeedVac.  A stir bar was added and 
the residue was dissolved in 4mL TFA/DCM (1:1) and stirred for 2hrs.  The solvent was 
80 
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removed in the SpeedVac, resulting in an oily residue.  200 μL of 20% piperidine in NMP was 
added to the residue.  Incubation at room temperature for 36hrs served to close the 
diketopiperazines.  After this, the product was precipitated into 1.5 mL of ether, in a 2mL 
microcentrifuge tube.  The final products of varying lengths (n=1-6 building blocks) were 
purified on a preparative HPLC column, as a single injection.  All peaks were collected and re-
injected on the LCMS to obtain the identity of the collected peak as well as the purity.  The tubes 
containing the desired product were lyophilized, redissolved in 0.5mL of 25% ACN in water.  
Using an HPLC calibration curve derived from the glycine methyl ester diamide of phthalic acid, 
a 5 μL injection allowed for quantitation of the amount of bivalent D-Ala-D-Ala.  The remaining 
samples were again lyophilized and the tubes were then stored at 4˚C. 
 
Synthesis of bivalent β-Ala-D-Ala-D-Ala of lengths n=1-6 (84). 
 
Figure 135 Bivalent β-Ala-D-Ala-D-Ala scaffolds. 
 
The 6 resins of differing lengths, consisting of approximately 6 x 2μmol deprotected 
scaffold (6 x 4μmol free amines), were swelled in DMF for 30min.  During which, Fmoc-β-Ala 
(37.3 mg, 120 μmol) and HATU (45.6 mg, 120 μmol) was dissolved in 600 μL 20% DCM/DMF, 
and then, after addition of 41.8 μL of DIPEA (240 μmol), the mixture was allowed to sit for ten 
minutes.  The preactivated substrate was then added to the resins in 6 equal portions, and allowed 
to react with argon bubbling for 30min.  The beads were then washed with DMF, 3x, and the 
coupling reaction was repeated again, followed by Fmoc deprotection for 30min in 0.5mL of 
84 
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20% piperidine/DMF.  The Abs at 301nm of a 1/100th dilution was measured to quantify the 
fullvene released.  The resins were then washed with DMF, IPA, DMF, IPA, DMF, and swelled 
in DMF for 10min.  This was followed by double coupling of the ortho-phthalate-D-alanine-D-
alanine-tert-butyl ester followed by drying in vacuo and cleavage as outlined above. 
 Removal of the solvent from the cleavage solution followed by methyl esterification 
using TMSCHN2, removal of the Boc groups and tert-butyl ester using TFA, and 
diketopiperazine closure in piperidine/NMP was done identically as outlined above.  Purification 
and quantifying the final purified product resulted in bivalent β-Ala-D-Ala-D-Ala, varying in 
length of the spacer from 1-6 building blocks. 
 
Solid-phase synthesis of resin-Dpr-(Boc)-pro4-(2S4S)n-Dpr-(Boc)-Fmoc (n=1-6) (88). 
 
Figure 136 Diamine scaffolds, before DKP closure. 
 
To a 10mL polypropylene solid phase peptide synthesis (SPPS) reaction vessel was 
added chlorotrityl chloride Resin (Novabiochem) (30mg, 36μmol loading).  The bottom on the 
reactor was capped and a small stir bar was added.  A solution of Fmoc-L-Dpr(Boc)-OH 
(Novabiochem) (76.7 mg, 180 μmol) in 900 μL of distilled DCM and 94.1 μL of DIPEA (540 
μmol) was prepared in a 1.5 mL microcentrifuge tube and then added to the reactor and stirred 
for 2hrs.  The stir bar and cap were removed, the solution drained and the beads were washed 5x 
with DCM, and then washed with DMF, 2x.  The Fmoc-protected amine was deprotected in 2mL 
of 20% piperidine/DMF for 40min.  By measuring the absorbance at 301nm of a 1/100 dilution, 
the number of moles of Fmoc removed was calculated by using ε = 7800 M-1 cm-1.  The resin 
was washed with DMF, isopropanol, DMF, isopropanol, DMF, for 2min each. 
In a 2mL microcentrifuge tube, the coupling solution was made by dissolving 39.2 mg 
(72 μmol) of Boc-protected pro4(2S4S) building block[20] and 27.4 mg of HATU (72 μmol) in 
88 
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360 μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 25.1 μL 
(144 μmol) of DIPEA was added to make the active ester.  After 10min activation time, the 
solution was added to the deprotected resin, and allowed to react for 30min.  The resin was then 
washed 3 x 2min with DMF.  Double couplings allowed for quantitative acylation, as judged by 
subsequent Fmoc release.  After the Fmoc deprotection, the resin was washed with DCM several 
times, and allowed to dry for five minutes via aspiration.  The beads were now easily removed 
from the reactor and then weighed.  An appropriate weight fraction (i.e. 1/6th removed after 1st 
building block was coupled, then 1/5th after second building block, etc.) was then removed, 
placed in a fresh 1.0 mL reactor and stored in a desiccator.  The resin was then swelled in DMF 
for 10 min.  The process of coupling/deprotection/aliquot removed was repeated five additional 
times, making 6 portions of equimolar amounts of 6 different lengths, 1-6 building blocks, with 
the final amine deblocked 
In a 1.5 mL microcentrifuge tube, the final coupling solution was made by dissolving 
46.0 mg (108 μmol) of Fmoc-L-Dpr(Boc)-OH (Novabiochem) and 41.1 mg of HATU (108 
μmol) in 540 μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after 
which 37.6 μL (216 μmol) of N,N-diisopropylethylamine (DIPEA) was added to make the active 
ester.  After 10min activation time, the solution was added, in six equal portions to the 6 resins of 
varying lengths, and allowed to react by argon mixing for 30min.  The resin was then washed 3 x 
2min with DMF, and the coupling was repeated.  The last Fmoc groups MUST be left on to 
ensure the success of the subsequent steps.  The resin was washed with DMF, IPA, DMF, IPA, 
DMF, MeOH, DCM, MeOH, DCM, MeOH, DCM, and then overnight drying, in vacuo. 
The 6 reactors were then cleaved in 1mL of 20% AcOH, 20% trifluoroethanol, in DCM, 
with stirring for 2hrs.  This was then drained and 3 x 1mL additional cleavage cocktail with 
stirring for 3 x 15min served to remove any residual product.  The pooled cleavage solutions 
were transferred into a 13mm glass tube, and the solvent was removed in a SpeedVac.  An 
additional ~4mL of DCM and ~2mL hexanes served to azeotropically distill off residual acetic 
acid, and was repeated an additional three times, resulting in a dry white powder. 
The white powder was dissolved in 1mL of dry MeOH, a stir bar was added and ~25eq 
trimethylsilyldiazomethane (TMSCHN2), as a 2M solution in ether was added dropwise.  Slight 
bubbling and yellow color resulted.  The reaction was stopped after 10min by addition of an 
identical volume of trifluoroacetic acid, also dropwise.  More bubbling was apparent and the 
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color disappeared.  The solvent was again removed in the SpeedVac.  A stir bar was added and 
the residue was dissolved in 4mL TFA/DCM (1:1) and stirred for 2hrs.  Each of the six reactions 
was split into 4 equal volumes for optimization of subsequent steps.  The solvent was removed in 
the SpeedVac, resulting in an oily residue.  The tubes were stored in a desiccator until needed. 
 
 
Solid-phase synthesis of resin-Dpr-(Boc)-pro4-(2S4S)n-Dpr-(Boc)-Fmoc (n=1-6) (90). 
 
Figure 137 Bivalent vancomyicn scaffolds. 
 
200 μL of 20% piperidine in NMP was added to the residue.  Incubation at room 
temperature for 36hrs served to close the diketopiperazines.  After this time, a 5uL injection was 
done on the LCMS and the product was precipitated into 1.5 mL of ether, in a 2mL 
microcentrifuge tube.  Using an HPLC calibration curve, made by dissolving a known amount of 
Fmoc-glycine in 20% piperidine/DMF, the number of moles of diamine substrate was found.  
For ever 1 equivalent of diamine, 5eq of HOBt, HBTU, and Vancomycin hydrochloride hydrate 
were used, along with 17.5eq of DIPEA at a concentration in DMF:DMSO (1:1) of  20mM.  The 
time, temperature and order of addition were critical variables, as the best conditions were found 
to consist of 1hr at 0˚C, while first dissolving the HBTU/HOBt in 0.2vol DMF:DMSO and 
sonicating, then separately dissolving vancomycin in 0.8vol of DMF:DMSO and sonicating.  
These two tubes, along with the ether precipitated pellet of the diamine in another tube were all 
incubated in an ice bath.  The vancomycin was mixed with the coupling reagents first, and then 
added to the diamine, with 3 cycles of sonication followed by cooling in the ice bath, as 
90 
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sonication tended to heat the tube.  Finally, base was added, and the reaction was incubated on 
ice for 1hr.  LCMS analysis confirmed successful synthesis of the bis-vancomycin.  In some 
cases, if the vancomycin starting material was present in large amounts or if its retention time 
was too close to the desired product, the vancomycin active ester could be scavenged by addition 
of a long chain amine, usually octylamine, added as a neat liquid in excess molar amounts.  The 
coupling reaction was stopped by addition of 20 volumes of 10% ACN in water with 0.5% 
formic acid.  The crude product was purified on a preparative HPLC column, as a single 
injection.  By observing at 278nm and 310nm, vancomycin-containing products were easily 
distinguished from HOBt derivatives.  All peaks were collected and re-injected on the LCMS to 
obtain the identity of the collected peak as well as the purity.  The tubes containing the desired 
product were lyophilized, redissolved in 0.5mL of 25% ACN in water.  Using an HPLC 
calibration curve derived from vancomycin, a 5 μL injection allowed for quantitation of the 
amount of bivalent vancomycin.  The remaining sample was again lyophilized and the tubes 





5. ELECTRON TRANSFER THROUGH CHIRAL SCAFFOLDS 
5.1 INTRODUCTION 
The process of electron transfer underlies many chemical and biological reactions and is of 
primary importance in many technologies.  Consequently, the nature of electron transfer has 
been under experimental and theoretical study for many years.[74, 75]  Despite these efforts, 
little attention has focused on the influence of molecular chirality on electron transfer.   
On a fundamental level, spin-polarized electrons have been used to perform chemistry 
and are implicated in the origin of chiral selectivity in biology.[74]  On a technological level, 
molecular chirality could be used to introduce a new control parameter for spin-sensitive devices.   
Naaman reported the first investigation of spin dependent electron transmission through 
thin chiral films of stearoylysine[74] and more recently observed an asymmetry for electron 
transmission through monolayers of L (or D) polyalanine films.[74]  The magnitude of the effect 
is 103 to 104 times larger than the chiral selectivity found for the interaction of polarized 
electrons with molecules that are not organized into two-dimensional arrays.[74-85] 
In photoemission through an organic monolayer film, the electron wavefunction can be 
delocalized among many chiral molecules in the film, whereas tunneling electrons are more 
localized. Hence, it is interesting to ask if such large effects are possible for electron tunneling. 
Spin polarized tunneling has been observed in Metal-Oxide-GaAs (MOS) structures with an 
asymmetry of the order of 1%.[74]  In those studies the polarized distribution of carriers is 
generated in the GaAs by circularly polarized light and tunneling occurs through a thin Al2O3 (2 
to 20 nm) on Al. In recent work spin polarized electrons were selectively transmitted between 
two quantum dots through organic molecules.[74] Those findings show that it is possible to 
create the polarized distribution of charge carriers and observe asymmetry in electron tunneling.   
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This study investigates the photocurrent, induced by circular polarized light, through 
organic monolayer films on Au electrodes that are immersed in an electrochemical cell. The 
films are composed of a chiral scaffold molecule, which is linked to the Au by a cysteine amino 
acid at one end and presents a porphyrin chromophore at the other end. Although related systems 
have been studied previously (e.g., Morita et al.[74] placed helical peptides containing a 
carbazolyl chromophore on gold electrodes), the effects of molecular chirality and light 
polarization were not explored. Under photoexcitation of the porphyrin, an electron is transferred 
to an acceptor (e.g., methylviologen in Figure 138), and the resulting cation of the porphyrin is 
reduced by the gold electrode (Figure 139).  By measuring the dependence of the photocurrent 
on the polarization of the light field and correlating it with the scaffold’s chirality, a preference 
for electron tunneling of one handedness may be determined.  
 




Figure 139 The process of "hole transport." 
5.2 RESULTS AND DISCUSSION 
(NOTE: some of the following figures were created by Jianjun Wei or Amit Paul in Prof. 
Waldeck’s lab, and for their work I am very grateful) 
 
The synthesis of these porphyrin containing scaffolds (Figure 140) was done on the Rink Amide 
resin.  Incorporation of trityl-protected cysteines, either L or D occurred first.  Then a series of 
four Boc-protected pro4 building blocks, either SS or RR (naming system stereochemistry based: 
D or L for cysteine, then SS or RR for building block; DRR or LSS), completed the scaffold 
sequence.  Incorporation of the carboxy-tetraphenyl porphyrin proceeded cleanly to yield the 
desired product, having a dark purple color.  Cleavage of the product in 95% TFA gave the crude 
product with a vivid green color.  Closure of the diketopiperazines (DKPs) in 20% 
piperidine/NMP gave the final product, having a red-purple color. 
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Figure 142 L-Cys-SS4-Porph crude DKP product. 
 
 





Several small breakthroughs were made in this project.  First, it was found that closing 
the DKPs in NMP instead of DMF gave cleaner product in this case.  This observation was 
subsequently validated by others, and from that point on, NMP has been universally adopted as 
the solvent of choice for DKP formation.  In some instances before NMP was used, DKP closure 
in DMF produced significant impurity (>50%) closely corresponding to incorporation of iron, by 
LCMS.  This iron could potentially have been incorporated into the porphyrin ring, as in heme, 
but this coordination was believed to require higher temperature.  Also, it was thought that 
incorporation of iron would change the UV-Vis spectrum of the porphyrin, which was not seen.  
As the only evidence of heme formation was a close match of the expected mass to the observed 
mass, this conclusion of an iron-containing impurity may be suspect.  Regardless, utilization of 
NMP suppressed this impurity to below 5%.   
A second breakthrough involved the initial attempts to remove this unknown impurity.  
This impurity was only observed when formic acid was used in the HPLC separation (with a 
Waters Xterra column) and not when TFA was used.  Therefore, these formic acid conditions 
were transferred to the preparative column which was a Varian Microsorb C18 column.  It was 
found that the compound, which normally eluted near 80% ACN would not elute even at 100% 
ACN for extended times.  It was at this time that a greater understanding of the features of a 
C18-silica particle was attained.  The Microsorb particle is an older-type particle, and is 
alkylated with C18 to less than 100% completion.  The un-alkylated silinol is acidic and is much 
less likely to be protonated by formic acid than by TFA.  As a consequence, the deprotonated 
silinol will interact ionically with the free amine in the scaffold.  This observation was seen in 
other compounds as well.  As we were moving more towards a formic acid system for the benefit 
of MS analysis, the obsolete Varian columns in the lab were universally replaced with the Waters 
Xterra columns, in which the un-alkylated silinols are then capped to enable performance in low 
acid, or even acid-free, conditions.  This column and formic acid conditions have also been 
adopted by all in our group, with great success.  
The third breakthrough came at the end of the project.  Throughout the project, the 
purification of the free-thiol containing product had been a real nuisance.  Closing the DKP in 
piperidine formed exclusively the disulfide product.  In the process of purification, obviously the 
disulfide, impurity-product mixed disulfide and free thiol products would all have different 
retention times, so the disulfide needed to be reduced.  This required large amounts of the 
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phosphine-reducing agent, tris-carboxyethyl phosphine (TCEP).  Also, it was learned that the 
final product HPLC fractions could not be lyophilized or else numerous impurities would appear.  
This was the main drawback of using unprotected cysteines, as only the most concentrated, most 
pure fractions could be used for subsequent photocurrent measurements.  This lead to a great 
waste of usable material, as slightly impure fractions could not be dried-down and repurified.  
This free-thiol nuisance was creatively remedied by employing a different cysteine protecting 
group: the acetamido protecting group (Acm = -CH2NH-Acetyl).  Transition metals like 
mercury, silver and thallium are known to cleave this group.  To our enjoyment, so did the gold 
of the electrode.  The gold removed the protecting group and then complexed  the liberated thiol, 
to form monolayers with exactly the same properties as those prepared with free thiols. 
 The following contains some results of the characterization of the scaffold-porphyrin 
monolayers, as well as the photocurrent measurements and analysis.  For more details on the 
measurements by Wei and Amit, as well as the mechanism, the reader is referred to the 
publication.[86]  A brief summary of the highlights follows. 
 
Figure 144 The two enantiomeric porphyrin-containing scaffolds used in this study. 
 
The figure below shows the absorption spectra of the two enantiomeric compounds in 
80%ACN/20%H2O/0.1%TFA acid solution. No significant peak shift is found in the Soret bands 
(λmax=435 nm) and Q bands (649 nm for original porphyrin and 650 nm for scaffold porphyrins) 
in comparison to the free porphyrin (H2TPP). This result suggests no significant change of the 
porphyrin electronic structure in the two compounds. The figure below also shows the CD 
spectra of the two porphyrin scaffolds in the far UV region (180-260 nm). It is well known that 
the transitions in a polypeptide involve the nonbonding electrons on the oxygen of the carbonyl 
group and the nearest nitrogen atoms. The complimentary signals of the two scaffolds reflect the 
different chirality of these molecules.  This CD spectrum was obtained in unideal conditions.  
The presence of the TFA in the sample likely absorbs a large amount of low UV light used for 
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the measurement.  Because of this, the preference of this molecule for absorbance of one 
elipticity over the other is less accurate, as this would be a situation of a small difference of large 
numbers.  The measurement would be more accurate if it was done in pure water or pure 
methanol, as they both absorb very little around 210nm. 
 
Figure 145 Panel A shows the absorption spectra of porphyrin only (black), DRR (red), and LSS (blue) scaffold 
with porphyrins attached in 80%ACN/20%H2O/0.1%TFA acid solvent. Panel B shows the CD spectra of chiral 
scaffold molecules, a) red (LSS) and b) blue (DRR). 
 
The action spectrum of scaffold porphyrins at gold electrodes was obtained by measuring 
the cathodic photocurrent under irradiation with light, whose wavelength was selected with 
bandpass filters. The figure below shows the photocurrent action spectrum of a DRR SAM, and 
the inset shows its absorbance spectra under different conditions. The greatest photocurrent is 
observed in the wavelength range of 400 to 450 nm, the Soret band region.  The films display a 
broadened Soret band (compared to the solution porphyrin). The photocurrent action spectrum 
and the absorption spectrum of scaffold porphyrins at the gold surface demonstrate that the 
porphyrin is the photoactive species responsible for the photocurrent generation. 
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Figure 146 The photocurrent action spectrum. The inserted graphic is the UV-visible spectra of a scaffold porphyrin 
(DRR) in solution (black curve), the scaffold assembled at a gold coated transparent (blue curve). 
 
Photoelectrochemical measurements were performed in a 0.1 M Na2SO4 aqueous 
electrolyte solution containing 10 mM methyl viologen (MV+) and saturated oxygen as electron 
acceptors. A cathodic photocurrent from the porphyrin modified gold electrode was observed 
immediately upon irradiation by a 435 nm laser beam with a power of 1.35 mW at an applied 
voltage bias of 0.0 V versus Ag/AgCl (3.0 M KCl) reference electrode. A time profile of the raw 
photocurrent for the LSS SAM is shown in the figure below. The dark current in cathodic 
photocurrent measurements changes positively with the voltage bias change from 0 to 0.6 V, 
indicating that the LSS SAM is not so compact. Nevertheless, the magnitude of photocurrent was 
stable, and reproducible.  The photocurrent was linear in light intensity for laser powers <3.0 
mW. The figure below shows the voltage dependence of the photocurrent, which decreases 
monotonically with increasing positive bias. These results demonstrate that the electron flows 
from the gold electrode to the electrolyte through the scaffold porphyrin SAMs.  
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Figure 147 Representative photoelectrochemical responses from the LSS scaffold porphyrin SAM modified Au 
electrode at an applied voltage bias of 0.0 V in a three-electrode cell (counter: Pt; reference: Ag/AgCl); the dark 
interval between photocurrent peaks is 60 s duration. B) The voltage bias dependent photocurrents for the Au-
Porphyrin/MV+/2+/Pt system. The excitation wavelength is 435 nm and the average power is 1.35 mW. The 
photocurrent in panel B is defined as Iphoto=Ion-Ioff. 
 
Similar wavelength responses and voltage dependencies were found for the DRR and 
LSS SAMs at gold electrodes. In addition, no photocurrent was observed from the bare gold 
electrodes under the irradiation. The photoelectrochemical characterization confirms that 
excitation of the porphyrin is responsible for photocurrent generation. 
To study the effect of molecular chirality and electron helicity on the electron transfer, 
photocurrent generated under irradiation with circularly polarized light (either right circularly 
polarized light, RCP, or left circularly polarized light, LCP) was examined for both LSS and 
DRR SAMs. The figure below shows representative photocurrents generated under illumination 
with circular polarized light for the two chiral scaffold pophyrins at gold electrodes. The RCP or 
LCP polarizations were obtained by rotating a λ/4 wave plate at a specific tilt angle (see 
experimental section for details). The incident light intensity was measured for every 
illumination. For the LSS scaffold porphyrins, the magnitude of photocurrent under LCP 
irradiation is slightly larger than that under RCP irradiation as shown in the figure below. In 
contrast, the DRR scaffold porphyin film has a larger photocurrent under RCP irradiation than 
that under LCP irradiation. Although the preference is small, less than 1%, it was highly 
reproducible for a given sample and stable over a period of many hours. In some cases, 
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measurements were performed over more than one day on the same electrode and found to be 
reproducible.  
 
Figure 148 Representative photocurrent signals generated under circular polarized light for A) LSS and B) DRR 
scaffold porphyrins at gold electrodes.  
 
About ten electrodes for each sample type (DRR and LSS) were studied under the same 
conditions and the propensities of the asymmetry in photocurrents were measured. Control 
experiments, using a linearly polarized laser beam, showed no asymmetry. 







jjA                                     
in which j(σ+) and j(σ-) are photocurrents (normalized to light power) for RCP and LCP 
illumination at the same electrode, respectively. The asymmetry factor was calculated for each 
RCP and LCP irradiation pair. The LSS scaffold (4-mer) gave an average asymmetry factor of -
0.0048, and the DRR scaffold (4-mer) gave an average asymmetry factor of +0.0054. 
The figure below plots the asymmetry factor obtained for all of the experiments. Panels 
a) and b) show the distribution (a descending sort) of asymmetry factors for DRR and LSS films, 
respectively.  The asymmetry factors of the DRR scaffold range from -0.017 to 0.034 and most 
of them are positive values, whereas the asymmetry factor of the LSS scaffold range from –
0.033 to 0.012 and most of them are negative values.  Panels c) and d) show a histogram (bin 
size of 0.001) for the asymmetry factors. A Gaussian function (solid curve in c and d) is fit to the 
distribution. This fit yields an average value of 0.004 and a standard deviation of 0.006 for the 
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asymmetry factor of the DRR scaffold, and it yields an average value of -0.005 and a standard 
deviation of 0.004 for the LSS scaffold. This analysis gives an average asymmetry factor of 
0.004±0.002 for the DRR scaffold and -0.005±0.001 for the LSS scaffold. 
 
Figure 149 Distributions of asymmetry factors and statistical analysis of the helicities. a) and b) respectively present 
the distributions of the asymmetry factors in a descending sort for DRR and LSS scaffold porphyrin electrodes, and 
c) and d) are the histograms of the number of observations vs. the observed ranges of asymmetry factors, 
corresponding to a) and b) respectively. 
5.3 CONCLUSIONS 
Porphyrin-containing bis-amino acid oligomers have been synthesized, purified and organized 
into a monolayer on a gold electrode.  The effect of the chirality of the scaffold backbone and the 
helical polarization of the excitation light on the photocurrent generation has been studied, and 
an asymmetry was found.  The average asymmetry factor obtained for a right-handed monolayer 
bin number bin number 
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is 0.004±0.002 and for a left-handed monolayer is -0.005±0.001, with confidence limits of 95%.  
Further studies are ongoing to elaborate and improve this asymmetry factor. 
5.4 EXPERIMENTAL 
General: Dichloromethane was distilled from CaH2.  All other reagents were used as received, 
unless stated otherwise.  Solid phase synthesis was performed in a 1.5mL disposable 
polypropylene reaction column, connected to a three-way valve equipped with vacuum and 
argon for mixing.  Dichloromethane (DCM) used in coupling reactions was distilled over 
calcium hydride.  Dry grade of dimethylformamide (DMF) from Aldrich was used for coupling.  
N,N-diisopropylethylamine (DIPEA) was distilled under nitrogen sequentially from ninhydrin 
and potassium hydroxide and stored over molecular sieves.  O-(7-azabenzotriazol-1-yl)-
N,N,N’,N’-tetramethyluronium hexafluorphospate (HATU) was obtained from Acros.  All solid 
phase reactions were mixed by bubbling argon up through reactor, allowing for mixing and an 
inert atmosphere over the reaction.  HPLC-MS analysis was performed on a Hewlett-Packard 
Series 1050 instrument equipped with a Waters Xterra MS C18 column (3.5μm packing, 4.6 mm 
x 150 mm) and a diode-array detector, while the MSD-ESI was Series 1100.  Preparative 
purification was done using a Varian Prostar 500 equipped with a Waters Xterra Prep MS-C18 
column (5μm packing, 10 mm x 100 mm), equipped with a dual wavelength detector. 
 




Figure 150 L-Cys-(pro4(2S4S))4-Porph, open form, cleavage product 
 
To a 1.5mL polypropylene solid phase peptide synthesis (SPPS) reaction vessel was 
added Rink Amide AM Resin (Novabiochem) (20mg, 12.6μmol loading).  The resin was swollen 
for 1hr in dimethylformamide (DMF).  The terminal Fmoc-protected amine was deprotected in 
0.5mL of 20% piperidine/DMF for 40min.  By measuring the absorbance at 301nm of a 1/200 
dilution, the number of moles of Fmoc removed was calculated by using ε = 7800 M-1 cm-1.  The 
resin was washed with DMF, isopropanol, DMF, isopropanol, DMF, for 2min each. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 36.9mg 
(63.0μmol) of Fmoc-L-Cys(Trt)-OH (Novabiochem) and 24.0mg of HATU (63.0μmol) in 315μL 
of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 21.9μL of N,N-
diisopropylethylamine (DIPEA) was added to make the active ester.  After 10min activation 
time, the solution was added to the deprotected resin, and allowed to react for 30min.  The resin 
was then washed 3x 2min with DMF.  Double couplings allowed for quantitative acylation, as 
judged by subsequent Fmoc release in the same manner described above. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 13.7mg 
(25.2μmol) of Boc-protected pro4(2S4S) building block[17, 20] and 9.6mg of HATU (25.2μmol) 
in 126μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 8.8μL 
of DIPEA was added to make the active ester.  After 10min activation time, the solution was 
added to the deprotected resin, and allowed to react for 30min.  The resin was then washed 3 x 
2min with DMF.  Double couplings allowed for quantitative acylation, as judged by subsequent 
Fmoc release.  This process of coupling/deprotection was repeated three additional times. 
91-LSS 
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In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 12.5mg 
(18.9μmol) of 5-(4-Carboxyphenyl)-10,15,20-triphenyl-21,23H-porphyrin (Porphyrin Systems) 
and 7.2mg of HATU (25.2μmol) in 126μL of DMF.  This solution was mixed using a 
micropipettor, after which 6.6μL of DIPEA was added to make the active ester.  After 10min 
activation time, the solution was added to the deprotected resin, and allowed to react for 30min.  
The resin was then washed 3 x 2min with DMF.  Double couplings produced the final product, 
after which the resin was prepped for cleavage by washing with DMF, isopropanol, DMF, 
isopropanol, DCM, methanol, DCM, methanol, DCM, for 2 min each.  The reactor was then put 
in vacuum tube, and dried, in vacuo, overnight. 
The resin-bound product was cleaved in 1mL of 2% water, 4% ethanedithiol, 8% 
thioanisole in trifluoroacetic acid (TFA), with stirring for 2 hours.  The green solution was 
filtered away from the resin beads, and one additional mL was used to wash the beads. The green 
solutions were pooled and the solvent was removed under a stream of dry nitrogen.  Residual 
solvent was removed, in vacuo, for one hour, yielding a very dark green residue. 
 
Closed form of Porphyrin Scaffold L-Cys-(pro4(2S4S))4-Porph (92-LSS). 
 
Figure 151 L-Cys-(pro4(2S4S))4-Porph, DKP closed, final product 
 
The cleaved product was dissolved in 1mL of 20% piperidine/ N-methylpyrrolidinone 
(NMP), changing the color to a dark red.  After 48hrs at room temperature, the product was 
precipitated by dripping into 40 mL of ether in a 50mL polypropylene tube.  Some precipitate 
was evident, but more was obtained by a 1hr incubation at -20°C.  The precipitate was collected 
by centrifugation at 3000 x g, 4°C, for 30min.  The pellet was washed with 40mL of fresh ether, 
92-LSS 
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vortexed, and the centrifugation was repeated.  The ether was removed and the pellet allowed to 
dry.  The pellet was dissolved in 2 mL of 1:3 water: acetonitrile, with 0.5% TFA, and mixed by 
pipetting.  Tris-(2-carboxyethyl)phosphine (TCEP) was added to a concentration of 10mg/mL, 
and allowed to reduce the disulfide bonds for 2 hrs, before analysis or purification. 
The reduced product was purified on a Varian ProStar instrument with dual wavelength 
detection using Varian Chrompack Microsorb 100 C18 column 8μm packing, 21.4m x 250mm 
(mobile phase, acetonitrile (0.05% TFA) / water (0.1% TFA), 5% to 100% acetonitrile over 
31.67 min, then 100% acetonitrile until 40min; flow rate, 15  mL/min; UV detection at 415 nm).  
It was found that when a purified fraction containing a single peak was lyophilized and 
resuspended, multiple peaks were found, even with added TCEP.  Fractions of sufficient 
concentration (100μM) were obtained by making a single large injection and collecting the 
eluting peak in numerous 3-5 mL fractions.  LC/MS was then used to confirm the purity. Then 
the most pure and most concentrated fractions were pooled to give the purified product 1.  The 
final concentration was found using a Varian Cary 50 UV/Vis spectrometer using ε = 232000 M-
1 cm-1 at λ = 435nm. 
 
Synthesis of Porphyrin Scaffold D-Cys-(pro4(2R4R))4-Porph (91-DRR). 
 
Figure 152 D-Cys-(pro4(2R4R))4-Porph, open form, cleavage product 
 
The enantiomeric compounds were prepared in an identical manner to what was 
described for above, except with the following obvious changes: used Fmoc-D-Cys(Trt)-OH 




Closed form of Porphyrin Scaffold D-Cys-(pro4(2R4R))4-Porph (92-DRR). 
 
Figure 153 D-Cys-(pro4(2R4R))4-Porph, DKP closed, final product 
 
 
For a detailed description of the monolayer preparation and characterization, and the 




6. MEASURING DISTANCE THE BETWEEN TWO ENDS OF A SCAFFOLD 
USING ESR 
6.1 INTRODUCTION 
The following is a quote about the properties of a molecular rod: “In contrast to freshman 
students' expectations, molecular "rigid" rods are not rigid at all but are highly flexible, even 
though their equilibrium structure may be linear. At room temperature, even quite short rods 
bend and flex vigorously and should be thought of as rubber sticks rather than steel rods. With 
the possible exception of nanotubes, truly long rods many nanometers in length should be 
thought of as boiled rather than raw spaghetti…  The rigidity issue is likely to complicate the 
construction of structures that use rods longer than 2-3 nm.”[87]    
Using the unique technology being developed in this lab, we hope to study the feasibility 
of creating a molecular rod that can hold a designed shape.  This study will utilize 2-D ESR 
techniques, which are capable of measuring distances between two unpaired electrons, to first 
study the control of distance and then the control of shape that are inherent to the bis-amino acid 
ladder oligomers being constructed in this lab. 
The flexibility of the molecular rods can be characterized by the standard deviation, σ, of 
the distribution function.  The sensitivity of Double Electron-Electron Resonance (DEER)-ESR 
experiment to the measurement of interspin distances in the ~15-80 Å length range[88, 89] has 
been used to determine global folding patterns in proteins,[90-93] nucleic acids,[94] ionic 
polymers,[95] and conformational and aggregation states of polypeptides.[96] 
The key advantage of the use of ESR is twofold.  First, large distance constraints can be 
measured from which the overall shape of the conformationally restricted material can be rapidly 
inferred.  NMR has been used to determine short-range distances in bis-peptides[17, 20] but the 
rod-like nature of these materials precludes the measurement of distance between residues far 
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apart in the linear sequence.  This can lead to a substantial uncertainty in the modeling of the 
overall structure.  In principle, energy transfer in fluorescence resonance energy transfer 
(FRET)[17, 97, 98] is sensitive to distances in these length scales. However, the correct 
interpretation of the energy transfer in terms of distances requires assumptions about the 
rotational averaging of the donor and acceptor groups and a careful accounting of molecular 
dynamics.  The second advantage is that ESR measures the full distance distribution function, 
from which the flexibility of the nanostructured materials can be directly assayed.  The shape and 
flexibility are both important criterions for the design of nanostructured materials with targeted 
functions.   
6.2 RESULTS AND DISCUSSION 
(NOTE: some of the following figures were created by Soraya Pornsuwan in Prof. 
Saxena’s lab, and for their work I am very grateful) 
 
The synthesis of bis-spin labeled scaffolds, consisting of 4-8 pro4(2S4S) building blocks utilized 
the Rink amide AM resin (Figure 154).  A single batch of resin was used, up until the Fmoc of 
the fourth building block was removed.  After this, the resin was split into 4/5th and 1/5th batches, 
with an additional building block being added to the larger 4/5th portion of the resin.  This Fmoc 
was removed, and again portioned into 3/4th and 1/4th.  The process was repeated until 5 lengths 
were produced, all with equimolar amounts of material attached to the resin.  The final 
deprotected amine was acylated with an excess of the pyrrolidine-based carboxylic acid 
nitroxide.  The scaffold was cleaved with TFA, the DKPs were closed, and a second nitroxide 
was attached to the remaining free amine.  An excess of the spin label, activated with HATU 
ensured complete coupling in less than 30min.  After this time, the coupling reaction of about 
~75 μL was dripped into 2 mL of ether, in which the excess unreacted nitroxide was 
conveniently soluble.  The resulting precipitate was centrifuged, redissolved in ~50 μL of 
methanol and purified on an analytical C18 HPLC column to give products 93-(4-8).  The 
nitroxide/α−β-unsaturated system had a modest absorbance at ~254 nm, although a distinct peak 
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was absent.  Using a HPLC calibration curve derived from a known amount of the carboxamide 
nitroxide, the concentration could be estimated (Figure 155).  This was used to make the 0.2 mM 
solution for subsequent distance measurements. 
 
Figure 154 Synthesis of bis-spin labeled scaffolds of different lengths. 
 






Figure 156 Representative structure of the different lengths studied (4mer, 5mer, 6mer, 7mer, and 8mer). 
 
The figures on this page and the following pages (Figures 157-161) show the distance 
distribution functions obtained from molecular dynamics and from ESR.  For compounds n = 4, 
5 molecular dynamics predicts a significant population of conformers with interspin distances 
shorter than 2 nm.  These conformers are unlikely to be sampled by the DEER experiments due 
to the use of pump pulses of 48 ns.  Limitations in the excitation bandwidth of this pulse are 
expected to suppress the distance distribution function below 2 nm,[99] which possibly accounts 




Figure 157 Overlay of the distance between nitroxide nitrogens calculated from a 5 nanosecond Amber molecular 
dynamics simulation at 300 K of the n = 4 labeled scaffold (black) on the distance distribution determined from ESR 






Figure 158 Overlay of the distance between nitroxide nitrogens calculated from a 5 nanosecond Amber molecular 
dynamics simulation at 300 K of the n = 5 labeled scaffold (black) on the distance distribution determined from ESR 
for the same molecule. 
 
 
Figure 159 Overlay of the distance between nitroxide nitrogens calculated from a 5 nanosecond Amber molecular 
dynamics simulation at 300 K of the n = 6 labeled scaffold (black) on the distance distribution determined from ESR 







Figure 160 Overlay of the distance between nitroxide nitrogens calculated from a 5 nanosecond Amber molecular 
dynamics simulation at 300 K of the n = 7 labeled scaffold (black) on the distance distribution determined from ESR 
for the same molecule. 
 
 
Figure 161 Overlay of the distance between nitroxide nitrogens calculated from a 5 nanosecond Amber molecular 
dynamics simulation at 300 K of the n = 8 labeled scaffold (black) on the distance distribution determined from ESR 
for the same molecule. 
 
The mean distance and standard deviation (σ) were calculated from the distribution 







































σ                                          [2] 
where P(r) is distance distribution function, r is distance, r1 and r2 is the lower and upper range in 
the distribution function and σ is the standard deviation.  The results are summarized in Figure 
162 below.  
 
Figure 162 Table comparing distances and standard deviations. 
 
Within experimental resolution, the estimates of the distances from dynamics are in 
reasonable agreement with the experiments for n = 4-7.  Note, that for n = 4 and n = 5 the 
experimental value of the average inter nitroxide distance is shifted to higher values possibly 
because the conformer with r less than 20 Å are inadequately sampled by the DEER experiment 
(see above).  However, molecular dynamics overestimates the mean distance for n = 4 by ~3.5 Å.  
Also, the molecular dynamics distributions overestimate the inter-nitroxide distance for long 
scaffolds (by as much as ~7 Å for n = 8).  
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In Figure 163 below, we compare the experimental data for n = 8 with simulated DEER 
data based on the probability distribution predicted by molecular dynamics.  It is evident that the 
experimentally derived distribution function yields a better fit compared to the simulated data 
based on molecular dynamics results.  
 
Figure 163 Overlay of the DEER time traces (a) and frequency spectra (b) of experimental data (red), ESR data fit 
(dashed black), and simulated DEER signal using the P(r) derived from molecular dynamics  (blue) for n = 8 
scaffold. 
 
Snapshots from the dynamics simulations for n = 4 and n = 8 shown in the Figures 164-
165 on the following pages are presented to illustrate the flexibility of these molecules according 
to the dynamics simulations. We are currently investigating the addition of explicit solvent and 




Figure 164 The superposition of the last 500 picoseconds of the 5 nanosecond molecular dynamics simulation for 
the n = 4. The central diketopiperazine ring was aligned for each structure and the nitroxide N-O atoms are rendered 




Figure 165 The superposition of the last 500 picoseconds of the 5 nanosecond molecular dynamics simulation for 
the n = 8. The central diketopiperazine ring was aligned for each structure and the nitroxide N-O atoms are rendered 













The mean distance and the standard deviation for these molecules, calculated using a 
moment analysis (see supporting information of [100]), are shown in Figure 166 below.  The 
error is estimated by the spectral resolution (~ 1.0-1.7 Å).  The “linear” rod-like shape of these 
materials is readily interpreted from the plot of in (D) below.  The linear fit to the data indicates 
that each building block adds 2.7 Å to the average distance between the spin probes. Five-
nanosecond molecular dynamics simulations were carried out in vacuo at 300 K on each 
oligomer. The DEER experiment inadequately samples conformers with r less than 20 Å (see 
previous pages). Within this experimental limitation, the estimates of the average distance from 
dynamics are in reasonable agreement with the experiments for n = 4-8.  However, molecular 
dynamics overestimates the mean distance for n = 8 by ~3.5 Å (see previous pages).  
Distributions from molecular dynamics also progressively overestimate the most probable 
internitroxide distance for long scaffolds (by ~2, 2.5, and 7 Å for n = 4, 5, and 6). The flexibility 
of the molecular rods can be characterized by the standard deviation of the distribution function, 
(E) below.  The standard deviation increases from 1.8 Å for n = 4 to 5.8 Å for n = 8.  
 
Figure 166 Compilation of length measurements: (A) general scaffold structure (B) modeled scaffold structures (C) 
distance distribution functions (D) plot of average distance vs. number of buidling blocks (E) standard deviation vs. 
number of buidling blocks. 
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With the ability to control distance between two ends having been demonstrated, the next 
question to ask was whether we can control shape.  From NMR solution structures, it is known 
that bends and kinks are formed when the stereochemistry of adjacent monomers is different.[17, 
20]  So, a series of ten sequences were identified, which result in curved structures spanning a 
broad distance range of 20-40 nm, as estimated by modeling.  The synthesis (Figure 167) was 
identical to what was described above.  All ten sequences (Figure 168) were successfully 
synthesized, based on crude cleavage LCMS trace (94-(1-10)).  However, three of the ten 
sequences “disappeared” during the DKP closure.  Only trace amounts of product containing a 
few DKPs open could be seen in these cases.  The other seven closed with issue and 3 of these 
seven were purified and their distances measured. 
 
 
Figure 167 Synthesis of “curved” bis-spin labeled 8mers. 
 
 
Figure 168 Table of 1st set of “curved" scaffold sequences which were synthesized.  Red = Distance measured, 






Figure 169 Representative chromatogram of the final purified product, “seq#1”. 
 
One thing that the three sequences which failed to fully close had in common was that 
they all had an alternating sequence motif of SS-RR repeated three times (or RR-SS or RS-SR).  
Issues with these motifs failing to close their diketopiperazines had been seen several times 
within the lab, but now we were aware of possible problems with this repeating motif (a 
hypothesis for this issue was discussed in the Phage Display chapter). 
Modeling suggested that the distances for the three measured sequences should have been 
32 nm, 29 nm, and 22 nm.  The experimentally measured distances were not consistent with the 
predicted measurements and no pattern was apparent. 
 







These first curved scaffolds were designed based on molecular mechanics predictions of 
the shapes of oligomers containing sequences of all four pro4 monomers.  Most of the scaffolds 
incorporated SR and RS building blocks.  The understanding within the lab of the 
conformational preferences of SR and RS building blocks is limited and based purely on 
molecular mechanics predictions.  Our knowledge of the conformational preferences of SS and 
RR building blocks is more advanced and based on several NMR structures of oligomers 
containing different sequences of SS and RR. So I proposed that we create curved sequences in 
which only SS and RR building blocks would be used.  Also, there would be very specific points 
of diversion between sequences (Figure 171).  RR “mutations” would be specifically 
incorporated into only three positions, illustrated below. 
                       
Figure 171 Table of 2nd set of “curved" scaffold sequences which were synthesized.  Plum = positions of variance.  
 
Again, these molecules were made as described previously (Figure 172). And as before, 
in one sequence the DKPs failed to fully close.  In C3, the problematic motif again resulted in a 
loss of material and stalling of the DKP closure.  The other 5 curved sequences had their 
distances measured by EPR (Figure 173).  Attempts to carry out in vacuo dynamics simulations 
on these sequences were foiled by the two ends coming in contact with each other early in the 
simulation, and remaining stuck throughout.  A solution to this problem is to simulate in explicit 





Figure 172 Representative chromatogram of the final purified product, “curved-6”.  
 
Figure 173 Distances measured for curved sequences, except C3, along with the all-SS 8mer for comparison. 
 
Upon first glance, these results appear unremarkable, however some trends are present.  
C1 and C6 are among the longest of the sequences, and both of them contain one RR monomer.  
The sequence SS-RR-SS produced a single bend in 3-D structure, as seen with modeling.  C4 
contains two RR monomers, which results in two curved SS-RR-SS sequences and a 3-D 
structure with a zig-zag or “Z” shape.  In this sequences the two bends curve in opposite 
directions and negate each other, resulting in a distance similar to C1 and C6.  The C2 and C5 
also have two RR monomers and each contain the strongly curved SS-RR-SS-RR-SS sequence 








key to these observations would be the C3 sequence, which, if it is indeed the shortest, would 
greatly substantiate these somewhat tentative trends and conclusions.   
New methods toward the synthesis of this SS-RR-SS-RR-SS-RR-SS containing motif 
needed to be developed.  As described in a previous chapter, this sequence has repeatedly failed 
to close all of its DKPs and our hypothesis is that an ordered hydrogen bonding network forms 
and intermolecular hydrogen bonding causes stalling of the DKP closure and precipitation and 
loss of the material.  I reasoned that perhaps by closing the DKP on the resin, these interactions 
could be thwarted.  Additionally, the hydrogen bonding network could be suppressed by 
including denaturant-like molecules in the DKP closure solution. 
These hypotheses were tested by first synthesizing two sequences containing the 
problematic motif (Figure 174), consisting of the desired SS-SS-(RR-SS)3-NH2 (96-1 = 95-3) 
and the “frame shifted” version SS-(RR-SS)3-SS-NH2 (96-2) sequence.  By employing the 
regular Rink amide resin, the Boc groups could be removed without cleaving the oligomer from 
the resin using the previously described TMS-triflate/lutidine conditions.  It was assumed that the 
highly reactive oxidizing environment that accompanies triflic acid cleavage would likely result 
in reduction and protonation of the nitroxide, thus ruling out TFA deprotection on an HF-
cleavable resin.  Nonetheless, repeated successes with these TMSOTf / lutidine Boc deprotection 
conditions provided confidence in the chosen approach, illustrated below. 
 




Both of the sequences were successfully synthesized, so conditions to close the DKPs on 
the resin were investigated.  First, the time was 20 hr, longer than the normal 10-12 hr known to 
close a normal series of DKPs and the temperature was 37˚C-40˚C, as usual.  Three different 
conditions were tested on each of the two sequences.  The first was the traditional 20% 
piperidine in NMP.  The second had the previous conditions supplemented with 0.5M ortho-
hydroxypyridine (HO-pyr), capable of simultaneously donating and accepting H-bonds.  The 
final conditions were identical to buffered conditions that I discovered years before that 
accelerated DKP closure by a factor of >5 (phenol-piperidine, both 0.5M in NMP).  After the 
20hr incubation, the resins were cleaved and analyzed by LCMS.  A preliminary conclusion was 
that the frame shifted (96-2) sequence totally closed, indifferent to the presence of additives, so 
the traditional conditions were subsequently used.  The other sequence (96-1 = 95-3) seemed to 
only fully close with the addition of additive, with a slight preference for HO-pyr.  These were 
significant breakthroughs, and were repeated on a larger scale on both sequences, followed by 
coupling of the spin label to both amines and cleavage with TFA.  Follow-up elaboration and 
confirmation of the observed preferences for closure conditions are required, as attachment of a 
more vivid chromophore would greatly substantiate the initial conclusions.  Nonetheless, 
material containing product was isolated (Figure 175), although clean and efficient are not 
synonymous with this process. 
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Figure 175 Final purified product, “curved-3”. 
 
We were ecstatic with the results of this measurement (overlaid with all other sequence 
95, in Figure 176).  This sequence was perfectly in line with our predictions: adding 3-RR 
“mutations” into the SS-sequence produces three bends, which cause a 95-3 to curve sharply. 
 





The conclusion of this experiment is that we are able to control shape.  The most curved 
scaffold has a distance of 23.1Å while the totally straight scaffold has distance of 34.8Å.  That is 
a difference of over 30%.  This technique of measuring distance using ESR has really given us a 
great deal of insight into the behavior of our molecules.  This should prove to be a very 
productive and fruitful collaboration long into the future. 
6.3 CONCLUSIONS 
In this chapter, it has been demonstrated that electron spin resonance (ESR) is effective at 
determining the long range distances of our water soluble bis-amino acid ladder oligomers.  In 
order to develop these oligomers as rod-like structural elements for applications such as bivalent 
display of ligands and as elements of future nanoscale devices, quantitative information on the 
lengths and flexibility are required.  We show that electron spin resonance provides a natural 
spectroscopic method to rapidly assay these structural parameters.  The conclusion from these 
experiments is that we are able to control both shape and distance with our molecules, putting us 
in a category all to ourselves. 
6.4 EXPERIMENTAL 
General: Dichloromethane was distilled from CaH2.  All other reagents were used as received, 
unless stated otherwise.  Solid phase synthesis was performed in a 1.5mL disposable 
polypropylene reaction column, connected to a three-way valve equipped with vacuum and 
argon for mixing.  Dichloromethane (DCM) used in coupling reactions was distilled over 
calcium hydride.  Dry grade of dimethylformamide (DMF) from Aldrich was used for coupling.  
N,N-diisopropylethylamine (DIPEA) was distilled under nitrogen sequentially from ninhydrin 
and potassium hydroxide and stored over molecular sieves.  O-(7-azabenzotriazol-1-yl)-
N,N,N’,N’-tetramethyluronium hexafluorphospate (HATU) was obtained from Acros.  All solid 
phase reactions were mixed by bubbling argon up through reactor, allowing for mixing and an 
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inert atmosphere over the reaction.  HPLC-MS analysis was performed on a Hewlett-Packard 
Series 1050 instrument equipped with a Waters Xterra MS C18 column (3.5 μm packing, 4.6 mm 
x 150 mm) and a diode-array detector, while the MSD-ESI was Series 1100.  Preparative 
purification was done using a Varian Prostar 500 equipped with a Waters Xterra Prep MS-C18 
column (5 μm packing, 10 mm x 100 mm), equipped with a dual wavelength detector. 
 
 
Synthesis of bis-spin labeled scaffolds of different lengths (93-(4-8)) or different shapes (94-
(1-10)), (95-(1-6)). 
 
Figure 177 Five bivalent spin probes, lengths ranging from 4-8 building blocks, or 8 building blocks with different 
stereochemistries. 
 
To five 1.5mL polypropylene solid phase peptide synthesis (SPPS) reaction vessels was 
added Rink amide AM Resin (Novabiochem) (5mg, 3.15μmol loading).  The resin was swollen 
for 1hr in dimethylformamide (DMF).  The terminal Fmoc-protected amine was deprotected in 
0.5mL of 20% piperdine/DMF for 40min.  By measuring the absorbance at 301nm of a 1/100 
dilution, the number of moles of Fmoc removed was calculated by using ε = 7800 M-1 cm-1.  The 
resin was washed with DMF, isopropanol, DMF, isopropanol, and DMF for 2min each. 
In a 1.5mL microcentrifuge tube, the coupling solution was made by dissolving 17.1 mg 
(31.5 μmol) of Fmoc-(Boc) pro4(2X4X) building block[17] and 12.0 mg of HATU (31.5 μmol) 
in 160 μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 11.0 
μL of DIPEA (63.0 μmol) was added to make the active ester.  After 10min activation time, an 
appropriate aliquot of the solution was added to each deprotected resin, and allowed to react for 
30min.  The resin was then washed 3x 2min with DMF.  Double couplings allowed for 





above.  This process of coupling/deprotection was repeated from three to seven additional times 
as needed to make the desired number of monomer units. 
After the final nth (n=4-8) building block was attached and Fmoc group removed, the 
first spin label was attached.  A solution of 29.0 mg (158 μmol) of 2,2,5,5-Tetramethyl-3-
pyrrolin-1-oxyl-3-carboxylic acid and 60.0 mg of HATU (158 μmol) in 800 μL of 20% 
DCM/DMF was mixed using a micropipettor, after which 55.0 μL of DIPEA (315 μmol) was 
added to make the active ester.  After 10min activation time, an appropriate aliquot of the 
solution was added to each resin, and allowed to react for 30min.  After the second coupling, the 
resin was prepared for cleavage by washing with DMF, isopropanol, DMF, isopropanol, DCM, 
methanol, DCM, methanol, and DCM for 2 min each.  The reactors were then put in vacuum 
tube, and dried, in vacuo, overnight. 
The resins were cleaved in 1mL of 2.5% water, 2.5% triisopropylsilane, in trifluoroacetic 
acid (TFA), with stirring for 2 hours.  The solution was filtered away from the resin beads, and 2 
x 1 mL was used to wash the beads. The solutions were pooled and the solvent was removed 
under a stream of dry nitrogen.  Residual solvent was removed, in vacuo, for one hour, yielding a 
colorless residue. 
The cleaved products were dissolved in 125 μL of 20% piperidine/ N-
methylpyrrolidinone (NMP).  After 48hrs at room temperature, the products were precipitated by 
dripping into 2 mL of ether stirring in a 2.2mL polypropylene microcentrifuge tube.  The 
precipitates were collected by centrifugation at 10000x g, 4°C, for 5min.  The pellets were 
washed with 2mL of fresh ether, sonicated, and the centrifugation was repeated.  The ether was 
removed and the pellets were allowed to dry.  The pellets were dissolved in a solution of the 
active-ester of the spin probe, using identical amounts and volumes as above.  This reaction was 
allowed to proceed for 30 min.  The final, crude, bis-spin labeled oligomers were precipitated by 
dripping into 2 mL of ether stirring in a 2.2mL polypropylene microcentrifuge tube, washed and 
collected as above, with most of the excess spin-label conveniently being soluble in the ether.  
The precipitates were dissolved in 30uL of 30% acetonitrile in water with 0.1% trifluoroacetic 
acid.  This crude material was purified on the analytical HPLC identified in the General Methods 
section.  A small aliquot of each final product was re-injected on the LC-MS and confirmed by 
mass analysis.  In all cases, the desired product was cleanly synthesized, with the only impurity 
being a small amount of HOAt. 
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Synthesis of bis-spin labeled 8-mer scaffolds with different shapes (96-(1-2)). 
 
Figure 178 Bivalent spin probes, with different shaes having different stereochemistries. 
 
Synthesis of this most curved motif containing (SS-RR)3-SS-SS was identical to that described 
above except for the three following changes:  
(1). Employment of the regular Rink Amide resin (NOT AM).   
(2). After last building block is attached, the Boc groups were removed using TMSOTf-lutidine, 
as follows-- The Boc groups on the building blocks were removed using procedure from the 
Burgess lab.[42]  The beads were washed with DCM for 5min.  A solution of 5mL of 1M 
trimethylsilyl triflate (Aldrich-TMSOTf-from a Schlenk bottle) and 1.5M 2,6-lutidine in DCM 
was prepared.  By adding 3 x 0.75mL x 5min, with slight bubbling, the Boc groups were 
removed while still attached to the resin, with DCM washes in between.  After deprotection, the 
resin was washed vigorously with DCM, followed by 5 cycles of MeOH / DCM washes, ending 
up with swelling in DMF for 5min.  The DKPs were then closed on the resin using a stirred 
solution of 0.5mL of 20% piperidine in NMP for 20hrs at 35˚C-40˚C.  Two other choices were 
employed for closing the DKPs (a) 20% piperidine/NMP with 0.5M ortho-hydroxypyridine. (b) 
0.5M piperidine, 0.5M liquefied phenol, in NMP.  After 20hrs, the resin was washed extensively 
with DMF and IPA. 
(3). Spin labels were attached to both amines, while still attached to the resin, 2 x 20eq of both 
HATU and spin label-CO2H, 40eq DIPEA, 0.2M in DMF, for 2 x 30min.  Cleavage with 95% 
TFA and HPLC purification are as described above. 
 




For ESR experiments, 0.2 mM of the double labeled molecules were dissolved in 70% 
buffer (50 mM phosphate buffer, pH 7.4, 200 mM NaCl, 3 mM NaN3, 1 mM EDTA) and 30% 
glycerol.  Each sample (~10 μl) was placed in a ~1.5 OD mm. pyrex capillary tube and flash 
frozen in liquid nitrogen immediately before insertion into the cavity.  
 
FT-ESR Spectroscopy 
The ESR experiments were performed using Bruker EleXsys E580 CW/FT X-band ESR 
spectrometer equipped with a Bruker X-band ER 4118X-MS2 split ring resonator for compounds 
n=4,6 and 7, and 4118X-MS3 for compound n=5 and 8.  Both resonators provided identical 
results for the same measurement.  The temperature was controlled by an Oxford ITC605 
temperature controller and an ER 4118CF gas flow cryostat.  All experiments were performed at 
the temperature of 80 K.   
 
Four-pulse DEER experiments were obtained with a resonator Q ≤ 100 and an ASE 
TWTA with an output power of 1 KW.  The pulse sequence for generating the dipolar time 
evolution data is shown in the figure below.  Two-step phase cycle was used for baseline 
correction.  The observer frequency, νA, was set at the central field of the spin label peak which 
is around 9.5-9.6 GHz, and the pump frequency, νB, was set at 70 MHz higher.  The length of the 
π/2 and π pulses was 24 and 48, respectively.  The interpulse delays were 200 ns for τ1, 2200 ns 
for τ2. The increment of time T after the second pulse was 16 ns for 128 points.  For each step of 
the phase cycle 500 averages were collected at a repetition rate of 1 KHz.  The acquisition time 
used for each sample was roughly 24 hours.          
 
Figure 179 Four-pulse DEER sequence. 
 
Analysis of ESR Data
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The 4-pulse DEER time domain data were processed before acquiring the distance 
distribution functions.  The background decay due to intermolecular interaction was subtracted 
by fitting the last 75% of the data with a first order polynomial function.  For compounds 3-5 
(n=6-8) the time domain data was smoothed by hamming function and zerofilled to 512 points 
before analyzing the data.  Fourier Transform of the processed data provided the frequency 
spectra.  
The time domain data was analyzed using DEERAnalysis 2004 program which is freely 
available on the web [www.mpip-mainz.mpg.de/~jeschke/distance.html].  The distance 
distribution functions were obtained using the Tikhonov regularization method with the 
regularization parameter of 4.0 for compounds 1-2 (n = 4-5), and 50.0 for compounds 3-5 (n = 6-
8).  In this analysis no constraints on the maximum possible distance was imposed. The 
experimental and simulated time domain signal and spectra are shown in the figure below. 
 
Figure 180 a) 4-Pulse DEER time domain.  b) Fourier Transform of the DEER 
distribution functions. 
 
The distribution functions for compounds 1-2 (cf. Figures S3-S4) appear to have 
physically unreasonable lobes on the upper end (large r-values).   These are possibly due to the 
fact that the Tikhonov procedure is mathematically ill-posed in the presence in the noise. The use 
of a better regularization parameter of 10, obtained by using an L-curve criterion, was successful 
in suppressing these lobes.   
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In an alternative approach the ESR data was also inverted using the Tikhonov 
regularization method with limits imposed on the maximum allowable distance.  Both methods 
yielded virtually identical distance distribution. 
 
Molecular Modeling 
Molecular dynamics simulations were carried out using the Amber94 force field.[101] 
Five-nanosecond in vacuo molecular dynamics simulations at 300 Kelvin were carried out on 
each compound. Histograms of the distance between the two nitroxide nitrogens were calculated 






7. SCAFFOLD DETERGENT FOR SOLUBLIZATION OF MEMBRANE 
PROTEINS 
7.1 INTRODUCTION 
The structure and function of membrane proteins are central to many areas of biomedical 
research.  Integral membrane proteins act as channels for transport of ions and small molecules 
into and out of the cell and as receptors for communication of signals and stimuli from outside 
the cell.  As the first potential messenger in complex signal transduction pathways, membrane 
proteins are a prime target for perturbation by pharmaceuticals.  However, in spite of the need for 
membrane protein structural information, only about 100 unique membrane proteins have  been 
structurally characterized.  Contrast that with the thousands of soluble proteins whose structures 
have been solved.  Estimates of 1 out every 3 genes coding for a membrane protein indicates 
that, potentially, there could be 10,000 membrane proteins,[102] necessitating the urgent need 
for exponentially improved methods and techniques 
In order to maintain the folded structure of a membrane protein outside of its native lipid 
bilayer, it must be stabilized by detergents which form micelles that mimic the lipid bilayer.  
Ideally, the detergent-protein complex needs to form small micelles, although even in these cases 
the mass of the complex doubles.  The idealized situation would entail 2-D and 3-D contacts 
between individual membrane proteins, while the detergent simply fills the interstitial space 
between the membrane proteins.  An alternative over-simplification may envision a smooth 
compact micelle providing shelter for a small number of membrane proteins.  Both situations are 
inaccurate.  A more accurate depiction would be that the micelle-protein complex is not well 
ordered or efficiently packed.  Packing defects are introduced when other detergents or solutes 
are incorporated into the pure detergent micelle.  Additional heterogeneity is inherent in the 
fluidity of the micelle itself.  Although the average radius or lipid composition may not change 
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much, there still exists a great deal of diversity in micellular structure.[103]  Diversity and 
heterogeneity are two features antithetic to well-ordered crystals capable of high resolution 
characterization. 
In the search for detergents capable of forming well-ordered complexes able to solubilize 
membranes, amphipathic peptides potentially fit the mold.  An early example of this potential 
was the de novo design of an amphipathic peptide that was found to fold into a four-helix 
bundle.[104]  Hydrophobic contacts between the leucines and alanines of adjacent peptides are 
the driving force behind the stable fold of this short peptide (Figure 180). 
 
Figure 181 PDB structure of the 4HB1 as a dimer. 
 
It was found that this peptide acted as a detergent, or a “peptitergent,” as judged by its 
ability to stabilize the folded structure of bacteriorhodopsin and rhodopsin, both α-helical even 
when the initial detergent concentration was diluted to 1/100th of the critical micelle 
concentration.  However, over the period of days to weeks, the peptitergent-membrane protein 
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complex was unstable.  Unfortunately, this is the same time frame needed for the growth of 
large, high-quality crystals. 
 The same concept of alternation of polar/charged and non-polar amino acids in order to 
sequester hydrophobicity on a single face of a peptide was again used to elaborate on the premise 
of peptitergents.[105]  In this case, simply by incorporating two ornithines at either end of the 
peptide, fatty acid chains of lengths (C12, C14, C16, C18, and C20) were able to be attached.  It 
was found that acyl chain length had an effect on the micelle size but not on the maintenance of 
the folded state of membrane proteins, both α-helical and β-barrel.  It was found that these 
peptitergents were capable of stabilizing the folded state of bacteriorhodopsin for periods in 
excess of 1 month, while the aggregational propensity of the particularly sensitive membrane 
protein, lac permease, was found to be less in the presence of a peptitergent than in any other 
detergent mixture known to date.   
 There is conceivably one area for improvement and that is in lowering the mass.  The 
mass of the lipopeptitergent is around 3000 Da.[105]  This has consequences for protein 
structural characterization by NMR in two areas.  First, the larger the mass of the detergent, the 
more unwanted peaks there are in the NMR spectra of the membrane protein.  Second, detergents 
with larger masses lead to detergent-protein complexes that have a longer rotational correlation 
time, which can lead to peak broadening and the blurring of interactions used for NOESY and 
ROESY spectral characterization.  A “scaffold” detergent would have about half of the mass of a 
peptitergent, making clear the potential benefits that our techniques and methods could bring to 
the field of membrane protein structural characterization. 
7.2 RESULTS AND DISCUSSION 
It was proposed that a scaffold detergent should have similar properties to previous peptitergents 
by exploiting the amphipathic nature of the polar scaffold backbone and non-polar long chain, 
fatty acids.  Methods and procedures had just been developed for the synthesis of nanoscale 
molecules,[20] and the synthesis of the scaffold detergent would stand to validate the generality 
of the these solid phase techniques, as well introduce some new approaches towards making 
functional, nanoscale molecules.  The number of building blocks (seven) was chosen because a 
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scaffold of this length should have an end-to-end distance of 30Ǻ, which is the distance of a 
typical membrane cross-section.  
Using the Rink Amide resin, the first residue, orthogonally protected Fmoc-
ornithine(methyltrityl)-OH, was attached using HBTU / HOBt.  Double couplings of 5 
equivalents, relative to initial resin loading, allowed for quantitative acylation in 2 x 30min 
reaction times, as judged by subsequent fluorenylmethyloxycarbonyl (Fmoc) release and small 
scale cleavages at each step.  Due to the large scale of this synthesis, illustrated in Figure 181, 
and the corresponding amount of building block that was being consumed, or wasted if a 
coupling failed for some reason, it was thought wise to proceed slowly and very cleave small 
amounts of resin to ensure reaction completion.  The Kaiser test for resin bound free amines is an 
excellent way to monitor reaction progress and is very sensitive for even small amount of free 
amines, producing a vivid blue-purple color in the presence of amines, however, due to the 
presence of an amine on a quaternary center, the Kaiser test is unreactive towards this type of 
amine.  Cleavage and analysis by LC/MS before each Fmoc release, in all cases, confirmed that 
2 x 2eq building block, along with the more reactive coupling reagent HATU were sufficient to 
quantitatively acylate the resin bound amine.  After the seventh building block had been 
incorporated, the second ornithine was added to complete the linear sequence.  Removal of this 
Fmoc was allowed to go for 2hr instead of the usual 30-40min.  Reaction between the liberated 
amine and the methyl ester occurred at this time to form a diketopiperazine (DKP).  Formation of 
this end-DKP spontaneously occurs any time an amino acid follows a building block.  Allowing 
this reaction to go for any extra period of time ensure that no free amines remained, which had 
significance for the following steps. 
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Figure 182 Synthesis of the fully protected scaffold prior to side chain derivatization. 
 
At this time the resin, now weighing in excess of 450mg, was dried in vacuo and small 
portions (~5mg) were used to work through the remaining steps.  Treatment of the resin with 1% 
trifluoroacetic acid (TFA), 5% triisopropylsilane, in dichloromethane DCM served to selectively 
remove the methyltrityl (Mtt) protecting group while preventing cleavage of the linker (Figure 
182).  As judged by LCMS, initial attempts at Mtt removal followed by acetylation with acetic 
anhydride resulted in the observance of a significant amount of product still containing a free 
amine.  It was judged that it was likely that the removal of the Mtt group was incomplete, as 
acetylation was known to be fast and quantitative when used in such large (>100eq) excess.  It 
was found that the vendor’s recommended procedure of 3 x 1mL x 2min was insufficient, 
because when the reaction was extended to 10 x 1mL x 3min followed again by acetylation, 
complete conversion to the amide was achieved.  Several lengths of fatty acid chains, first C8, 
C12, and C16 were chosen initially as these lengths would have been capable of spanning the 
lengths of the scaffold.  Later, lengths of C4 and C6 were included for the purpose of exploring 





Figure 183 Synthesis of the fully protected scaffold with alkyl chains (R-groups). 
   
 Improved cleavage protocols were developed that allowed for cleavage and Cbz 
deprotection in a single step.  Previously, cleavage was done using 95%TFA, followed by 
hydrogenation of the Cbz groups using H2, Pd/C in MeOH:H2O:AcOH (7:3:1).  Difficulties can 
ensue because of the drastic polarity change upon conversion of multiple benzyl groups into 
protonated amines.  Especially when long fatty acid chains were attached to the scaffold, 
difficulties in recovery of product were observed, perhaps due to interactions between the alkyl 
chains and carbon.  In light of these difficulties, alternative conditions were explored utilizing 
stronger acid cleavage cocktails capable of protonating off the Cbz groups and cleaving the 
linker as well.  Several sets of conditions were tested, employing a variety of scavengers and 
trimethylsilyl trifluoromethanesulfonate (TMSOTf) or trifluoromethanesulfonic acid (TfOH).  It 
was found that ideal conditions consisted of 4% TfOH, 4% ethanedithiol, and 8% thioanisole in 
TFA.  These conditions reliably removed all Cbz groups, while keeping other spurious impurities 
or oxidation products to a minimum, as judged by LC/MS (Figure 183). 
 With these improved conditions in hand, initial attempts at synthesizing a scaffold 
detergent were made by acylating the scaffold with fatty acids of chain length C2, C8, C12, and 
C16.  In spite of the lack of a good chromophore, the amide bonds provided sufficient 
absorbance at 220nm,to prove that the desired products were successfully synthesized as judged 
by LC/MS.  On a 5% - 95% acetonitrile (0.05% TFA), water (0.1% TFA) gradient over 30min 
98 
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(3% change per minute), it was clear that elution time was directly related to fatty acid chain 
length.  C2 eluted around 5min, C8 around 10min, C12 around 15min and C16 around 20min, all 
containing 7 free secondary amines.  Initial attempts at closing the DKP proved frustrating.  At 
this time, the knowledge base for clean and efficient closure of multiple DKP rings in 20% 
piperidine in DMF, while keeping potential epimerization to a minimum, was not very 
developed.  In most cases, complete closure of all 7 DKP took at least 48hrs, while the sight of a 
single LCMS peak containing the desired final product mass was a rarity.  More often, several 
peaks of identical mass would be present, as well as multiple products clearly having one or 
more DKP still in the often form were also present.  In the case of the C16 alkyl chain, 
hydrophobicity increased so much that it would not even elute during the normal 5-95% ACN 
gradient, as the only way to see it would be to pump 100% ACN for several minutes at the end of 
the gradient.  Because of this, there was zero potential for precise characterization of the extent 
of complete closure as well as any possible epimerization, nor would preparative purification 
have been able to resolve any impurities.  C12 had similar problems of late elution on a 5-95% 
ACN gradient.  C8 provided a DKP closed product eluting at around 15min which was prep 
purified, albeit not to total homogeneity. 
 






Additional scaffold detergents, having C4 and C6 alkyl chains were synthesized.  
Likewise these lengths eluted between 5-10min on a 30min 5-95% ACN gradient, and could be 
prep purified.  Again difficulties were encountered in getting total DKP closure and minimizing 
the appearance of epimerization.   
 Solubility tests ensued to evaluate the extent the length of the alkyl chain played on 
aqueous solubility.  C2, C4, C6, and C8 all were dissolved in 25% ACN / water.  All were 
soluble at about 10mg/mL as judged by LCMS, however, when the organic solvent was diluted 
to 2.5% - 5% by addition of water, only the C2 and C4 remained soluble at this organic solvent 
composition.  Even at this relatively dilute concentration of ~1mg/mL, solubility was not 
possible for C6 and C8.  Other organic solvents such as DMF or DMSO were evaluated, as well 
as different ways of enhancing solubility, such as sonication or addition of buffers or small 
amounts of urea or guanidinium, however, similar results were found.  At this point there were 
three deficiencies in this attempt at making a scaffold detergent capable of self-associating into 
micelles.  The first was the presumed insolubility of the longer chains such as C12 and C16.  
These lengths were needed, as they were modeled to be of the appropriate length to fully span 
the scaffold from end to end.  Even shorter lengths that would be unable to span the scaffold, 
such as C6 and C8 were soluble in aqueous solutions only with large amounts of organic 
cosolvent.  Secondly, the absolute solubility in water, with minimal amounts of organic solvent, 
was low to non-existent, for any fatty acid of potential utility.  Solubility in excess of 5-
10mg/mL was thought to be a requirement of any detergent molecule, as these concentrations are 
required for NMR structural analysis or crystal growth for X-ray structural determination.  
Thirdly, it can be inferred that the lack of high solubility in primarily aqueous solvent was a 
result of a failure to associate into micelles.  This last point was the more glaring.  Formation of 
micelles was an absolute requirement for any potential to solubilize a membrane protein.  There 
obviously was not a driving force for the two fatty acid chains to associate on a single face of the 
scaffold, which could lead to self-association into cylindrical micelles.  It turned out to be a quite 
an irony: an attempt was made to make a molecule that could maintain the water solubility of a 
membrane protein, but this molecule itself was not even water soluble. 
 Another attempt two years later was made on a second version of the scaffold detergent 
that was the result of the accumulation of knowledge gained in those two years.  This version of 
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the scaffold detergent was designed to form the full 8 DKPs, instead of the previous 7 DKPs.  
This extra rigidity was hypothesized to aid in the pre-organization of the two fatty acid chains on 
the same face.  In the analysis of the 3-D conformation of this molecule versus the previous 
attempt, it was obvious that the new attempt was going to be more rigid at both ends, while the 
previous version was highly flexible at one end.  This decrease in conformational flexibility was 
thought to potentially lead to pre-organization of the alkyl chains on one face.  By forcing the 
two side chains to point off of the same face, perhaps this could result in enhanced solubility in 
water. 
 This scaffold detergent with 8 DKPs required a different approach, because a methyl 
ester would need to present at the end of the scaffold that was attached to the resin, while in the 
previous version that end was a primary amide.  Based on previous knowledge developed, this 
was accomplished by using a resin that produces a carboxylic acid upon cleavage.  This was then 
converted to the methyl ester selectively.  In order for this to be selective, all other protecting 
groups needed to still be intact.  This required that the resin linker be particularly sensitive to 
cleavage, ideally a weak acid cleavable linker.  The chlorotritylchloride resin fits these 
requirements.  Cleavage is accomplished by treatment with acetic acid, which would maintain 
the integrity of the Boc protected building blocks, now used exclusively for scaffold synthesis.  
However, this presented another issue to consider: the methyltrityl side chain protecting groups 
that were used in the previous version would be incompatible with these cleavage conditions.  
Orthogonality was found in the ivDde (isovaleryl-dimethyl-dioxocyclohexylidene) protecting 
group for amines.  This protecting group forms a cyclic aromatic indazole upon treatment with 
hydrazine, thus by using diaminobutanoic acid (Dab) with an ivDde protecting, this scaffold 
detergent was assembled in a similar manner. 
 Attachment of the first residue to the trityl resin was accomplished by dissolving Fmoc-
Dab(ivDde)-OH in dry dichloromethane, with 5eq of base (Figure 184).  The first step resembles 
an Sn1 reaction, where the chloride leaves the triphenylmethyl position of the resin and the 
carboxylate anion acts as the nucleophile.  Because of this, DMF could not be used, because it 
would tend to solvate the ions, thus making the reaction less favorable.  Also, because of the 
mechanism, coupling reagents were not necessary.  After 2hrs the reactor was washed and the 
Fmoc was removed in the normal fashion.  Additionally, any electrophilic sites left unreacted on 
the resin would likely have been attacked by the piperidine, effectively capping the resin and 
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preventing the synthesis of truncated sequences in subsequent steps.  Attachment of the 
subsequent building blocks was exactly as for the first version.  Likewise when the last amino 
acid was attached, closure of the end DKP was facilitated by extending the Fmoc release for 
2hrs.  After this time, there were no free amines (100).   
 
Figure 185 Synthesis of the fully protected scaffold prior to side chain derivatization. 
 
Removal of the ivDde was done in 5 x 3min x 1mL of 3% hydrazine in DMF.  At this 
point the resin was portioned into smaller amounts for the coupling of different lengths of fatty 
acid chains.  Coupling of C2, C8, C12, and C16 was done the same way (Figure 185).   
 






Cleavage was carried out in 0.5mL of AcOH:trifluorethanol:DCM (1:1:3) for 2hrs, and 
then the resin beads were again cleaved with 0.5mL of fresh cleavage cocktail, for 3 x 20min 
additional time (Figure 186). The cleavage solutions were pooled and the solvent was removed 
in a SpeedVac.  By addition of DCM:hexanes (3:1) to the oily residue followed by removal of 
the solvent in the SpeedVac, and repeating this two more times, the oily residue turned into a 
white pellet.  This indicated that all of the AcOH had been removed, which would prove to be 
important for the success of the next step.  Dissolving the pellet in MeOH and treatment of the 
pellet with 25eq (based on initial resin loading and amounts) of trimethylsilyldiazomethane 
(TMSCHN2) in ether, resulted in the conversion of the carboxylic acid to a methyl ester, while 
not reacting anywhere else in the molecule.  Quenching of the excess TMSCHN2 with TFA, 
followed by removal of the solvent in the SpeedVac resulted in an oil that was subsequently 
treated with TFA:DCM (1:1) to remove the Boc groups.  Solvent was again removed in the 
SpeedVac.  LCMS analysis of intermediates up to this point was troubled by two factors: lack of 
any free amine for MS and lack of good chromophore for LC analysis.  However, quality MS 
chromatograms could be generated at this point to prove the success of reactions up to this point 
(Figure 187), 102-2, 102-8, 102-12, 102-16.   
 














Figure 188 Extracted ion chromatograms of C2, 8, 12, and 16, after removal of Boc groups. 
 
Treatment of this oil with a solution of the 20% piperidine in NMP, both from dry sure-
seal bottles, resulted in the closure of the DKPs.  Precipitation into ether yielded the final 
product.  The solubility of the final product, C2, C8, C12, and C16 (103-2, 103-8, 103-12, 103-
16) in water with 10% or less of organic composition, again yielded the same results.  The C2 
was readily soluble, while the other sequences were totally insoluble, as judged by the absence of 
ions with expected masses.  Again despite extensive sonication, nothing more lipophilic than an 
acetyl group was able to be dissolved in water with minimal organic cosolvent. 
7.3 CONCLUSIONS 
Long chain fatty acids are easily incorporated onto orthogonally protected di-amino acids, upon 
completion of the synthesis of the scaffold.  This demonstrates the versatility and adaptability of 
the solid phase methods that have been developed.  Two different approaches to the synthesis of 
a scaffold detergent have been developed.  Both proved to have little solubility in water, with any 










organization of the alkyl chains on one face.  This is one key difference between the approach 
taken by Prive and our approach.  Both approaches utilize Ornithine side chains spaced a similar 
distance apart as the point of attachment for long chain fatty acids.  Prive’s peptitergent 
accomplishes pre-organization presumably by hydrophobic interaction between the non-polar 
amino acid side chains on one face of the alpha helix and the methylenes of the fatty acid chain.  
These interactions serve to hold the fatty acid in one place, facilitating formation of a stable 
cylindrical micelle.  In both of our attempts, there is no potential for pre-organization, beyond the 
simple inherent rigidity of the scaffold.  In fact there are actually interactions forcing the fatty 
acids away from the scaffold backbone.  The polar amide bonds of the backbone actually would 
be a driving force against organization into micelles.   
Solutions to this problem would fall into two categories.  Firstly, incorporation of 
hydrophobic groups along one face of the scaffold backbone may interact with the alkyl chains 
to hold the chains in a position that could form a micelle.  However, this would involve advances 
beyond what is presently available.  Secondly, ligating or locking the fatty acid chains in place 
would allow for pre-organization to take place.  This could be accomplished in two ways.  The 
first would be to one end of the chain to a particular face of the scaffold backbone.  The second 
would be to lock the two ends of the fatty chains together.  This could potentially be possible by 




Figure 189 Proposed metathesis product. 
 
Long chain, unsaturated, fatty acids are commercially available and could be converted to 
terminal olefins.  These terminal olefin fatty acids could be incorporated in the same manner as 
the saturated fatty acid chains.  Olefin metathesis would serve to “staple” the two chains together 
(104) in such a way that formation of cylindrical micelles may be formed.  
7.4 EXPERIMENTAL 
General: Solid phase synthesis was performed in a 1.5mL disposable polypropylene reaction 
column, connected to a three-way valve equipped with vacuum and argon for mixing.  
Dichloromethane (DCM) used in coupling reactions was distilled over calcium hydride.  Dry 
grade of dimethylformamide (DMF) from Aldrich was used for coupling.  Diisopropylamine 




stored over molecular sieves.  O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium 
hexafluorphospate (HATU) was obtained from Acros.  O-(benzotriazol-1-yl)-N,N,N’,N’-
tetramethyluronium hexafluorphospate (HBTU) and N-Hydroxybenzotriazole hydrate (HOBt) 
were obtained from Novabiochem.  All solid phase reactions were mixed by bubbling argon up 
through reactor, allowing for mixing and an inert atmosphere over the reaction.  HPLC analysis 
was performed using a Hewlett-Packard Series 1050 instrument equipped with a Varian 
Chrompack Microsorb 100 C18 column (5μm packing, 4.6 mm x 250 mm) and a diode-array 
detector.  HPLC-MS analysis was performed on a Hewlett-Packard Series 1100 instrument 
equipped with a Waters Xterra MS C18 column (3.5μm packing, 4.6 mm x 100 mm) and a diode-
array detector. 
Synthesis of Scaffold Detergent, Open form version 1: 
 
Figure 190 Scaffold detergent version 1, initial resin product. 
 
To a 50mL polypropylene solid phase peptide synthesis (SPPS) reaction vessel was added Rink 
Amide AM Resin (Novabiochem) (165mg, 104μmol loading).  The resin was swollen for 1hr in 
dimethylformamide (DMF).  The terminal Fmoc-protected amine was deprotected in 5mL of 
20% piperidine/DMF for 40min.  By measuring the absorbance at 301nm of a 1/200 dilution, the 
number of moles of Fmoc removed was calculated by using ε = 7800 M-1 cm-1.  The resin was 
washed with DMF, isopropanol, DMF, isopropanol, DMF, for 2min each. 
In a 15mL polypropylene conical tube, the coupling solution was made by dissolving 317 
mg (520 μmol) of Fmoc-L-Orn(Mtt)-OH (Novabiochem), 80mg of HOBt (520 μmol) and 198mg 
of HBTU (520 μmol) in 2600 μL of 20% DCM/DMF.  This solution was mixed using a 
micropipettor, after which 181 μL (1040 μmol) of N,N-diisopropylethylamine (DIPEA) was 
added to make the active ester.  After 10min activation time, the solution was added to the 
deprotected resin, and allowed to react by argon mixing for 30min.  The resin was then washed 
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3x 2min with DMF.  Double couplings allowed for quantitative acylation, as judged by 
subsequent Fmoc release in the same manner described above. 
Because this was such a large scale and this was the student’s initial solid-phase 
experience, small very small portions of beads (~20beads, much less than 1 mg total) were 
sampled before each Fmoc-deprotection to confirm complete coupling.  This was most necessary 
when probing the completion of double –coupling of build-block, because the presence of a 
primary amine on the quaternary center prevents utilization of the Kaiser/ninhyrdrin solid phase 
assay for the presence of free amines.  Therefore beads were sampled in the following manner: 
Using a long bore, disposable glass pipette, the tip was gently touched to the pile of resin beads, 
until a visible amount of beads were adhered to the extreme tip.  The pipette was moved to a 
small 1.5mL reactor column, and isopropanol was squirted down the inside and outside of the 
pipette, until all the beads were washed into the reactor.  Preparation of the beads for cleavage 
was accomplished by sequential dichloromethane and methanol washes, for 1min each, repeating 
at least 5x.  The reactor was then capped at the top, and placed in the under vacuum for at least 
4hours.  Then the beads were cleaved using 0.5mL of 2.5% triisopropylsilane, 2.5% water in 
trifluoroacetic acid for 2hours.  LC/MS analysis was used to confirm complete coupling before 
subsequent Fmoc release and coupling of the next monomer. 
In a 2mL microcentrifuge tube, the coupling solution was made by dissolving 113 mg 
(208 μmol) of Cbz-protected pro4(2S4S) building block[20] and 79mg of HATU (208 μmol) in 
1040 μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 72.4 
μL (416 μmol) of DIPEA was added to make the active ester.  After 10min activation time, the 
solution was added to the deprotected resin, and allowed to react for 30min.  The resin was then 
washed 3x 2min with DMF.  Double couplings allowed for quantitative acylation, as judged by 
subsequent Fmoc release.  This process of coupling/deprotection was repeated six additional 
times. 
The final residue was attached in a manner identical to the first, except that the Fmoc-
deprotection was allowed to go for 2hr instead of 40min.  This ensured that diketopiperazine 
formation was complete, thus all free amine was converted to an amide. 
It was at this point that the following steps proceeded slowly, first testing the conditions 
and behavior of subsequent steps on small scales. 
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The resin was swelled in DCM with slight bubbling for 30min.  The Ornithine side chain 
protecting group, methytrityl, was removed using a 1% trifluoroacetic acid, 5% triisopropylsilane 
solution in DCM.  10 x 1mL, each reacting for about 2-3 minutes was sufficient to completely 
unmask the two side chain amines.  Neutralization with 2 x 0.5mL of 5% DIPEA in DCM 
followed by swelling in DMF readied the resin for acylation.  These amines were acylated with a 
variety of long-chain alkyl carboxylic acids.  Approximately 10eq of fatty acid, 10eq HATU, 
20eq DIPEA in a 0.2M 20% DMF/DCM, double coupling, was more than sufficient to ensure 
complete acylation.  The resin wash extensively washed with DMF, IPA, DMF, IPA, DMF, 
MeOH, DCM, MeOH, DCM, MeOH, DCM, and then overnight drying, in vacuo. 
The acylated scaffold was cleaved in 1mL of 4% trifluoromethanesulfonic acid, 4% 
ethanedithiol, 8% thioanisole in trifluoroacetic acid, with stirring for 2hours.  This served to 
cleave the scaffold from the resin as well as remove the Cbz groups from the secondary amines.    
The cleavage cocktail along with 2 volumes of TFA for washing the beads, were dripped into 10 
volumes ether, which was then spun at 3000rpm in a benchtop centrifuge.  The pellet was 
washed with fresh ether and centrifuged again.  The pellet was allowed to dry for an hour.  The 
cleaved product was analyzed by LC/MS. 
 
Figure 191 Scaffold detergent version 1, final closed product. 
 
The diketopiperazines were closed by incubation for 48hr in 20% piperidine in DMF.  
After the reaction was complete as judged by LC/MS, the product was precipitated into ether, as 
described above.  Solubility in a variety of solvents, such as water, methanol, and 25% ACN in 
water, was assessed by first sonicating the solution followed by centrifugation and LC/MS 
analysis to ascertain solubility. 
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Synthesis of Scaffold Detergent, Open form version 2: 
 
Figure 192 Scaffold detergent version 2, initial resin product. 
 
To a 10mL polypropylene solid phase peptide synthesis (SPPS) reaction vessel was added 
Chlorotritylchloride Resin (Novabiochem) (20mg, 24μmol loading).  The bottom on the reactor 
was capped and a small stir bar was added.  A solution of Fmoc-L-Dab(ivDde)-OH 
(Novabiochem) (66 mg, 120 μmol) in 500 μL of distilled DCM and 63 μL of DIPEA (360 μmol) 
was prepared in a 1.5 mL microcentrifuge tube and then added to the reactor and stirred for 2hrs.  
The stir bar and cap were removed, the solution drained and the beads were washed 5x with 
DCM, and then washed with DMF, 2x.  The Fmoc-protected amine was deprotected in 2mL of 
20% piperidine/DMF for 40min.  By measuring the absorbance at 301nm of a 1/100 dilution, the 
number of moles of Fmoc removed was calculated by using ε = 7800 M-1 cm-1.  The resin was 
washed with DMF, isopropanol, DMF, isopropanol, DMF, for 2min each. 
In a 2mL microcentrifuge tube, the coupling solution was made by dissolving 24.5 mg 
(48 μmol) of Boc-protected pro4(2S4S) building block[17] and 18.2 mg of HATU (48 μmol) in 
240 μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 16.7 μL 
(96 μmol) of DIPEA was added to make the active ester.  After 10min activation time, the 
solution was added to the deprotected resin, and allowed to react for 30min.  The resin was then 
washed 3x 2min with DMF.  Double couplings allowed for quantitative acylation, as judged by 
subsequent Fmoc release.  This process of coupling/deprotection was repeated six additional 
times. 
In a 1.5 mL microcentrifuge tube, the final coupling solution was made by dissolving 
52.5 mg (96 μmol) of Fmoc-L-Dab(ivDde)-OH (Novabiochem) and 36.5mg of HATU (96 μmol) 
in 480 μL of 20% DCM/DMF.  This solution was mixed using a micropipettor, after which 33.5 
μL (192 μmol) of N,N-diisopropylethylamine (DIPEA) was added to make the active ester.  
After 10min activation time, the solution was added to the deprotected resin, and allowed to react 
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by argon mixing for 30min.  The resin was then washed 3 x 2min with DMF, and the coupling 
was repeated.  The final Fmoc-deprotection was allowed to go for 2hr instead of 40min.  This 
ensured that diketopiperazine formation was complete, thus all free amine was converted to an 
amide. 
The resin was swelled in DMF for 30min.  The Diaminobutanoic acid side chain 
protecting group, ivDde, was removed using a solution of 4% hydrazine hydrate in DMF.  4 x 
1mL, each reacting for about 3-5 minutes was sufficient to completely unmask the two side chain 
amines.  These amines were acylated with a variety of long-chain alkyl carboxylic acids.  
Approximately 10eq of fatty acid, 10eq HATU, 20eq DIPEA in a 0.2M 20% DMF/DCM, double 
coupling, was more than sufficient to ensure complete acylation. 
The fully protected, acylated scaffold was cleaved in 1mL of 20% Acetic acid, 20% 
Trifluoroethanol in DCM, with stirring for 2hours.  This was then drained and 3 x 1mL 
additional cleavage cocktail with stirring for 3 x 15min served to remove any residual product.  
The pooled cleavage solutions were transferred into a 13mm glass tube, and the solvent was 
removed in a SpeedVac.  An additional ~4mL of DCM and ~2mL hexanes served to 
azeotropically distill off residual Acetic acid, and was repeated an additional three times, 
resulting in a dry white powder. 
The white powder was dissolved in 1mL of dry MeOH, a stir bad was added and ~25eq 
trimethylsilyldiazomethane (TMSCHN2), as a 2M solution in ether was added dropwise.  Slight 
bubbling and yellow color resulted.  The reaction was stopped after 10min by addition of an 
identical volume of trifluoroacetic acid, also dropwise.  More bubbling was apparent and the 
color disappeared.  The solvent was again removed in the SpeedVac.  A stir bar was added and 
the residue was dissolved in 4mL TFA/DCM (1:1) and stirred for 2hrs.  The solvent was 
removed in the SpeedVac, resulting in an oily residue. 
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Figure 193 Scaffold detergent version 2, final closed product. 
 
200 μL of 20% piperidine in NMP was added to the residue.  Incubation at room 
temperature for 36hrs served to close the diketopiperazines.  After this time the tube was 
centrifuged for 20 min to remove any insolubles, the product was precipitated into 1.5 mL of 
ether, in a 2mL microcentrifuge tube.  Solubility in a variety of solvents, such as water, 
methanol, and 25% ACN in water, was assessed by first sonicating the solution followed by 
centrifugation and LC/MS analysis to ascertain solubility. 
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